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Abstract 
 
     Alpha 1 antitrypsin deficiency (AATD) is the only established genetic predisposition 
to chronic obstructive pulmonary disease (COPD). The development of COPD in AATD 
is highly variable, probably relating to complex interactions between multiple genetic 
and environmental factors. This thesis will describe the COPD phenotypes observed in 
AATD and their inter-relationships, forming the basis for examining phenotypic 
associations with specific candidate genes and HLA class II type. Finally it examines the 
potential role of ambient air pollution.  
     Associations were seen for TNFA with chronic bronchitis, SFTPB with FEV1, TGFB 
with small airways disease and GC with bronchiectasis, consistent with the role of protein 
products in pathogenesis. Of four MMPs studied, association with gas transfer occurred 
in two. HLA-DQA1*0301 and HLA-DRB1*04 contributed significantly to gas transfer in 
regression models, and anti elastin antibodies were higher in HLA-DRB1*04 and HLA-
DQA1*0301 homozygotes. Ozone levels contributed to the burden of disease in cross 
sectional and longitudinal models of pollution exposure, whilst PM10, NO2 and SO2 were 
associated only in the longitudinal model. 
      In conclusion this thesis demonstrates the importance of genetic variation and 
environmental factors in determining respiratory phenotype in AATD. It also suggests a 
key role for adaptive immunity in pathogenesis of emphysema.  
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Chapter 1: Introduction 
 
     Respiratory diseases are a leading cause of morbidity and mortality in the United 
Kingdom (UK), with deaths due to respiratory disease being the third most common 
cause of death after diseases of the circulatory system and neoplastic diseases[1]. Within 
non-neoplastic respiratory diseases pneumonia remains the leading cause of death, with 
1151 deaths per million members of the UK population, followed by chronic obstructive 
pulmonary disease (COPD) which is the registered cause of death in 920 cases per million 
of the population[1]. In the UK it is estimated that 1.5 million people may have COPD, 
with up to 1 in 8 hospital admissions related to the condition[2]. These simple statistics 
highlight the importance of studying lung diseases, and COPD in particular. 
 
1.1 Chronic obstructive pulmonary disease (COPD) 
     COPD is characterised by airflow obstruction, together with an abnormal 
inflammatory response to noxious particles or gases[3]. Airflow obstruction is diagnosed 
by spirometry, such that the ratio between the forced expiratory volume in the first 
second of expiration (FEV1) and the the total volume expired (the forced vital capacity, 
FVC) is less than 0.7[4]. As with many lung diseases cigarette smoking is an important 
aetiological factor in COPD, and is widely accepted to be the main environmental risk 
factor for developing the disease. Despite this only about 15% of smokers develop 
clinically significant disease[5], suggesting that there are other influences on disease 
expression. Previous studies estimated that smoking contributes 15% to the variability 
of lung function[6], whilst genetic factors account for a further 40%[7]. The remainder of 
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the variability may be accounted for by other environmental influences, but formal 
studies have not been reported, possibly in part because of the methodological issues 
inherent in studies of environmental exposures, which are covered in more detail in 
chapter 7. 
        
1.1.1 Clinical features 
     COPD is defined by airflow obstruction that is not fully reversible after 
administration of short acting bronchodilators (such as salbutamol)[3]. There are two 
main classification systems worldwide, issued by national respiratory societies, based on 
the severity of reduction of FEV1 compared to that predicted by age, gender and height 
(see Table 1.1). The most widely accepted is the American/European system, which 
differs from the  British version only in that the lowest level of severity (very severe) is 
omitted in the UK[8]. Typically subjects present in middle age and are (or have been) 
tobacco smokers. 
     Several pathologies may contribute to the impairment of lung function, and it is likely 
that COPD in its current definition comprises overlapping syndromes (see Figure 1.1). 
Subjects may exhibit a range of pathologies, including chronic bronchitis[9], 
emphysema[10], bronchiectasis or a combination of these. Although the majority of 
subjects with such pathology will exhibit the fixed airflow obstruction that characterises 
COPD, there may be some that do not. In addition there may be an element of 
bronchodilator reversibility, defined by the change in FEV1 relative to baseline, or 
predicted normal value, after administration of short acting bronchodilators. 
Physiological tests of lung function can also identify impairment of small airway 
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function, which is measured using forced mid expiratory flow (FEF25-75%), and 
impairment of gas transfer, usually reported relative to lung volume (KCO). The small 
airways have been of great interest in COPD[11], as changes in their function may be the 
earliest sign of disease. Impairment of gas transfer usually indicates disease of the lung 
parenchyma, which in the case of COPD predominantly relates to emphysema. In 
addition subjects may exhibit systemic manifestations of the disease, including cachexia 
and co-morbid diseases, such as cardiovascular disease[12], diabetes[13] and 
osteoporosis[14].  
 17
  
 
British Thoracic Society American & European Thoracic Societies  
FEV1 % predicted 
Mild 50-80 80-100 
Moderate >30<50 >50<80 
Severe <30 >30<50 
Very severe - <30 
 
Table 1.1: Classification of severity of COPD by spirometry 
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Chronic bronchitis 
Emphysema 
Reversibility with short 
acting bronchodilator 
Bronchiectasis 
Fixed airflow obstruction 
 
Figure 1.1: Phenotypic heterogeneity in COPD 
The majority of subjects with chronic bronchitis, bronchiectasis or emphysema will have 
airflow obstruction diagnostic of COPD. Within those with COPD these pathologies may 
overlap such that subjects may have 1, 2 or 3 conditions present. In addition 
bronchodilator reversibility may exist, sufficient to diagnose co-existent asthma. The 
diagram illustrates the concept of these overlapping phenotypes.  
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          Chronic bronchitis is defined as sputum production on most days for at least three 
months of at least two consecutive years[15]. Emphysema results from destruction of the 
lung parenchyma (the functional tissues of the lung, predominantly the alveoli) and may 
be diagnosed histologically[9], or more recently by computed tomographic (CT) 
scanning[16]. Its presence is also suggested by a pattern of raised residual volume (RV) 
and (to a lesser extent) total lung capacity (TLC) alongside impairment of KCO on 
pulmonary function testing[9]. Emphysema may be further subdivided according to its 
appearance and distribution on high resolution CT scan (HRCT). Typical radiological 
appearances of emphysema are shown in Figure 1.2. Emphysema in usual COPD is 
typically centrilobular in appearance, and predominantly in the upper zone. If it is due to 
alpha 1 antitrypsin deficiency (AATD), the only widely accepted genetic predisposition 
to emphysema, it is classically panacinar and lower zone dominant[17]. Differences in 
physiology have been seen according to emphysema zone[18], though this aspect has not 
been studied in detail in COPD unrelated to AATD. This, together with genetic 
associations of emphysema zone[19, 20], suggest that upper and lower zone emphysema 
may also be distinct pathologies.  
     Bronchiectasis is usually diagnosed by CT scanning[21], the classical features being 
thickening of the bronchial wall, lack of tapering of the bronchi, bronchi visible within 
1cm of the pleura and nodular densities due to mucous filled bronchi. Various patterns of 
bronchial dilatation are recognised, described by their shape, including cylindrical, 
varicose and saccular forms[21], illustrated in Figure 1.3. Subjects typically expectorate 
large volumes of sputum daily, though this may not always be the case where the 
condition exists alongside emphysema[22].  
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 Centrilobular emphysema 
The diseased areas, some of which 
are highlighted by arrows here, 
appear low in density, and are 
related to central bronchioles. This 
produces a patchy appearance to 
the scan image. 
 
Panacinar emphysema 
Disease is uniform and widespread 
within this image. 
 
 
 
CT densitometry  
 
 
 
 
 
 
 
 
 
Low density areas below a given 
threshold of Hounsfield Units are 
identified by quantitative CT. 
This is an example generated by 
Pulmo software (Leiden, 
Netherlands) using an image from 
the same patient as the panacinar 
image above, where the 
emphysematous areas are 
highlighted in pink. 
 
 
 
 
Figure 1.2: The radiological appearance of emphysema subtypes 
The pictures show the two main subtypes of emphysema. 
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Tubular bronchiectasis 
Lack of tapering of the bronchi and 
bronchial wall thickening can be seen.  
Varicose bronchiectasis 
The classical ‘tree in bud’ nodular 
appearance of mucus filled bronchi is 
indicated by the arrow, alongside 
irregular variceal bronchial dilatation.  
 
 
Saccular, or cystic, bronchiectasis 
Large dilated airways are shown in 
the right lower lobe. 
Figure 1.3: The radiological appearance of bronchiectasis on CT scan 
The three main subtypes, which may exist alone or together in an individual, are shown 
here, each being described by the appearance of the bronchi.  
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1.1.2 Management 
     Therapy in COPD is mainly directed at airflow obstruction and inflammation, with 
additional treatment for exacerbations, which may be infective or non-infective. Thus 
short and long acting bronchodilators, acting via beta adrenoceptors (β2 agonists) and 
anticholinergic pathways are recommended to be used in a stepwise manner, with the 
addition of inhaled steroids later in the disease. Current British Thoracic Society 
Guidelines suggest that they should be added combined with a long acting β2 agonist 
when FEV1 is below 60% of the predicted normal value, and when the patient is 
experiencing regular exacerbations[8]. Many of the newer treatments for COPD have 
been directed at individual components of inflammation, given its’ importance in 
pathogenesis (discussed in section 1.1.3). However most, such as anti-TNFα, have been 
disappointing[23]. Some of the newer treatment strategies and their effects in clinical 
trials are shown in Table 1.2.  
     It may also be important to note that variability of response to established treatments 
(such as β2 agonists) and to newer ones (such as anti-TNF) may occur due to genetic 
variation[24-26] though it is not yet known if this is relevant in COPD. It is also possible 
that treatment response could vary between subphenotypes of COPD, such as those 
described in section 1.1.1. The importance of genetic variation is discussed further in the 
context of anti-TNFα therapy in chapter 3. Non-pharmacological interventions, such as 
pulmonary rehabilitation, which aims to improve patient fitness,  are also effective[27].  
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 Treatment Mechanism Clinical effects Refs. 
Cilomilast PDE4 inhibitor Improvement in FEV1 and quality of life. 
reduced FEV1 decline, fewer 
exacerbations 
[28, 
29] 
Roflumilast PDE4 inhibitor Improvement in FEV1 [30] 
BAYx1005 LTB4 synthesis 
inhibitor 
Reduced bronchial inflammation [31] 
ABX-IL8 Monoclonal AB 
specific to IL8 
Improves dyspnoea and FEV1 early in 
treatment, but no sustained improvement 
in lung function by the end of the trial 
[32] 
N-acetylcysteine Antioxidant No improvement in lung function or 
exacerbation frequency 
[33] 
Infliximab Anti-TNFα No benefit except in cachectic subjects 
whose 6MWT distance and frequency of 
hospital admissions improved 
[23] 
Marimastat MMP inhibitor Tested in asthma; reduced airway hyper-
responsiveness 
[34] 
Al-trans-retinoic 
acid 
Repairs 
elastase/smoke 
induced lung 
damage 
Clinical trials in progress. Pilot studies 
confirm safety. 
[35] 
Montelukast Leukotriene 
receptor 
antagonist 
Improved FEV1 and quality of life, 
observational study suggested reduced 
hospital admissions & medication usage 
[36, 
37] 
 
Table 1.2: Potential new medical treatments for COPD, their mechanism of action and 
reported clinical effects 
PDE4 = phosphodiesterase 4, LTB4 = leukotriene B4, IL8 = interleukin-8, AB = 
antibody, TNFα = tumour necrosis factor-α, MMP = matrix metalloprotease, 6MWT = 6 
minute walk test 
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1.1.3 Pathogenesis 
A number of pathological processes have been deemed important in COPD, within which 
three main themes have emerged: 
• Protease-antiprotease imbalance 
• Oxidant-antioxidant imbalance 
• Inflammation 
 
The first theme concerns imbalance between proteases that digest elastin and other 
components of the extra-cellular matrix in the lung parenchyma, and anti-proteases that 
protect[38, 39]. The origin of this theory comes from the observation that patients with 
AATD develop early onset emphysema[40]. Alpha one antitrypsin (AAT) is an anti-
protease, which acts predominantly to block the action of neutrophil elastase (NE), a 
protease released by neutrophils. Neutrophil elastase is a serine protease, the first of three 
classes of protease important in COPD. The remaining two classes are the cysteine 
proteases, such as cathepsin-B, and the matrix metalloproteases (MMP’s) [41]. In general 
the serine and cysteine proteases are capable of degrading elastin and some forms of 
collagen [41], whilst MMP’s have more of an effect on collagen, gelatin and laminin [39]. 
Each protease is inhibited by one or more anti-proteases, may inactivate other anti-
proteases, or activate pro-inflammatory cytokines via interaction with proteinase 
activated receptors (PARs) [42]. A key inflammatory cytokine activated in this way is 
tumour necrosis factor alpha (TNFα). The proteases function to clear debris and 
damaged tissue, but if their action is not effectively controlled they may produce 
excessive lung damage. 
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     Second, disparity between levels of harmful oxidants and protective antioxidants may 
lead to dominant oxidative stress. Cigarette smoke is a major source of oxidants (mainly 
free radicals and nitric oxide), though reactive oxygen species (ROS), such as O2-,  are also 
produced by interaction of cigarette smoke with the epithelial cells, and released by 
inflammatory leukocytes, which accumulate in the lungs of smokers[43]. Certain 
pollutants, predominantly particulate matter, may also affect oxidant-antioxidant 
balance[44] and could contribute to disease by this mechanism, a concept discussed 
further in chapter 7. Antioxidant enzymes present in the airway include glutathione-S-
transferase, superoxide dismutase and catalase[45]. Free radicals and ROS have direct 
toxic effects on the respiratory epithelium, leading to epithelial cell detachment, and 
increased cell lysis[46]. These processes also enhance pulmonary inflammation via up-
regulation of genes encoding pro-inflammatory cytokines[46], exacerbating the damage 
to the lung.  
     Inflammation is the third key concept in COPD pathogenesis, and may also be 
stimulated by cigarette smoke[43], ozone[47] and particulate matter pollution[44]. The 
processes by which pollution may affect the lung are discussed further in chapter 7. The 
importance of inflammation in pathogenesis is supported by transgenic mouse models, 
such as that for IL13 – when this pro-inflammatory cytokine is  over-expressed the mice 
exhibit induction of MMPs and develop emphysema[48], whilst TNFα knockout mice are 
relatively protected from developing these features after exposure to cigarette smoke[49]. 
In man the role of inflammation is supported by the observation of infiltration of the 
airways by inflammatory cells in increasing numbers as disease progresses[11] and of 
correlations between airway inflammatory cytokine levels, such as intereukin 8 (IL8), 
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and progression of respiratory disease[50]. Furthermore, subjects with COPD have higher 
circulating levels of several inflammatory markers[51], though the relationship between 
pulmonary and systemic inflammation is not yet clear. The hypothesis that systemic 
inflammation results from ‘overspill’ of inflammatory mediators from the lung is not 
consistent with the lack of correlation between inflammatory markers in sputum and 
plasma[52], although recent data suggests some signal communication between the 2 
components when repeated sputum measures are used[53]. Inflammation is, however, a 
significant driver of proteolytic and oxidant damage, as shown in Figure 1.4, with many 
mediators implicated in pathogenesis [54], as summarised in Figure 1.5. 
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Figure 1.4: The pathogenesis of COPD 
Cigarette smoke and other inhaled pro-inflammatory agents (such as ozone [47] or 
particulate matter [44]) activate macrophages (1), and neutrophils (2) leading to the 
direct release of proteases or neutrophil chemotracctants, together with the release of 
oxidants (3) resulting in subsequent breakdown of connective tissue in the lung (4), 
causing emphysema. Epithelial cell stimulation (5) by oxidants, such as oxygen free 
radicals, promotes fibroblast activity (6), eventually leading to fibrosis and small airways 
disease (7). 
 28
  
 
 
 
 
 
 
 
 
2 
Macrophage 
1 
Neutrophil 
TNFα 
IL8 
4 
5 
NFκβ 
TGFβ 
6 
3 IL8 
LTB4 
7
Fibroblast 
 
Proteases Fibrosis Neutrophilic inflammation  
 
 
Figure 1.5: Inflammatory mediators in COPD 
There are many pro-inflammatory mediators involved in COPD, some of which are 
illustrated here. Cigarette smoke, or another inhaled pro-inflammatory agent, activates 
macrophages (1) to release TNFα, leukotriene B4 (LTB4), interleukin 8 (IL8) and other 
neutrophil chemotactic factors (2), as well as proteases (3). TNFα promotes further IL8 
release from other cells in the respiratory tract by nuclear factor kappa beta (NFκβ) 
mediated effects on gene transcription (4). This in turn increases local neutrophilic 
inflammation (5), and hence the release of proteases. TNFα itself may directly increase 
neutrophilic inflammation by upregulation of endothelial adhesion molecules (6). 
Epithelial cells also stimulate fibroblasts via transforming growth factor beta (TGFβ), 
leading to fibrosis (7).  
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1.1.4 Genetic aspects 
     Family based studies support a role for genetic susceptibility in COPD by 
demonstrating ancestral aggregation of spirometric measures in the general population 
[55, 56] and higher rates of airflow obstruction in first-degree relatives of subjects with 
COPD[57]. This suggests that lung function runs in families, whether or not they have 
developed any respiratory disease. This in turn is indicative of a genetic component, 
although assumes that all environmental influences have been taken into account prior to 
the analysis. Accounting for environmental factors is key in COPD since smoking also 
tends to aggregate in families; the more recent family studies in the area have accounted 
for this by regression analysis. Aggregation of pulmonary function parameters has been 
shown in families with AATD[58] and in the last year both CT diagnosed emphysema 
and airway wall thickness have been shown to aggregate in families with usual 
COPD[59], suggesting a genetic contribution to lung architecture, as well as to 
physiology.  
     Continued smoking is generally considered to be a risk factor for more rapid decline of 
lung function over time, compared to the general population, but major differences in the 
rate of decline of lung function occurs between smokers[60]. This suggests there may also 
be an interaction between genetic and environmental influences.  
 
Approaches to genetic analysis  
     In diseases where multiple genetic influences are likely to be present, like COPD, 
several approaches have been used to identify susceptibility genes. These include linkage 
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analysis and population based case-control studies. Variation, or polymorphism, within 
genes can be classified in different ways[61], which describe the resultant change in the 
DNA sequence or protein. Common changes in the DNA sequence include microsatellites 
- multiple repeats of a short segment of DNA, and single nucleotide polymorphisms 
(SNPs) - a change of a single base, being the most common type of polymorphism in the 
human genome [62]. Such changes may occur in coding or non-coding regions of DNA. 
Changes in coding regions may be synonymous or non-synonymous, depending whether 
they affect the amino acid sequence of the protein product - synonymous changes do not 
alter the product, non-synonymous changes do. Non-synonymous changes in coding 
regions were thought to be most important for many years, since intuitively a change in 
the amino acid seuquence may alter the function of a protein[63]. However it is now 
recognised that alterations in non-coding regions may be equally important in complex 
disease. 
     Copy number variation (CNV) is a newer concept of interest for genetic association 
studies. CNV means that differing numbers of copies of a segment of DNA occur in a 
given population, this segment being anything from 1 kilobase to several megabases in 
size. The CNV can be caused by deletions, duplications, inversions or translocations of 
genetic material and might involve a candidate gene (or indeed many genes) thus has 
great potential to influence pathogenesis. CNVs are very common in the human genome 
[64], this again being a good reason to examine further for associations with disease. An 
example in lung disease is CNV of the endothelial growth factor receptor gene (EGFR), 
where higher copy numbers are seen in lung cancer and relate to response to treatment 
[65].  
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Linkage analysis 
     This approach identifies susceptibility areas within the genome by seeking markers 
that co-segregate with disease; if a marker is inherited together with a disease, and this is 
significant across many families then the marker must be located close to a susceptibility 
gene, and the two are said to be linked. Linkage analysis does not rely on prior knowledge 
of the gene product, or its role in pathogenesis. Microsatellites are the most commonly 
used markers in such analyses.  
     Parametric linkage analysis requires specification of a genetic model, including 
parameters such as penetrance, allele frequency and mode of inheritance. Results are 
expressed as a logarithm of the odds (LOD) score[66], which is a likelihood ratio derived 
from the recombination fraction between the marker and the proposed locus of the 
disease-causing gene. The threshold level of LOD score needed for genome-wide 
significance varies depending on the study design, from 3.3 for parametric linkage 
analyses to 3.6 in sibling pair studies[67]. The latter is a commonly used non-parametric 
linkage study design, which works on the principle that there will be an excess of allele 
sharing between sibling pairs with disease, compared to that expected by chance. Unlike 
parametric designs such methods do not require a mode of inheritance and are therefore 
more useful in complex diseases (like COPD) where multiple influences exist, than in 
single gene disorders where the mode of inheritance may be inferred from the pattern of 
disease observed clinically.  
     Linkage studies allowed relatively crude whole genome screening, but have been 
disappointing in their results in common complex diseases, in that they have either failed 
to deliver novel loci, or have failed to replicate well in independent populations. 
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Developments in genotyping technology mean that is now possible to screen the whole 
genome using hundreds of thousands of SNPs, whose genotypes can be detected by 
fluorescence on a chip. Sequencing technology is also progressing rapidly and it is now 
possible to ascertain the exact nucleotide sequence of an individual’s genome using high 
throughput methods. Since linkage studies can only report ‘linkage’ of disease to a 
genomic region, which may be very large, they required follow up by other work, usually 
case-control association analyses, to locate the gene responsible for disease association. 
Historically false positive studies have been a problem[68]. Furthermore, follow up work 
has tended to concentrate on candidate genes suggested by current knowledge of 
pathogenesis in the regions identified, limiting the discovery of new processes relevant to 
disease. 
 
Linkage disequilibrium 
Linkage disequilibrium (LD) is a relevant concept to consider when discussing linkage 
studies, and prior to considering other study designs. This is the term used to describe 
how closely genetic markers are related to one another, such that two markers exhibiting 
a high degree of LD will usually be inherited together, whilst those with a low degree of 
LD may not. The degree of LD between two markers can be ascertained from the 
correlation coefficient between genotypes (r2) or an alternative measure known as D-
prime, which is calculated by dividing the observed degree of linkage between the two 
markers by the theoretical maximum. A higher r2 indicates a higher degree of LD 
between the markers. Effectively linkage studies rely on this concept to narrow the 
region of genetic association. 
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Case-control association studies 
     International projects, such as the SNP consortium[69], which catalogues common 
SNPs in the human genome, and HapMap[70, 71], which has genotyped SNPs in 
Caucasian, African, Chinese and Japanese subjects, have contributed to the many 
databases available on genetic variation. Potential disease causing polymorphisms, or 
markers within genes and their likely population frequencies can be identified using such 
resources. This allows the design of case-control association studies, either following up a 
linkage study, or as a primary study of one or more candidate genes. This is a powerful 
and widely used approach, though sometimes producing inconsistent results[72]. This 
may be because of variation in the definition of cases, underpowered studies, racial 
differences and population heterogeneity.  
     The issues of case definition and power are particularly important when examining a 
complex disease such as COPD, as each gene may contribute to a particular sub-
phenotype, or contribute only a small amount to the clinical phenotype. For instance, 
cases of COPD might be defined by standard spirometric measures, or sub-phenotypes 
might be chosen based on CT parameters or symptoms. If different genes contribute to 
each of these disease features, then studies which have used differing case definitions 
might not replicate each others’ results. Similarly, if a number of genes contribute to each 
specific clinical feature as part of a cascade, as is likely given the complexity of 
pathogenesis (section 1.1.3), then each one may only lead to a small additional risk of 
that feature. The power of a genetic association study is dependent on the odds ratio 
(OR) of disease conferred by a specific polymorphism and the sample size, such that to 
detect the effect of a SNP conferring a small OR  of disease a larger sample size will be 
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needed to have adequate power to detect it. Power calculations for case control 
association studies are usually based around an OR of disease of 1.5. Other problems can 
be limited by choosing subjects from only one racial group and genotyping markers 
specifically to assess population heterogeneity. 
 
Genetic associations 
     During the years that the work contained in this thesis was performed the level of 
knowledge of the genetic associations of COPD has increased exponentially. At 
commencement of the studies contained herein the majority of COPD genetic association 
work was in small cohorts, phenotyped in many different ways, or were linkage studies. 
Since then the problems of these approaches have been recognised and the technology 
has improved to the extent that large, genome-wide studies replicated in similar sized 
groups have recently been reported [73]. It is now recognized that both airways and 
parenchymal disease are likely to have a genetic component [59], and that the gold 
standard for genetic association work should be to report associations in two COPD 
populations, phenotyped in the same way, in the same paper. Alternatively, confidence 
in the truth of the association might be gained by meta-analysis of the studies of any 
given polymorphism.  
     A range of genetic associations with recognised COPD phenotypes have been reported 
and are summarised in Table 1.3. These are predominantly in candidate genes suggested 
by the three pathogenetic themes of protease-antiprotease imbalance, oxidant-
antioxidant imbalance and inflammation. Major studies of genes in each of these areas 
are discussed below, concentrating on the pre genome-wide era, with further detail on 
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those studied in this thesis in the relevant chapters. The results of genome-wide 
association studies (GWAs) in COPD, and the future of genetic association studies in the 
post-genome era will be considered in chapter 8, in order to put this thesis into context of 
the published work available at its inception. 
 
Protease-antiprotease pathways 
     AATD is the most widely accepted genetic susceptibility to COPD, and exerts its 
influence by decreased antiprotease protection, as discussed in section 1.2. Other 
candidate genes relating to increased proteolytic destruction, or decreased antiprotease 
protection have been studied in COPD, predominantly in matrix metalloprotease genes 
(MMPs) or their inhibitors. This family of genes and protein products is discussed in 
more detail in chapter 6. 
     The most widely studied MMP polymorphism is a promoter region SNP in MMP9 (C-
1562T, rs3918242), located on chromosome 20q11. This increases MMP9 activity via 
higher levels of gene transcription resulting from preferential binding of a transcription 
repressor protein to the C allele[74], and has been linked to COPD in both Chinese[75] 
and Japanese populations[76]. Both of these studies were relatively small, having 100 
and 45 cases respectively, together with a similar number of controls. A later study in 84 
Japanese subjects reported that the association was specific to upper zone dominant 
emphysema (UZDE)[20].  
     SNPs in MMP1 and MMP12 have also been studied in COPD. The single G allele 
variant of a promoter region SNP in MMP1 (rs1799750, G-1607GG) has been associated 
with predisposition to rapid decline of lung function, as were combinations of this and a 
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non-synonymous SNP in MMP12, though the latter SNP was not associated when 
examined alone[77]. This suggests that the true variant linked to decline may be 
rs1799750, however the associated variant results in decreased MMP1 expression[77] 
thus the association is not consistent with the role of MMP1 in COPD pathogenesis. The 
true association may, therefore, be in LD with these SNPs. The same SNP (rs1799750) 
was associated with UZDE in Caucasians in the National Emphysema Treatment Trial 
(NETT) genetics study[19], but not with features of lung function (such as FEV1)[72] or 
functional status[78]. It is of note that the region in which both genes lie has been 
associated with emphysema in a recent genome wide association study[79], detailed 
results from which will be discussed in chapter 8. Two SNPs in a gene coding for an MMP 
inhibitor (TIMP2) - tissue inhibitor of metalloprotease-2 (TIMP2) - have also been 
associated with COPD in Japan[80]. This result has not yet been reproduced in other 
ethnic groups, and the functional consequences of each SNP remain theoretical. 
     Alpha-1 antichymotrypsin (also known as SERPINA3) inhibits cathepsin G and mast 
cell chymase in a reversible fashion. Two SNPs in SERPINA3, associated with low α-1 
antichymotrypsin levels (rs17473, rs1800463), have been associated with COPD in 
Swedish subjects [81, 82], though their cases were defined by a measure of airway 
resistance, rather than standard spirometric parameters. These associations were not 
reproduced in Japan[83, 84], though a non-synonymous SNP affecting the signal peptide 
region (rs4934) was found more commonly in the Japanese COPD group. None of these 
variants showed association in Italian subjects with airflow obstruction, though this 
included those with bronchiectasis as well as COPD[84]. The lack of replication could be 
explained on racial grounds or by the different diagnostic criteria used by each group. 
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     SERPINE2 is an inhibitor of trypsin-like serine proteases, related to AAT[85], though 
its major function is in coagulation and fibrinolysis[86]. SERPINE2 was identified as a 
potential candidate gene in COPD by integration of an area of linkage on chromosome 
2q33 from the Boston early-onset COPD cohort[87, 88] with knowledge of gene 
expression during murine lung development and human lung microarray datasets[89]. 
This showed SERPINE2 to be within the area of linkage (chromosome 2q33) and to be 
highly expressed in the lung, making it a logical candidate gene. Several studies now 
support a role for this gene in COPD, though the precise location of functional variants 
has yet to be determined. In the NETT cohort many SNPs were significantly 
associated[89] (the most associated being rs6734100 with FEV1/FVC, p=0.00004) most of 
which were replicated by the International COPD Genetics Network (ICGN) and in a 
Norwegian case-control group[90]. Conversely, a large European case-control study did 
not find any association with COPD[91] and questioned the validity of some of the 
results reported in the original study since SNPs in complete LD in the European cohort 
had different p values for association from one another in the original study. Over-
expression of SERPINE2 is associated with an increased risk of COPD[89], which is not 
consistent with its protective anti-protease actions. The mechanism of association may be 
through its role in coagulation, since enhanced prothrombotic markers are associated 
with decline of FEV1 in COPD[92] though the role of such pathways in COPD 
pathogenesis has not been widely investigated. Alternatively SERPINE2 mediated 
inhibition of plasminogen activator urokinase (PLAU) may be important as PLAU is 
involved in activation of TGFβ and MMPs, and is over-expressed in COPD [93]. 
Gene Markers/alleles Function COPD phenotype N (cases: controls) Effect size p  Refs. 
MMP9 rs3918242 C-1562T ↑gene 
transcription 
UZDE, COPD 84:85 
110:94  
100:98 
6.51 
2.69 
6.17 
0.04 
0.02 
<0.01 
[20, 75, 
76] 
MMP1 rs1799750 G-1607GG ↑gene 
transcription 
UZDE, FEV1 
decline 
282 
284:306 
4.1 
0.62 
0.02 
0.02 
[19, 77] 
TIMP2 rs2277698 
* 
G853A 
G-418C 
Altered protein  
↓protein level 
COPD 88:40 5.4 
2.3 
<0.0001 
0.05 
[80] 
SERPINA3 rs4934 
rs17473 
rs1800463 
Ala-15Thr 
Pro227Ala 
Leu55Pro 
Altered protein 
↓protein level 
↓protein level 
Altered airway 
resistance 
100:100 Not given 0.04 
0.02 
0.04 
[81, 82] 
SERPINE2 Various§ N/A N/A COPD 949 & 204:441 
1910 & 975:956 
Not given 
-0.113 
4x10-5 
0.008 
[89, 90] 
GSTP1 rs947894 Ile105Val ↑enzyme activity UZDE, COPD, 
FEV1 decline 
282 
286:308 
1940 
53:50 
1098:544 
-5.0 
2.83 
-0.21 
3.5 
1.69 
0.001 
0.03 
0.03 
0.01 
0.02 
[19, 94-
97] 
GSTM1 Gene deletion Null No protein Emphysema, CB 1098:544 
168:384 
87:162 
3.49 
1.36 
1.50 
0.005 
0.03 
0.002 
[97-99] 
SOD3 rs1799895 Arg213Gly ↑ protein level COPD 230:210 4.3 0.02 [45] 
EPHX1 rs1051740 
rs2234922 
Tyr213His 
His139Arg 
↓enzyme activity 
↑enzyme activity 
Emphysema, 
UZDE, FEV1 
decline 
282 
304:441 
304 & 127 families 
94:203 
40:358 
283:308 
Slow -5.9 
Fast 0.73 
Slow 1.75 
Slow 4.1 
Slow 2.9 
Slow 4.9 
0.005 
0.03 
0.03 & ns 
0.01 
0.02 
0.04 
[19, 72, 
78, 100-
102] 
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HMOX1 Microsatellite 
in promoter 
GT(n) ↑gene 
transcription 
↓enzyme activity 
Emphysema, 
COPD, FEV1 
decline 
749 
101:100 
-62.0 
1.62 
0.009 
0.01 
[103, 
104] 
TNFA rs1800629 A-308G ↑ protein level Emphysema, CB, 
COPD 
106:110 
44:40 
42:42 
2.58 
2.15 
11.1 
<0.01 
0.09 
<0.01 
[105-
107] 
TGFB rs1800469 
rs1982073 
C-509T 
C613T 
↑ protein level 
↑ protein level 
COPD, dyspnoea 304 
304:441 
5.4 & 5.7 
Not given 
0.0002 & 
0.0005 
Both 0.02 
[78, 
108] 
GC rs4588 
rs7041 
Thr436Lys 
Asp432Glu 
↓conversion to 
MAF 
Emphysema, 
COPD, FEV1 
decline 
63:82 
104:413 
75:64 
GC1F 2.2 
GC2 0.8 
GC2 0.17 
0.01 
0.04 
<0.01 
[109-
111] 
IL13 rs1800925 C-1055T ↑gene 
transcription 
COPD 151:99 Not given 0.02 [112] 
SFTPB 
 
rs1130866 
rs2118177 
Thr131Ile Altered protein COPD, 
dyspnoea, 
exacerbations 
304:441 
127 families & 304 
101:81 
1.58 
Not given 
3.65 
0.05 
0.03 & ns 
0.03 
[72, 78] 
[113] 
Table 1.3: Some genetic polymorphisms associated with COPD 
The table lists some studies of genetic association in COPD. Details of studies are given in the order that they appear in the references 
listed. Where the studies were case: control in nature the effect size is shown as an OR; where they were quantitative analyses in one group 
of cases the B value from the regression analysis is shown, and the data given in italics. Where quantitative studies concern FEV1 or FEV1 
decline a negative B value is equivalent to a higher risk of disease, in contrast to most emphysema studies where this is indicated by a 
positive B value. Where studies have computed statistics by different risk alleles this is indicated in the effect size column with the allele 
name. If more than one cohort was studied results 
*SNP unidentifiable in dbSNP[114]. §16 SNPs were associated with either FEV1 or FEV1/FVC; p value and effect size of most associated 
is shown. See abbreviations list for definitions of genes used in this table; common allelic variant descriptors used in published work are 
included for ease of cross-referencing to such studies. Clinical abbreviations used here are: UZDE = upper zone dominant emphysema, 
CB=chronic bronchitis, COPD=airflow obstruction with low FEV1, equivalent to BTS mild COPD or greater (table 1.1). 
Oxidant-antioxidant pathways 
     Polymorphisms affecting the function of antioxidants in the airway might influence 
oxidative stress, and are thus logical candidates. The most widely studied class of 
antioxidant genes are the glutathione S transferases, GSTP1 and GSTM1, thats protein 
products detoxify some of the harmful contents of tobacco smoke [115]. A number of 
polymorphisms with functional consequences have been examined in COPD[19, 94, 96, 
97]. 
      A non-synonymous SNP in GSTP1 (rs947894, Ile105Val) which increases the 
metabolism of carcinogenic aromatic epoxides[116] has been widely studied in COPD. 
Studies of its relationship to lung disease have varied in their findings. The 105Ile variant 
encodes a change in protein structure which alters the substrate binding site[116], 
resulting in less anti-oxidant activity. It has been associated with UZDE in the NETT 
cohort[19], with airflow obstruction in a Japanese population[96] and with a rapid decline 
of FEV1 in the Lung Health Study (LHS)[94]. Conversely, it has also been associated 
with low baseline lung function[97] and 105Val homozygous children exhibit reduced 
annual growth of FEV1[95]. Gene-smoking or gene-gene interactions have been considered 
as causes for these disparate results. No evidence of a gene-smoking effect was seen in the 
LHS[97], but there was an additive effect of polymorphisms in GSTP1 and other 
GSTs[94], suggesting a role for gene-gene interaction.  
     GSTM1 has a null allele, such that null homozygotes have no GSTM1 activity. This 
genotype has been associated with emphysema[98] and chronic bronchitis[99], with 
conflicting results concerning its role in lung cancer[98, 117]. It was not associated with 
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decline of FEV1 in the LHS[97]. In common with most other genetic studies in COPD the 
positive results have been difficult to replicate[72], though this may be because of 
differences in case definition. The studies of GSTM1 have varied in their dataset size, from 
111 emphysematous subjects in the smallest[98] to over 1000 participants in the LHS[97]. 
    Microsomal epoxide hydrolase (EPHX1) is an enzyme expressed in bronchial epithelial 
cells and metabolises highly reactive epoxide intermediates in cigarette smoke [118, 119]. 
There are 2 known SNPs in EPHX1 that affect enzyme activity; the first is in exon 3 
(rs1051740, Tyr113His), the second in exon 4 (rs2234932, His139Arg). In both cases the 
His variant is associated with lower levels of enzyme activity [120, 121]. Each 
polymorphism only accounts for a modest change in activity[121], and are insufficient on 
their own to explain the association with COPD. However, variation in the gene’s 
regulatory regions can account for up to 30% of gene activity[122], such that SNPs here 
could also be important in COPD. Subjects carrying both His variants were at the highest 
risk of developing COPD and emphysema in a Scottish population[100]; the result being 
replicated in subjects with advanced COPD in Japan[101]. The LHS also demonstrated a 
relationship with rapid decline in FEV1 for subjects with the same His-His 
combination[102]. The His139 variant alone was associated with a spirometric diagnosis 
of COPD in the Boston early-onset COPD cohort[72] and with UZDE in NETT 
genetics[19], consistent with the observation of better gas transfer in those with the 
Arg139 variant[78]. 
      Extracellular superoxide dismutase (SOD3) is present at high concentrations in areas 
of the lung containing large amounts of type 1 collagen, especially around large airways 
and adjacent to alveoli[123] and protects the lung, particularly during episodes of 
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increased inflammation [124]. A SNP (rs1799895, Arg213Gly) in SOD3 that increases 
plasma enzyme levels was found to be protective against COPD in New Zealand[45], and 
in the Copenhagen City Heart Study[125].This effect was not observed in non-smokers 
suggesting a gene-smoking interaction, although robust statistical evidence of this was not 
reported[125]. 
     Heme oxygenase-1 (HMOX1) catalyses the oxidative cleavage of haem - a molecule 
consisting of an iron atom within a porphyrin ring, of which there are four main types in 
man. This results in the release of carbon monoxide, biliverdin and iron[126]. Biliverdin is 
then broken down into bilirubin, which scavenges local ROS such that HMOX1 
contributes to a pathway which generates antioxidants. It is present at higher 
concentrations in the lungs of smokers than non-smokers[127] suggesting up-regulation in 
response to increased ROS. A microsatellite (GT)n repeat in the 5’ region of HMOX1 
alters transcription[128] such that with greater numbers of repeats it is not induced as 
effectively by ROS[104]. Thus in the presence of a long GT repeat (n≥30) smokers would 
be unable to protect their lungs from ROS induced damage, and would be susceptible to 
emphysema[103]. A French study associated GT repeats ≥33 in length with airflow 
obstruction and rapidly declining lung function[103], whilst Japanese subjects with GT 
repeats ≥30 in length were more likely to have emphysema[104]. The effect on decline was 
not reproduced in the LHS, despite the fact that this was a larger study in a similar racial 
group[94]. The association with emphysema has not been replicated to date. 
 
 43
Inflammation and inflammatory mediators 
     Since inflammation is central to the pathogenesis of COPD many mediators have been 
examined as candidate genes for association with disease. A key driver of inflammation in 
COPD is TNFα, that’s gene has been studied relatively widely in COPD. A SNP in its’ 
promoter (G-308A, rs1800629) directly affects gene regulation, and is associated with high 
TNFα production[129]. This has been studied in several COPD phenotypes with differing 
results. An initial case-control study in Taiwanese subjects with chronic bronchitis found 
an association with disease, consistent with greater airways inflammation[107]. It has also 
been linked to airflow obstruction without chronic bronchitis, and severity of emphysema 
in Japanese subjects [105, 106]. Studies in Caucasians have not been able to reproduce 
these results [72, 102]. 
     A number of other genes associated with pro-inflammatory pathways have also been 
examined in COPD. The four surfactant proteins contribute to regulation of alveolar 
surface tension and have a role in host defence, both of which are processes relevant to 
lung homeostasis. Surfactant proteins B and C are hydrophobic membrane proteins that 
increase the rate at which surfactant spreads across the alveolar surface; both are required 
for normal respiratory function because of their effect on alveolar surface tension[130]. 
Surfactant proteins A and D have carbohydrate recognition domains that allow them to 
coat bacteria, to promote phagocytosis by macrophages[131]. Variations within 
surfactant protein B (SFTPB) have been associated with a variety of COPD phenotypes 
in Caucasian [72, 78, 132] and Hispanic subjects [133], and more recently a genome-wide 
study has reported association near to the gene for its binding protein[73]  
     The Boston early-onset COPD study showed linkage between FEV1 and chromosome 
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19q13, which contains the transforming growth factor beta (TGFB)[108]. The role of its 
protein product (TGFB) in COPD has been outlined in section 1.1.3. Subsequent studies 
have supported a role for variation within TGFB in COPD susceptibility[78, 134, 135]. 
Studies of the Group specific component gene (GC) (also known as Vitamin D binding 
protein) in COPD have concentrated on known allelic variants; such as the GC2 and GC1S 
alleles, caused by non-synonymous SNPs (rs4588 and rs7041). The GC2 allele appears to 
be protective in Caucasians [110, 111], whilst the GC1S allele has not been associated with 
COPD[72]. The GC1F allele has been consistently associated with a range of COPD 
phenotypes in Japanese subjects [109, 136] but results in Caucasians have been 
inconsistent [102, 110, 111]. This is probably because Caucasians have a lower frequency 
of GC1F and studies were therefore underpowered (section 4.1.3 and appendix 4). 
     Another polymorphism in an inflammatory pathway gene which has been less well 
replicated is in the promoter region of IL13 (rs1800925, C-1055T). This variant is 
associated with increased IL13 production[137]. It is more common in COPD[112] though 
this may only be important in the presence of a gene-smoking interaction[138]. Studies in 
transgenic mice have shown that when IL13 is over expressed, it results in cathepsin and 
MMP dependent, rather than NE driven, emphysema [48, 139]. In mice IL13 induced 
emphysema is characterised by excessive pulmonary mucus production, but this feature 
has not been examined in genetic association studies in man.  
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1.2 Alpha-1-antitrypsin deficiency 
     Alpha one antitrypsin deficiency constitutes the only widely accepted genetic 
susceptibility factor to COPD. It was first described in 1963 by Laurell and Eriksson, who 
reported an absence of the α1 band on protein electrophoresis of human serum[140]. 
Serum electrophoresis separates serum proteins into five major bands: albumin, alpha-1-
globulins, alpha-2-globulins, beta globulins and gamma globulins. Alpha 1 antitrypsin 
constitutes the majority of alpha-1-globulin band, thus in AATD the band is not present. 
The absence of this band was originally noted in conjunction with early onset emphysema 
and COPD[40], suggesting a role for pathways involving AAT in pathogenesis. 
    Alpha one antitrypsin is an acute phase glycoprotein, synthesised in hepatocytes[141], 
and subsequently secreted into the plasma. It is also produced in small quantities by 
alveolar macrophages, circulating monocytes[142] and lung epithelial cells[143, 144]. 
Figure 1.6 shows the structure of AAT, highlighting some of the features that classify it 
into the serpin family of proteins. It is comprised of 394 amino acids with an active site 
residue of methionine at position 358, and a predominant target protease of neutrophil 
elastase (NE), though it can also bind irreversibly to proteinase 3 and cathepsin G. Point 
mutations in its mobile domain can lead to protein polymerisation within the liver[145], 
such that it is not secreted effectively into the plasma, resulting in low pulmonary levels 
and vulnerability to NE induced damage. Mutations like these underlie the most common 
forms of AATD. 
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Figure 1.6: The structure of alpha 1 antitrypsin, including the PiZ mutation 
AAT is part of the serpin family of proteins, thats structure is based around three beta 
pleated sheets and a reactive loop[146, 147], as shown. The function of AAT is determined 
by the active site, where NE binds irreversibly, inhibiting its function. Genetic variants 
influencing the shape, or movement, of the reactive loop where the active site is located 
are often associated with AATD, because alterations tend to allow the molecule to 
polymerise within the liver, such that there is a relative serum deficiency. 
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1.2.1 Clinical features 
     AATD is associated with COPD, emphysema, chronic bronchitis, bronchiectasis, 
neonatal jaundice, liver cirrhosis, vasculitis and panniculitis[17]. Although AATD 
represents a predisposing factor for development of COPD phenotypes, including 
emphysema, not all subjects develop pulmonary disease. Such variation in clinical 
phenotype may be due to environmental factors, such as cigarette smoking, but may also 
be influenced by other genetic factors. The evidence for genetic influences on clinical 
disease expression is discussed later in this chapter (section 1.2.3) and is the subject of the 
majority of studies contained in this thesis. 
     The diagnosis is usually made after investigation of pulmonary or liver disease, but is 
influenced by local and national practice, particularly with regard to neonatal screening. 
In countries where a screening programme exists subjects may be diagnosed at birth, 
rather than when symptoms of disease develop. Many of the symptoms of AATD are non-
specific, with subjects experiencing cough, wheeze and chest infections, contributing to 
the delay in diagnosis experienced by many, of approximately 5.6 years from onset of 
symptoms[148]. The classical presentation is with progressive dyspnoea (breathlessness), 
with or without chronic bronchitis, similar to usual COPD, though often at a younger age 
or with less smoke exposure[17]. Regression modelling in the UK AATD population 
suggests that features of emphysema may occur in late teenage years[149], in contrast to 
the usual COPD presentation in middle age (>45). In the UK current national guidelines 
suggest testing for the condition only in people under the age of 45 or with a disease 
severity inconsistent with their level of cigarette smoke exposure[8]. Cigarette smoke 
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exposure is usually quantified in pack years, one pack year being equivalent to one pack of 
cigarettes a day for a year (i.e. 20 per day). A ten pack year or more exposure history is 
seen in most subjects with usual COPD, but this is likely to be far less in AATD[17].  
     Lung function tests usually show features typical of usual COPD (section 1.1.1), such 
as airflow obstruction with or without low gas transfer, and increased static lung volumes. 
However it is not uncommon for changes more usually associated with asthma, such as 
reversibility after bronchodilators, to be seen[150]. In the NHLBI AATD registry 
reversibility of at least 12% of baseline FEV1 was present in 28% of subjects at their 
initial assessment after administration of a bronchodilating agent[150]. Normal lung 
function may also be seen, most often but not exclusively in asymptomatic subjects. 
Smoke exposure is likely to be the most important determinant of lung function, with 
differences detectable between smokers and non-smokers even at age 18 years[151], and a 
significant relationship between smoking and lung function decline in adults, with a mean 
decline per year of 70ml in FEV1 in current smokers compared to 47ml in those who had 
never smoked[152]. Other determinants of rapidly declining lung function include male 
sex, low body mass index, frequent exacerbations and the severity of upper zone 
emphysema[153]. 
     HRCT scanning is now being used more widely in the assessment of COPD and AATD 
because of advances in the interpretation of such images[154]. Scans can be used not only 
to diagnose emphysema and bronchiectasis, but also their type, distribution and 
severity[22, 154]. Emphysema distribution in AATD relates to lung function[18]. Most 
subjects with AATD have lower zone predominant emphysema on HRCT, in contrast to 
usual COPD where upper zone disease is more common. Bronchiectasis occurs in the 
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majority of subjects, often alongside emphysema, but is the predominant pathology in a 
small subgroup[22].  
     Specific tests for AATD include measuring the serum level of AAT, with a level of less 
than 11µM considered pathophysiologically important, and phenotyping (protein 
electrophoresis) or genotyping for the common disease associated variants, such as the Z 
allele – these are discussed further in section 1.2.3. 
 
1.2.2 Management 
     At present treatment for AATD depends on the individual presentation: for most 
subjects this will mean interventions targeted at COPD (section 1.1.2). Treatment 
approaches targeting the molecular basis of disease, rather than its consequences, have the 
potential to treat all aspects of the condition, and are the subject of much current 
research. Such approaches include AAT augmentation[155], blocking the polymerisation 
process within hepatocytes[156, 157] and gene therapy[158]. A recent clinical trial has 
shown AAT replacement to be beneficial in reducing emphysema progression as quantified 
by CT scanning [159]. Gene therapy is in the early phase of clinical trials, but is not yet of 
proven efficacy. Blocking polymerisation, and hence enhancing secretion into the 
circulation, remains at the in vitro stage of development at present but has the current 
drawback of undertreating the problem. Alternatively liver transplantation from an 
individual homozygous for the normal allele returns AAT levels to normal. If this is 
performed prior to the development of lung disease it offers likely protection, but can only 
be used in those with end stage liver disease at present due to the shortage of suitable 
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organs, and the implications of subsequent life-long immunosuppression. 
 
1.2.3 Genetic aspects 
     Alpha one antitrypsin is encoded by the protease inhibitor (Pi) locus on chromosome 
14q32[160-162] which is 12.2kb in length with four coding exons (II, III, IV, V), three non 
coding exons (IA, IB, IC) and six introns (Figure 1.7). The region coding for the reactive 
loop, where the binding site for NE is located, is within exon V. It has been fully 
sequenced and cloned[163] and shows a co-dominant pattern of inheritance[40]. It is a 
highly pleomorphic gene with approximately 125 single SNPs (genotypes) reported in 
public databases[164], some of which have an effect on AAT level or function.   
     Traditionally the protein product is identified by its speed of migration on gel 
electrophoresis, the most common isoforms being F, M , S and Z (fast, medium, slow and 
very slow respectively)[165]. Changes in protein charge, resulting from alterations in 
amino acid composition[166] are the cause of differential migration speeds. The protein 
isoform is often termed ‘phenotype’, though this term will be avoided in this thesis to 
minimise confusion with clinical phenotypes. Theoretically this isoformic classification 
means that different genotypes resulting in a similar protein product would be grouped 
together. Nevertheless, it is usual to refer to isoforms identified in this way so that they 
seem analogous to the underlying genotype. Thus alleles encoding a protein of medium 
speed are termed PiM, and those encoding slow isoforms PiZ. Variants may also be 
classified by their effect on AAT level and function- normal, deficient, null (nil detectable) 
or dysfunctional. This classification is seen alongside the isoform and genotypic 
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classifications, since each describe a different aspect of the genetic variation. Serum 
deficiency or absence of AAT occurs because of alterations in gene expression or 
translation, or abnormal intracellular processing[167]. Dysfunctional variants are 
abnormal forms of AAT, which whilst present at a detectable level, do not function 
normally. The F isoform is an example of a dysfunctional variant[168]. Amongst the 
dysfunctional proteins described, those associated with poor inhibition of NE may be 
associated with lung disease. An example of this is PiMmineralsprings[169] caused by a 
non-synonymous SNP (rs28931568, Gly67Glu) which also contributes to disease by serum 
deficiency due to intracellular aggregation of AAT. A different amino acid substitution  at 
the active site (unidentifiable in dbSNP, Met358Arg), known as  PiPittsburgh, not only 
leads to reduced anti-NE activity, but also to an increased anticoagulant effect by way of 
inhibition of factor IXa, kallikrein and factor XIIf[170].  However, the majority of 
clinical disease due to AAT is from plasma deficiency and null variants, some of which are 
discussed below.    
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Figure 1.7: The structure of the alpha 1 antitrypsin gene 
The gene encoding AAT is composed of 3 non coding exons and 4 coding exons, and is 
located on chromosome 14q32. There is a large intron between the non-coding and coding 
exons, and a small promoter (approximately 15kb) at the 5’end of the DNA sequence. The 
start of the transcription initiation site differs by 9bp between lung tissue and monocytes, 
suggesting a role for local control in the lung[171]. AAT expression systemically is 
regulated by synergistic action of two hepatocyte nuclear factors (1α and 4), and enhanced 
by sites induced by cytokines. Upstream oncostatin-M and IL-1 inducible enhancer sites 
are located 100bp and 13kb respectivelyfrom the 5’ end, whilst an enhancer site 1.2kb 
from the 3’ end of the final exon is induced by oncostatin-M and IL-6[172].  
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     The PiZ mutation is a non-synonymous SNP (rs28929474, Glu342Lys) which causes a 
conformational change in the reactive loop, opens up β sheet A and allows the reactive 
loop of a second molecule to insert at this point[147]. This process extends to form AAT 
polymers as inclusion bodies in hepatocytes, preventing secretion into the circulation, a 
process which has been reproduced in vitro under physiological conditions[145]. This 
process causes hepatocyte death and ultimately clinical liver disease in some subjects, 
though the precise mechanisms for this are not well understood. Additional 
polymorphisms within the AAT gene may play a role in determining susceptibility [173]. 
     In the UK the PiZZ genotype occurs in about 1 in 2000 individuals and the PiMZ 
genotype in 1 in 25 individuals[174]. In general the PiZZ genotype is that accepted to 
constitute a risk factor for both lung and liver disease[167], whilst the PiMZ genotype (a 
combination of a deficiency allele and a normal allele) probably does not in non-smokers. 
Nevertheless amongst patients with a diagnosis of COPD the PiMZ genotype has a 
prevalence up to 17.8%[175], greater than would be expected if it has no influence on 
disease expression. This might be because of interaction between the genotype and 
exposure to cigarette smoke. A meta-analysis of studies assessing risk of COPD due to the 
PiMZ genotype concluded that it represents a small riak factor, but was unable to account 
for smoking effects, or assess for gene-smoke interaction[176]. Further studies of this 
would certainly be interesting. In PiZZ subjects the expression of liver disease varies 
widely, from jaundice only at birth, through to cirrhosis, perhaps because of other genetic 
influences on this phenotype[173, 177]. Similarly variation in respiratory phenotype is 
observed even after standardisation by Pi genotype[17]. 
     Polymerisation of AAT also underlies the PiMmalton (no dbSNP[114]reference number 
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available, 52Phe deleted)[178] and Siiyama (rs55819880, Ser53Phe)[179-181] forms of 
AATD, common in Sardinia and Japan respectively. As a result the clinical effect of these 
variants is very similar to the PiZ allele. A slower rate of polymer formation occurs with 
the PiS allele (rs17580, Glu264Val), because the structural change in β sheet A is not as 
radical[182, 183], resulting in a milder serum deficiency and little evidence of clinical 
disease. The PiS deficiency variant is more common in South-West Europe than the PiZ 
variant, which is more common in Northern Europe[184].If an individual has the PiSZ 
genotype their clinical phenotype, for liver disease[183] and lung disease in smokers[185] 
is usually intermediate between PiZZ and PiSS subjects. 
     Many null allelic variants have been described which result in an absence of AAT, and 
are denoted as QO rather than Pi. These are caused a variety of alterations in the DNA 
sequence, generally resulting in the formation of premature stop codons. A deletion of a 
single base pair (bp) in exon 1, which would usually contribute to the code for a tyrosine 
residue at position 160 in the protein, leads to the QOgranite falls genotype, resulting in a 
premature stop codon and unstable mRNA[186]. Deletion of 2bp in exon IV characterises 
QOhongkong, which also has a premature stop codon, hence translates to a truncated 
protein[187], which is then retained in the endoplasmic reticulum of the liver, thus 
accounting for its absence in serum. Three other null alleles have been described, which 
also result from the formation of stop codons due to either substitution, deletion or 
addition of base(s) in coding regions[188-190]. A larger 17 bp deletion is seen in the 
QOisola di procida allele, which is so substantial that no detectable mRNA or protein is 
produced[191]. Since such genotypes do not result in accumulation of polymers within the 
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liver subjects with null alleles are not susceptible to liver disease but may be more 
susceptible to lung disease than PiZZ individuals[192]. 
 
Some of the polymorphisms discussed here are summarised in Table 1.4.  
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Allele Genetic defect Cellular defect Disease 
association 
Z 1bp substitution IC aggregation Lung, liver 
S 1bp substitution IC aggregation Lung* 
Mmalton 3bp deletion IC aggregation Lung, liver 
Siiyama 1bp substitution IC aggregation Lung 
Mprocida 1bp substitution IC degradation Lung 
Mheerlen 1bp substitution IC degradation Lung 
QOgranite falls 1bp deletion Unstable mRNA Lung 
QOhongkong 2bp deletion Truncated protein Lung 
QOisola di procida Deletion exons II-IV No mRNA Lung 
Pimineral springs 1bp substitution Poor inhibition of NE Lung 
PiPittsburgh 1bp substitution Antithrombin III activity Bleeding 
diathesis 
 
Table 1.4: Effects of genetic variation within the Pi locus 
The table shows some of the variants within the Pi locus that are associated with disease. 
All are listed by their usual allelic decriptors, rather than dbSNP references numbers, 
since this is the more usual nomenclature used. 
*The risk of lung disease due to the S allele has been demonstrated only in smokers, and 
has not been studied in SS homozygotes[193]. 
IC=intracellular. 
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     There is some evidence that other genes contribute to the clinical phenotype of AATD, 
as there is familial clustering of spirometric abnormalities in PiZZ and PiMZ subjects[58, 
194] and declining lung function in PiMZ individuals[102]. The majority of genetic 
association work in AATD has concentrated on genes thought to have an influence in 
subjects with usual COPD, working on the premise that additive genetic risk would occur. 
Case-control studies examining candidate genes in AATD have not been widely published, 
but have implicated polymorphisms in endothelial nitric oxide synthase (NOS3) and 
GSTP1[195]. NOS3 regulates platelet aggregation, leukocyte adhesion, monocyte 
chemotaxis and smooth muscle tone[196]. The NOS3 polymorphism was shown to have a 
significantly correlated with severity of lung disease, defined by FEV1 [197]. A lack of 
association with a functional variant in NOS3 suggests the presence of LD with an effect 
in a neighbouring gene.  
     GSTP1 is an antioxidant (section 1.1.3). The associated GSTP1 SNP (rs947894, 
Ile105Val) [198] increases the metabolism of carcinogenic aromatic epoxides[116], a type 
of oxidant contained in cigarette smoke.  Association studies of this variant with COPD 
have produced inconsistent results; the 105Ile variant is less active against oxidants and 
thus intuitively would be associated with higher levels of lung damage, but in AATD the 
opposite was found[195]. The study was small making a false positive result possible. A 
larger family based study has also suggested a role for variation in IL10, TNFA, 
SERPINE2 and EPHX1[199], genes which were chosen for study based on their 
suspected role in either asthma or COPD. Evidence of a functional effect was seen for 
IL10, thats plasma levels varied with genotype[199]. 
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1.3 Aims of this thesis 
     There is growing evidence that COPD is associated with a number of genetic 
predispositions, and exhibits a number of distinct sub-phenotypes. Subjects with AATD 
exhibit considerable clinical phenotypic variability, which cannot be explained by 
differences in smoke exposure. This suggests that AATD is part of the spectrum of genetic 
influences upon respiratory phenotype that interact with environmental factors to cause 
COPD. Genetic association studies in COPD, prior to the commencement of the work 
contained herein, had often been poorly replicated largely because of inadequate 
phenotyping and small datasets. Consequently, the only widely accepted genetic risk 
factor is AATD. Genetic associations in AATD have been less widely studied, being 
limited by the rarity of the condition, making recruitment of large datasets difficult. This 
thesis aims to examine selected candidate genes for association with COPD phenotypes in 
AATD, and dissect these from other clinical and environmental influences. 
 
• Chapter 2 describes the methods used for clinical phenotyping of subjects, DNA 
extraction, quantification and genotyping, and the statistical methods used for 
analysis of clinical and genetic data. It also describes the use of public genetic 
resources in study design and interpretation. 
 
• Inflammation, particularly that driven by TNFα, is key in COPD 
pathogenesis[200]. In AATD inflammation is more marked than in usual 
COPD[201] perhaps because interaction between AAT and TNFα[202] may 
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amplify TNFα effects. Chapter 3 investigates the relationship of variation within 
TNFA to clinical phenotypes in AATD, and the relationship of plasma and 
sputum TNFα levels to genotype and clinical phenotype.  
 
• A number of other genetic associations in pathways relating to inflammation have 
also been identified in usual COPD, raising the question: do the same genes 
influence phenotype in AATD? The aim of chapter 4 is to examine phenotypic 
associations for three genes that had relatively well replicated associations in usual 
COPD, namely SFTPB, TGFB and GC. 
 
• Protease driven lung damage is another key area of COPD pathogenesis. Matrix 
metalloproteases have been linked to two specific phenotypes in COPD: rapid 
decline of lung function and UZDE. Lung function decline tends to be faster in 
AATD[152], whilst UZDE is relatively uncommon. These phenotypes might, 
therefore, be of particular interest with regard to MMP genotype in AATD. 
Furthermore, a cluster of MMPs lie in an area of linkage found by a European 
study of AAT deficient discordant sibling pairs [203]. Chapter 5 details studies 
examining selected MMP variants to lung function, decline and UZDE in AATD. 
 
• The HLA region was one of the first to be studied in COPD genetic association 
work[204], but only one gene in the HLA class III region has been associated 
(TNFA). The TNFA promoter shows strong LD with HLA class II alleles, but 
these have not been investigated, despite the observation of HLA class II 
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dependent cellular responses in emphysema[205]. HLA class II and III genes show 
association with autoimmune diseases, and emphysema also shows some features 
consistent with an autoimmune response in the lung[205, 206]. Chapter 6 describes 
phenotypic associations of HLA type in AATD, and evidence of autoimmunity in 
disease pathogenesis. 
 
• Pollution, like cigarette smoke, is associated with airway inflammation and 
respiratory disease[207]. AAT provides the majority of protection from some 
pollutants, thus pollution could influence phenotype in AATD. The aim of this 
chapter was to test the hypothesis that pollution also plays a role in the 
pathophysiology of lung disease in AATD. Consideration was also given to the role 
of inhaled agents in the workplace and social deprivation.  
 
• Chapter 8 concludes the thesis. 
 61
Chapter 2: Methods 
 
2.1 Clinical phenotyping 
2.1.1 Subject selection 
     Subjects were recruited from the UK national registry for AATD, which is based in 
Birmingham, UK. This is part of ADAPT (Antitrypsin Deficiency and Assessment 
Programme for Treatment), a programme started in 1996 and funded by a non-
commercial grant from Bayer Biological (USA). Subjects were referred to the registry by 
health care professionals, including chest physicians and general practitioners, or 
identified through family screening of those related to someone with AATD. ADAPT has 
ethical approval to conduct clinical and genetic studies on registered participants (South 
Birmingham Local Ethics Committee 3359 and 3359a). Informed, written consent is 
obtained from all participants at registration, the consent forms being included in 
Appendix 1. All subjects registered with ADAPT have their diagnosis confirmed by 
genotyping (Heredilab, Salt Lake City, USA). Only Caucasians with a confirmed PiZZ 
genotype, and a stored sample suitable for DNA extraction, were selected for the studies 
included in this thesis, giving a total of 548 subjects. Subjects were divided into an 
unrelated group, for the case-control studies (n=444), and a familial group (n=104), acting 
as a replication dataset. Subdivisions in Chapter 7 differ from this, and are specified there. 
 
The procedures described in this section are those for all subjects attending ADAPT. 
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Clinical data was collected by all research fellows in the department, including me, as well 
as research nurses. Extraction of data from the ADAPT records and calculation of specific 
phenotypes for use in studies contained in this thesis was performed solely by me. 
 
2.1.2 Demographic data collection 
     At the baseline assessment a full clinical history was taken, including the symptoms 
necessary to diagnose chronic bronchitis[15] and frequency of exacerbations[208]. All 
basic demographic details (gender, date of birth, height, weight and home address) were 
recorded, alongside a full smoking history, including age started, age stopped (if relevant) 
and amount smoked per day, allowing calculation of pack year exposure (calculated by 
dividing the number cigarettes per day by 20 and multiplying by number of years 
smoked). Subjects were classified as index cases if they were diagnosed with AATD after 
investigation of their symptoms and non-index if they were diagnosed through family 
screening. This classification was of importance only in the familial replication dataset for 
the studies contained herein, but was available for all subjects. 
 
2.1.4 Lung function 
     All tests were performed in the stable state by trained respiratory physiologists within 
the Lung Investigation Unit at University Hospitals Birmingham, UK, and compared to 
predicted values derived from standard reference equations for Caucasian adults 
(Appendix 2). At the baseline visit spirometry was performed before and after nebulised 
short acting bronchodilators were given[209]. Positive bronchodilator reversibility is 
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defined as an increase of greater than 200ml and greater than 12% predicted of the forced 
expiratory volume in 1 second (FEV1)[4] and was calculated for all subjects based on this 
definition from the raw data recorded in ADAPT databases. At subsequent annual visits 
spirometry was performed only after bronchodilatation, such that changes in lung 
function over time were derived from post-bronchodilator values. Annual follow up has 
been offered throughout the period that ADAPT has been established, such that those 
registered in the early years of the programme may have up to 12 years data available, 
with correspondingly fewer years for those registered later. 
     Static lung volume measurements including total lung capacity (TLC) and residual 
volume (RV) were assessed using helium dilution[210]. Gas transfer measurements 
(DLCO) were obtained by the single breath carbon monoxide method[211]. Together these 
values were used to calculate the uptake of gas per unit of effective alveolar volume 
(KCO). All these values wre determined only after bronchodilatation. The equation used 
to calculate this, and the reference equations for predicted values are in Appendix 2. 
 
 2.1.5 Computed tomography 
     High resolution computed tomography (HRCT) scans of the chest to detect 
emphysema and bronchiectasis were acquired using Prospeed and Lightspeed scanners 
(General Electrical Systems, Milwaukee, USA) at full inspiration, with the patient lying 
prone, as described elsewhere[212]. The presence of emphysema[213] or bronchiectasis[21] 
was documented according to published guidelines and reported by a single radiologist. 
Emphysema was quantified by the same radiologist, and by previous research fellows 
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within the department, using density mask analysis at a threshold of -910Hounsfield 
Units (HU), as described previously[209, 212]. The upper zone was assessed using a slice at 
the level of the aortic arch and the lower zone using a slice at the level of the inferior 
pulmonary veins. These regions were chosen in earlier studies as they were easily 
identifiable structures, giving greater reproducibility[209]. Density mask analysis of this 
type results in upper and lower zone voxel indices (UZVI and LZVI) at -910HU. Normal 
values for this have been derived from scans of healthy non-smokers[214] and are listed in 
Appendix 2. Relative predominance of emphysema in the upper zone (UZDE) was defined 
as a scan having a visual appearance of emphysema and UZVI>LZVI, whilst lower zone 
dominant emphysema had a similar radiological appearance but with LZVI>UZVI.  
     For the studies contained in this thesis the radiological diagnoses and density mask 
analyses were extracted from medical records and added to the ADAPT databases.  
The clinical phenotypes obtained using the above data are shown in Table 2.1. 
 
2.1.6 ADAPT databases 
     The ADAPT programme comprise 2 clinical databases, the older of the two was used to 
collect data from 1996, the newer one started in 2000 to improve both the quality and 
quantity of data collected. There is also a microbiological database and a laboratory 
database containing information on the location and type of stored samples. Data was 
extracted from all four sources, and unified with a project database, set up in Access 2000 
and employing referential integrity to link all data types to individuals. Additional data 
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from CT scan reports was extracted from medical notes and intranet based hospital 
records.  
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 Phenotype Data type Derived from 
Chronic bronchitis History * 
Exacerbation frequency 
per year 
History Symptoms using Anthonisen criteria[208] 
FEV1 %predicted Lung function Raw ADAPT data and reference 
equations 
FEV1/FVC Lung function * 
KCO %predicted Lung function Raw ADAPT data and reference 
equations 
FEV1 decline over 3 years Lung function Linear regression of raw ADAPT data 
KCO decline over 3 years Lung function Linear regression of raw ADAPT data 
Emphysema Radiological HRCT reports 
Bronchiectasis Radiological HRCT reports 
UZVI Radiological HRCT reports 
LZVI Radiological HRCT reports 
Emphysema zone Radiological LZVI-UZVI 
 
Table 2.1: COPD phenotypes derived from clinical data 
*Data regarding chronic bronchitis and FEV1/FVC was extracted directly from ADAPT 
databases and did not require any calculation or transformation for the studies contained 
within this thesis. 
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2.2 Laboratory methods 
This section gives a general overview of methods used for DNA extraction, quantification, 
genotyping and other laboratory procedures. Specific details appear in the relevant 
chapters, and the composition of solutions used is in Appendix 3. 
 
2.2.1 DNA extraction 
DNA precipitation method 
     This method is a modified form of a commercially available kit (Nucleon Bacc II, 
Tepnel Life Sciences, UK) and was used for all subjects where at least 5ml whole blood, 
collected into an EDTA tube (Greiner Bio-one, UK) to prevent clotting, was available. 
Blood was mixed by inversion and transferred to a 50ml Falcon tube (BDH, UK), where 
20ml of Reagent A (Appendix 3) was added to lyse the red blood cells. This was rotary 
mixed at 170rpm for 4 minutes at room temperature, followed by centrifugation at 
2400rpm for 4 minutes. The supernatant was discarded without disturbing the white cell 
pellet and the centrifugation step repeated after addition of a further 10 ml of Reagent A. 
The supernatant was again discarded and the final cell pellet was then resuspended in 2 ml 
of Reagent B (Appendix 3) and vortexed briefly to lyse it. The cell suspension was 
transferred to a 4.5ml centrifuge tube (Alpha labs, UK), 500µl of 5M sodium perchlorate 
(Fisher Scientific, UK) added and contents mixed by inversion. Two ml of chloroform (at -
20°C) was then added and the tube was inverted 10 times by hand. The tube was 
centrifuged at 3000rpm for 10 minutes and the resulting supernatant transferred to a new 
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4.5ml cryovial (alpha labs, UK) using a Pasteur pipette, without disturbing the lower pink 
protein layer. One hundred percent ethanol (Fisher Scientific, UK) at -20°C was added to 
fill the tube, which was then inverted several times to precipitate the DNA. If the DNA 
was not visible at this point the sample was incubated at -80°C for 30 minutes prior to the 
next step. The sample was then centrifuged at 3000rpm for 10 minutes to pellet the DNA, 
and the ethanol discarded. The DNA pellet was then washed with 1ml of 70% ethanol, 
and centrifuged again at 3000rpm for 5 minutes. The supernatant was discarded and the 
pellet left to air dry for at least 3 hours before resuspension in 200µl TE buffer (Appendix 
3).  
 
Spin column method 
     This method using a commercially available kit (DNEasy, Qiagen, UK) was employed 
for subjects where only a small blood sample (<1ml) was available. All reagents and 
sample tubes required are provided with the kit. Twenty µl Proteinase K was added to a 
microcentrifuge tube, together with 100µl of whole blood. The solution was made up to 
220µl using phosphate buffered saline (PBS, appendix 3) prior to addition of the first 
buffer solution (Buffer AL), vortexing and incubation for 10 minutes at 70°C. This process 
lyses the cells to allow DNA extraction.  
     Subsequent steps were undertaken to bind the DNA to the filter in the spin column, 
and wash away other cell contents (such as proteins). Two hundred µl of ethanol was 
mixed with the sample and this mixture pipetted into a spin column, within a 
microcentrifuge tube, and spun at 8000rpm for 1 minute. The flow through and collection 
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tube were discarded and the process repeated using 500µl of buffer AW1, spinning at 
8000rpm for 1 minute, followed by 500µl of buffer AW2 and further centrifugation at 
14000rpm for 3 minutes. The DNA was then eluted from the spin column using 200µl of 
buffer AE. The column was incubated at room temperature for 1 minute and centrifuged 
at 8000rpm for 1 minute on 2 consecutive occasions to maximise the yield. 
 
2.2.2 DNA quantification 
Picogreen® method 
     The Picogreen® double stranded DNA (dsDNA) quantitation reagent is a fluorescent 
nucleic acid stain which integrates into the DNA and allows measurement of DNA 
concentrations down to 25ρg/ml using a standard spectrofluorimeter. The method relies on 
a standard curve prepared using calf thymus DNA (Sigma, UK) as shown in Table 2.2, 
and is unaffected by the presence of single stranded nucleic acids or RNA. 
     The DNA quantitation process was carried out over 2 days. On the first day 1:100 
DNA dilutions were prepared in 1.5ml sterile eppendorfs (Alpha labs, UK) using 2µl of 
DNA and 198µl TE buffer (Appendix 3). Samples were mixed by vortexing and left 
overnight at 4°C to resuspend the DNA. On the next day the process was completed, using 
96 well plates set up as shown in Figure 2.1, where rows A & B contain duplicates of the 
standard curve and rows C to H contain duplicate DNA samples to be measured. A 1:1200 
dilution of Picogreen was made by mixing 1194µl of TE buffer with 6µl Picogreen in a 
1.5ml eppendorf, which is referred to as Picogreen Solution A. This was vortexed and 
added to the blanks and standards in rows A and B. Picogreen solution B is a 1:280 
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dilution, made by mixing 7580µl of TE buffer with 20µl of Picogreen in a 30ml sterile foil 
wrapped Falcon tube (BDH, UK). This was vortexed prior to adding 95µl of Picogreen 
Solution B to each of the samples in rows C-H.  
     Plates were read at the standard fluorescein wavelength (excitation 480nm, emission 
520nm) in a spectrofluorimeter (Perkin Elmer (Wallac 1420), UK). The fluorescence value 
of the blank was subtracted from the each of the sample values, and the DNA 
concentration of each sample was derived from the standard curve. If the standard curve 
duplicates deviated by more than 20% from one another the plate was rejected and 
repeated with new standard curve dilutions. If individual paired sample readings deviated 
by more than 20% from one another they were repeated. 
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  Calf thymus DNA TE 
(µl) 
Concentration after addition of 
Picogreen® (ng/ml) 
1 4µl of 1mg/ml stock 1246 1600 
2 600µl of 1 600 800 
3 600µl of 2 600 400 
4 600µl of 3 600 200 
5 600µl of 4 600 100 
6 600µl of 5 600 50 
7 600µl of 6 600 25 
8 600µl of 7 600 12.5 
9 600µl of 8 600 6.25 
 
Table 2.2: Preparation of a standard curve for the Picogreen® method of DNA quantitation 
 
 
 1 2 3 4 5 6 7 8 9 10 11 12 
A BLANK 800 400 200 100 50 25 12.5 6.25    
B BLANK 800 400 200 100 50 25 12.5 6.25    
C S1 S1 S2 S2 S3 S3 S4 S4 S5 S5 S6 S6 
D S7 S7 S8 S8 S9 S9 S10 S10 S11 S11 S12 S12 
E S13 S13 S14 S14 S15 S15 S16 S16 S17 S17 S18 S18 
F S19 S19 S20 S20 S21 S21 S22 S22 S23 S23 S24 S24 
G S25 S25 S26 S26 S27 S27 S28 S28 S29 S29 S30 S30 
H S31 S31 S32 S32 S33 S33 S34 S34 S35 S35 S36 S36 
 
Figure 2.1: Arrangement of 96 well plate for Picogreen® DNA quantitation 
Blank = 50µl TE, Rows A-B 2-9 = 50µl of prepared standards, at the given concentration 
(ng/ml), Rows C-H = 5µl of each sample in duplicate. 
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2.2.3 Polymerase chain reaction 
This section provides an overview of the principles of the technique, with specific details 
of the compositions of each reaction, specific methods and cycling conditions appearing in 
relevant chapters.  
 
     The polymerase chain reaction (PCR) amplifies a segment of DNA between regions of 
known nucleotide sequence. Two oligonucleotides are used as primers, which are different 
in sequence and complementary to the sequence on the opposite strand of the DNA 
template flanking the segment of interest. This allows amplification of the area of interest 
which lies between the primers. The other components of the reaction are 
deoxyribonucleotide triphosphates (dNTPs), Taq polymerase, magnesium chloride (MgCl2) 
and a buffer. Template DNA is denatured at 95°C, and cooled to allow annealing of the 
primers to the template DNA. The action of Taq polymerase then amplifies the segment of 
interest through addition of complementary dNTPs, and the cycle is repeated many times, 
with the product of each cycle acting as the template for the next. This process is 
illustrated in Figure 2.2. Each PCR reaction should be optimised both in terms of the 
amount and concentration of its components and the thermal cycling conditions. 
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Figure 2.2: The polymerase chain reaction 
Double stranded DNA is denatured at 95°C, to form single stranded DNA. The 
oligonucleotide primers can anneal to the exposed areas where their sequence is 
complementary, the temperature at which this occurs being dependent on the 
oligonucelotide sequence. When Taq polymerase is present it amplifies the region between 
the primers, the optimum temperature for being 72°C. The end result is an amplified 
amount of the DNA of interest. 
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Oligonucleotide primers 
     Primers are designed so that they are complementary to the template DNA flanking 
the segment of interest. The technique, therefore, requires knowledge of the nucleotide 
sequence. Access to relevant information has become easier with the advent of a number 
of online public genetic databases that catalogue sequences and known SNPs within the 
human genome, including services hosted by the National Centre for Biotechnology 
Information (NCBI), such as Entrez SNP[114], and Ensembl[215], hosted by the 
Wellcome Trust and the Sanger Institute. Both of these resources were used for studies 
within this thesis.  
     In general primers are between 20 and 30 base pairs in length, and should have <50% 
GC content in order to avoid high annealing temperatures (Tm). Primer pairs should have 
a similar GC content, whilst being non-complementary, to decrease the formation of 
primer dimers. For the HLA studies contained in Chapter 6 the primer sequences had 
already been determined and published elsewhere[216]. In fluorescence based PCR 
techniques, such as TaqMan®, the primers have a fluorescent marker attached which is 
cleaved during extension by Taq polymerase. This then emits a signal detectable and 
quantifiable by fluorimetry. This technique was used for most of the SNP genotyping 
studies within this thesis, and as such there were 2 fluorescent signals per reaction to 
detect the two possible alleles present within a diallelic SNP - these being named VIC and 
FAM, and allocated by the manufacturer of the primers. The highest VIC signal 
represents homozygotes for one allele, the highest FAM signal homozygotes of the other 
allele and those of an intermediate level represent heterozygote DNA. Both signals are 
 75
read by fluorimetry based techniques which produces plots on which the signal from each 
subject can be visualised (see results in chapters 3, 4 and 5). This system works well with 
low DNA concentrations, such that all samples were diluted to a fixed concentration of 
20ng/µl for the studies reported in this thesis. The manufacturers of TaqMan® genotyping 
technologies (Applied Biosystems) both prepared and optimise the primers based on 
sequence supplied to them by me, and the precise primer sequence was not released to me. 
      
MgCl2 concentration 
     Buffers used in PCR are at the optimum at pH (8.3) for Taq polymerase activity, 
however the pH of the reaction falls to 7.2 when incubated at the extension temperature 
(72°C) such that the presence of divalent cations is critical. Magnesium cations are the 
most effective, although the concentration required varies between reactions, dependent 
on the primer pairs used. Optimisation can be achieved by performing an assay at 
concentrations from 0.5-4.0mM. This step was not necessary for the studies contained 
herein, as all reactions worked well under the published conditions for HLA[216] and for 
the TaqMan® studies the PCR reagents were supplied pre-mixed by Applied Biosystems. 
 
dNTP concentration 
     Deoxyribonucleotide triphosphates (dNTPs) are present to allow synthesis of the new 
DNA during PCR. Usually they are used at a concentration of 200µM, which is sufficient 
to synthesise 12.5µg of DNA when half the dNTPs are incorporated. An increased 
concentration may increase the efficiency of the PCR, but can also increase the error rate 
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of Taq polymerase, or even inhibit it. Alterations in dNTP concentration also affect the 
optimal MgCl2 concentration required. No alteration of published conditions was required 
for HLA genotyping[216] and for the TaqMan® studies the PCR reagents were supplied 
pre-mixed by Applied Biosystems. 
 
Taq DNA polymerase 
    This enzyme catalyses the PCR and amplifies the product. As such increasing 
concentrations increase the efficiency of the reaction, although this must be balanced 
against the risk of producing non-specific PCR products alongside the area of interest. No 
alteration of published conditions was required for HLA genotyping[216] and for the 
TaqMan® studies the PCR reagents were supplied pre-mixed by Applied Biosystems. 
 
Reagent purity 
     A blank sample containing all components except DNA was run alongside each PCR to 
confirm the lack of PCR product, adding validity to positive results. If a PCR product was 
detected in the blank it indicated that contamination of the reagents had occurred; results 
from the same reaction were discarded and PCR repeated with fresh reagents. 
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Thermal cycling conditions 
Denaturation 
     This separates the dsDNA template into single strands and was achieved by incubating 
the PCR mixture at 94°C for between 30 and 60 seconds (sections 3.2.2 and 6.3.2). Higher 
temperatures can decrease the activity of Taq polymerase, which must be taken into 
consideration when designing an assay. 
 
Annealing 
     This step was used prior to extension and took 30 to 60 seconds to enable primers to 
anneal completely and stabilise the template DNA. The temperature at which the primer 
anneals can be estimated from the following equation 
 
Tm =4(GC) + 2(AT) 
 
Tm = annealing temperature 
A, T, G and C = adenine, thymine, guanine and cytosine, the nucleotide bases 
 
Tm, therefore, varies directly with the GC content of the primer. In the case of PCR 
reactions containing multiple primers, like those for HLA typing (section 6.3.2), primers 
had similar annealing temperatures.  
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Extension 
     This occurs at 72°C, which is close to the optimal temperature for Taq polymerase 
action (75°C) but prevents detachment of the primers from the template. The duration 
depends on the length of the sequence to be amplified, though 1 minute per 1000bp is 
usually sufficient. The TaqMan® PCR technique combines the annealing and extension 
steps (section 3.2.2). 
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2.2.4 Gel electrophoresis 
     Agarose gel electrophoresis was used to visualise the PCR products for the non-
TaqMan® genotyping techniques, namely HLA typing. Gels were prepared at a 
concentration appropriate to the size of the product generated using electrophoresis grade 
agarose (Sigma, UK). All gels were made with an appropriate buffer (TBE, Appendix 3) 
and run in an electrophoresis tank filled with the same. The agarose was dissolved in the 
buffer by warming in a microwave and allowed to cool prior to addition of ethidium 
bromide (Sigma, UK) to aid visualisation, as it cross links DNA and fluoresces under UV 
light, which is used to view the results. The gel was then poured into a casting tray with 
combs and allowed to set. Once set the gel was placed in the electrophoresis tank, samples 
were mixed with a loading dye (see appendix 3), electrophoresed and visualised under UV 
light. Photographs were taken to record results.   
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2.2.5 Enzyme linked immunoadsorbent assay (ELISA) 
     This technique was used to measure TNFα and anti-elastin antibody levels. This 
section describes general methods for an ELISA; the specific process for the TNFα assay 
and anti-elastin antibody assay are given in the relevant chapters (sections 3.3.2 and 6.3.4 
respectively) 
      
     A quantitative sandwich enzyme linked immunosorbent assay (ELISA) is illustrated in 
Figure 2.3. The amount of measured substance is quantified by means of comparison to a 
standard curve, this being set up using samples of known concentration, such that 
unknown samples are expressed relative to this. The final colour generating step must be 
stopped at a given time point (specific to the ELISA performed) prior to reading the plate 
in a standard microplate reader. All ELISA measurements were run in duplicate on 96 
well plates, the set-up of the plates being similar to that shown for Picogreen 
measurements of DNA concentration (Figure 2.1). 
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 (1) Capture antibody or antigen is bound to the plate 
(2) Sample is added, and the corresponding antigen or 
antibody binds to that coating the plate 
(3) Detecting antibody is added, and binds to the 
antigen 
(4) Enzyme linked secondary antibody is added, and 
binds to the detecting antibody 
(5) Substrate is added, and is converted to a detectable 
signal by the enzyme 
 
Figure 2.3: The process of a sandwich ELISA 
Microplates are coated with a specific antibody or protein (1) to bind the corresponding 
protein present in the samples (2). Unbound substances are washed away, and a 
polyclonal antibody specific to the protein being measured is added to the plate (3). A 
second wash removes unbound antibody and an enzyme linked antibody specific for the 
primary antibody is added (4), followed by an amplifier solution which develops colour in 
proportion to the amount of measured substance present (5). The reaction is stopped by 
addition of a stop solution (usually an acid); plates are then read using a microplate 
reader. 
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2.2.6 Quantitative sputum culture 
     Bacterial colonisation status was required for studies reported in chapters 3 and 4 of 
this thesis. Some quantitative sputum culture results were already recorded in ADAPT 
databases. Fresh stable state sputum samples were also obtained from subjects who 
spontaneously produced sputum and attended ADAPT for assessment. Bacterial 
colonisation was taken to be >1 x 105 colony forming units/ml (cfu/ml) of recognised 
respiratory pathogens in a stable state sample.  
 
Quantity of organisms 
     One gram of sputum was taken from the samples and homogenised by addition of an 
equal volume of dithiothreitol (Sputasol, Oxoid, UK) and vortexing for 60 seconds. Serial 
dilution of the sample was carried out using a pipette to remove 100µl, which was added to 
an appropriate volume of distilled water (Baxter, UK) to create dilutions starting at 1:10 
and continuing to 1:1000000. Each dilution was vortexed prior to use and 10µl of neat or 
diluted sample was spread onto chocolate agar plates (Oxoid, UK) using a sterile plastic 
‘hockey stick’ (Appleton Woods, UK) in the 4 zone streak method, illustrated in figure 2.4. 
The 1:10000 dilution was also added to a blood plate (Oxoid, UK) to aid subsequent 
species identification. Plates were incubated at 37°C for 24-48 hours and the number of 
colonies counted from the most appropriate dilution (a plate with no more than 300 
colonies). The number of colony forming units per ml (cfu/ml) was then calculated based 
on the dilution of sample on the plate. 
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2 1 
 
Figure 2.4: Plating of sputum samples 
The four zone method ensures even spreading of the sample across the plate, such that 
most colonies are in zone 1 and progressively fewer down to zone 4.  
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Identification of organisms 
     The predominant organisms were identified using the appearance of the colonies, 
microscopy (identifying bacterial morphology), Gram stain and a series of functional tests, 
usually performed in the order in which they are listed here. Further physiological testing 
was carried out by a microbiologist if needed. The features seen with some common 
respiratory pathogens are shown in Table 2.3. 
 
Gram stain identification of bacteria 
     Gram positive bacteria have a thick cell wall containing a high proportion of 
peptidoglycans (50-90%), whilst Gram negative bacteria have a thinner cell wall 
containing much less of these substances (around 10%). A small amount of sputum from 
the sample was smeared onto a clean microscope slide (Appleton Woods, UK) and allowed 
to air dry for a few minutes. This was stained by addition of crystal violet (Biomerieux, 
UK), which was allowed to act for 1 minute and rinsed with tap water prior to addition of 
Lugol’s solution (Biomerieux, UK). This was left for 1 minute then washed off prior to 
decolourisation with ethanol (Fisher Scientific, UK). Finally a counter stain (Safranin, 
Biomerieux, UK) was added. Gram positive organisms retain the crystal violet based 
complexes within the cell due to the high peptidoglycan content of the cell wall, thus 
appear purple. The violet coloured complexes are washed out of Gram negative cells by 
the ethanol, and then appear pink due to the counterstain. This was visualised using a 
microscope and the results noted into the ADAPT microbiology database. The microscope 
did not have the facility to photograph magnified samples. 
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Functional tests 
     The following list is not an exhaustive list of the functional tests that are performed 
but contains those needed to identify the common respiratory pathogens. The results of 
the oxidase and catalase tests, together with colony appearance, with or without a Gram 
stain result (see also Table 2.3) guided the specific tests of bacterial species listed by the 
bacterial name. 
 
Oxidase test  
     This identifies bacterial species able to oxidase tetramethyl-sp-phenylene-diamine-
dihydrochloride (BDH, UK), such that when a colony was added to a drop of this solution 
the colour changed from colourless to purple.  
 
Catalase test  
     This identifies bacterial species able to reduce hydrogen peroxide (BDH, UK) such that 
bubbles of hydrogen were seen if a colony was added to a drop of this solution.  
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Characteristic Growth on 
agar  
Colony appearance  Gram 
stain  
Cell morphology Oxidase 
test 
Catalase 
test 
Other tests 
Haemophilus 
influenzae 
Chocolate Small, grey, translucent Negative Small 
coccobacilli 
Negative Negative X & V 
Moraxella 
catarrhalis 
Chocolate 
Blood 
Opaque, small,  white, dry, pushes 
along agar surface 
Negative Large diplococci Positive Positive Tributyrin 
Pseudomonas 
aeruginosa 
Chocolate 
Blood 
Mucoid or rough, usually colourless, 
green haemolysis of blood agar 
Negative Bacilli Positive Positive Cetrimide 
plate 
Streptococcus 
pneumoniae  
Chocolate 
Blood 
Dark green, green haemolysis, 
draughtsman colonies 
Positive Diplococci Negative Negative Optochin 
Staphylococcus 
aureus  
Chocolate 
Blood 
Large, yellow, relatively small area 
of haemolysis 
Positive Clusters of cocci Negative Positive Agglutination 
β-haemolytic 
Streptococci 
Chocolate 
Blood 
Small, dry, white, large clear 
haemolytic zone 
Positive Chains of cocci Negative Negative - 
 
Table 2.3: Identification of common respiratory pathogens by their appearance and functional testing 
The table shows the preferred growth medium, colony appearance, microscopic appearance after Gram staining and basic functional test 
results for selected respiratory pathogens.
Haemophilus spp 
    X and V factor testing was used to identify Haemophilus spp. X factor is comprised of 
protoporphyrin IX, haemin or other iron containing porphyrins. X dependent strains are 
unable to convert d-aminolaevulinic acid to protoporphyrin, thus require this factor for 
growth. V factor comprises nicotinamide adenine dinucleotide (NAD) or nicotinamide 
adenine dinucleotide phosphate (NADP)2. Both factors are present in blood, so care must 
be taken to avoid carryover of blood from the original plates when picking the colony for 
testing. Testing was performed by placing discs containing either or both factors (Oxoid, 
UK) onto agar, to which the colony to be identified was applied. H.influenzae (a common 
respiratory pathogen) requires both factors for growth, thus colonies will appear only 
around the disc containing both.  
 
Streptococcus pneumoniae 
     The optochin test was used for Streptococcus pneumoniae. This detects susceptibility to 
ethylhydrocupreine hydrochloride (optochin) and differentiates S. pneumoniae from other 
α haemolytic Streptococci. The bacterial cell membrane of S.pneumoniae lyses in the 
presence of optochin due to changes in surface tension. The test was performed by 
applying a paper disc impregnated with optochin (Oxoid, UK) to an inoculated agar plate, 
and if positive a zone of inhibition was seen around the disc. 
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Pseudomonas spp 
     Suspected Pseudomonas spp were grown on cetrimide plates (Biomerieux, UK). Most 
non-Pseudomonas species will not grow on this medium. These plates identify P.aeruginosa 
because only this species of Pseudomonas produces pyocyanin, a blue-green pigment, and 
fluoresces under UV light.  
 
Staphylococcus aureus 
     Specific agglutination kits (Biomerieux, UK) were used to identify Staphylococcus 
aureus (Figure 2.6) using colonies emulsified in normal saline (added to the two reagents 
provided.  
 
Moraxella spp 
     The tributyrin hydrolysis test was used to identify Moraxella spp. Oxidase and catalase 
positive colonies of suggestive morphology can be distinguished from Neisseria spp by this 
test which detects the enzyme butyrate esterase, present in Moraxella spp, but not 
Neisseria spp. Some colonies were emulsified in water, sufficient to create a cloudy 
solution, to which a tributyrin tablet (Bioconnections, UK) was added. Initially this 
causes the solution to go peachy-white in colour. If Moraxella spp are present it will turn 
yellow, usually within twenty minutes, though samples were left for several hours to avoid 
false negatives. 
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Figure 2.5: Positive agglutination test 
A positive result is indicted by the appearance of agglutination with solution 1. A negative 
result would have the same appearance with both solutions as shown here for solution 2. 
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2.3 Statistical analysis 
All data with the exception of that for familial genetic association, haplotype associations 
and HLA type associations were analysed using SPSS version 12 (SPSS Inc, Chicago, 
USA).  
 
2.3.1 General statistical tests 
     Studies reported have generated data pertaining to a variety of COPD sub-phenotypes 
(described in section 1.1.1), TNFα levels in both plasma and sputum, and anti-elastin 
antibody levels, as well as genetic polymorphisms. Thus, for each chapter it has been 
necessary to describe the cohort studied, and then compare subgroups. In each case data 
normality was assessed using the Kolmogorov-Smirnov test. Parametric data has been 
displayed as mean with standard error (SE) and non-parametric data as median with 
inter-quartile range (IQR). Subgroup comparisons between clinical phenotypes and 
genotypes were made using the t-test, Mann-Whitney or Kruskal-Wallis test as 
appropriate. Spearman’s test was used for continuous correlations where the distribution 
of data was non-normal and Pearson’s for normally distributed data. Frequency 
comparisons were made using the Chi squared (χ2) test.  
    Linear regression was used to calculate decline in lung function. Subjects were included 
for the genetic studies if they had at least 4 data points in the regression: a baseline and 3 
subsequent values. Other methods of considering decline for pollution analyses are 
described in Chapter 7 (section 7.3.2). The slope of the resultant regression line was used to 
indicate decline in the given lung function parameter per year. Those variables that were 
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non-normally distributed within the group were transformed appropriately prior to use in 
subsequent regression models assessing influences on this phenotype.  
     Statistical significance was taken as p<0.05. Where correction for multiple statistical 
testing was appropriate a Bonferroni correction was used. However, all values of genetic 
studies are reported uncorrected, since this type of correction may be too conservative in 
this type of study[68]. Genome wide significance was accepted as p<5 x10-5 [68]; though 
more stringent cut off values have been proposed by some groups[217]. Where genome 
wide significance was not reached in the case-control genetic association analyses the 
studies were repeated in a replication dataset of AATD sibling pairs. This is a recognised 
method of confirming the significance of a genetic association in complex disease[68]. 
       
2.3.2 Genetic association studies 
     For the genetic studies reported within this thesis the majority of analyses were carried 
out using haplotype tagging SNPs. Methods relating to their selection, prior to the actual 
analyses performed are discussed below. 
 
Choice of haplotype tagging SNPs 
     The HapMap is a catalogue of common genetic variation in different ethnic groups 
(originally, and on the build of HapMap used herein, in just four races: Caucasians, 
Japanese, Chinese and Africans)[70]. Haplotype blocks are present throughout the human 
genome because of the limited number of recombination sites present in human DNA. 
During meiosis chromosomal strands can cross over such that pieces of DNA are swapped, 
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resulting in a hybrid chromosome composed of parts of each original chromosome. Genetic 
variants, such as SNPs, vary in their frequency between racial groups, as does the 
structure of resulting haplotype blocks. Genes can be broken down into component blocks, 
each of which will contain a number of SNPs, at known frequencies. Since these SNPs will 
be inherited together (in LD) if they are in the same haplotype block, it is only necessary 
to genotype 1 SNP per block. This is illustrated in Figure 2.6. A SNP that marks a block 
in this way is known as a tag SNP. Tag SNPs can be chosen using programmes within 
HapMap, for the specified racial group, setting limits for the minor allele frequency (MAF) 
you wish to detect and the level of correlation between SNP pairs. For tags in strong LD 
the r2 between them will be at least 0.8 (see section 1.1.4) and it is this value that identifies 
the blocks. Conversely values of r2 between 0.2 and 0.8 indicate incomplete LD and values 
<0.2 no LD. This may be visualised by the use of LD plots which show areas of high r2 in 
red and low LD in white. Examples of such plots obtained for studies within this thesis 
can be seen in chapters 3-5. 
     For all the tag SNP studies in this thesis a cut off of MAF = 5% (0.05) and r2 >0.8 were 
chosen and tags identified in HapMap build 35. HapMap output files detail the reference 
SNP[114] number of the tag, and those that it captures within the haplotype block. Using 
this algorithm a total of 38 tags were chosen to cover the following candidate genes: GC, 
SFTPB, TGFB, MGC4093, CCDC97, MMP1, MMP3 and MMP12. For each block the 
tag with the highest MAF was chosen, where possible, in order to improve the power of 
the study (see appendix 4). At the time of the studies reported here HapMap had not fully 
reported all genes, such that some known SNPs within the literature were not reported 
there. This was most notable for TNFA  and thus other published resources were used for 
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studies of this gene[218]. Details of the tags explored in this series of studies, and the 
number of captured SNPs, are shown in Table 2.4. 
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Figure 2.6: The formation of haplotype blocks and concept of tagging a block 
During meiosis chromosomal segments may cross over (1) resulting in the formation of 
gametes with different combinations of genotypes (2). This process is repeated over many 
generations (3). HapMap provides information about the current haplotype blocks present 
for any given chromosome (4), by genotyping of SNPs within them. For any given block 
there will be a number of SNPs present, illustrated by lines (5), the colour indicating the 
allele present, any of which might be chosen as a tag. In this case the tag SNP chosen has 
been marked by showing the SNP with a thicker line. 
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 Gene Tag SNPs Number of captured SNPs 
rs222035 rs2070741 
rs1491718 rs705117 
rs222023 rs1352844 
rs2298849 rs3733359 
GC 
rs222029 rs3755967 
28 
SFTPB rs2118177 rs1130866 3 
rs8110090 rs11466338 
rs4803455 rs11466345 TGFB 
rs8179181 rs1800469 
6 
MGC4093 rs11083616  3 
rs8109627 rs1041794 
CCDC97 
rs8109167  
9 
rs470747 rs7125062 
rs996999 rs3213460 
rs7125320 rs5031036 
MMP1 
rs470358  
13 
rs678815 rs3025066 
MMP3 
rs476762 rs650108 
14 
rs476185 rs11225442 
rs652438 rs17368659 MMP12 
rs632009  
13 
rs1800629 rs1799964 
TNFA 
rs361525 rs3093662 
8 
 
Table 2.4: Tag SNPs covering selected candidate genes 
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Genetic association analyses 
     Deviation from Hardy-Weinberg equilibrium (HWE) was checked for all SNPs 
(Appendix 4). This is a crude measure of genotyping error, as well as being an indicator of 
the stability of a SNP between generations. A SNP not in HWE may represent a 
genotyping error, particularly if this is seen in control subjects. It is possible for deviation 
from HWE to occur in cases if the SNP adversely affects survival, and procreation, but 
this is less common than problems of genotyping. Those that were not in HWE were 
excluded from further analysis in the studies contained herein.  
     The power of the study to detect phenotypic differences between groups was calculated 
for qualitative phenotypes, prior to adjustment for covariates, based on the genotype 
frequencies obtained (Appendix 4).  
     Primary comparisons were made against AATD subjects without the phenotype for 
which association was sought. All AATD subjects were UK Caucasian, thus controlling for 
racial genetic variation. 
 
Case-control multiple regression analyses 
     Binary logistic regression was used to test for independent predictors of qualitative 
phenotypes, with genotypes coded as a categorical variable for genotypic association, 
effectively being a general genetic model. A dominant model was also constructed with 
coding of 1 or 0 to indicate presence or absence of the minor allele. The OR of disease 
conferred by the associated allele or genotype was indicated by the B value in these 
regressions. Stepwise linear regression was used to test for independent predictors of 
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quantitative phenotypes. The B value from the regression indicates the amount of change 
in the outcome variable if the predictor is increased by 1 unit and all other features remain 
constant, whilst the r2 value indicates the proportion of variation in the outcome variable 
attributable to the predictor. It should be noted that in a regression the r2 is not the same 
as that derived from correlations, such as those used to ascertain LD, even though the 
annotation is identical, so this has been clarified where needed. 
 
Haplotype analyses 
     Haplotype analyses were carried out in Haploview[219] for qualitative phenotypes 
only, between affected and unaffected AATD subjects. Where they were required for 
quantitative outcomes the haplotypes were identified in Haploview and the association 
analyses performed in SPSS using coding of each haplotype in a general model in the same 
manner as the regression analyses above. 
 
Familial genetic association 
Theory 
     Genetic data from related individuals cannot be analysed in the same way as a 
standard case-control association study, since affected and unaffected family members will 
share a proportion of alleles due to common ancestry. In the UK ADAPT databases there 
are a number of sibling pairs, who comprise the replication dataset for the larger case-
control studies contained within this thesis. Sibling pair genetic studies are ‘model free’; 
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the rationale being that an excess of disease causing alleles will be seen in affected family 
members regardless of the mode of inheritance. The first step is to calculate the proportion 
of alleles identical by descent (IBD). This can be used to assess qualitative or quantitative 
phenotypes, the latter having been chosen where possible for the studies in this thesis. The 
basis of this is to regress the squared difference in the trait value between siblings on the 
proportion of alleles IBD[220]. Two siblings that share more alleles IBD would be 
expected to have more similar trait values if the alleles were influencing the phenotype. 
Consequently there would be a negative relationship between the squared trait differences 
and the IBD sharing. Since this is a linear regression covariate effects can be taken into 
account as they would in any stepwise regression, and interactions between covariates 
(including genes) can be specified with most software packages. 
Sibling pair trait analyses 
     All analyses were carried using the software package Statistical Applications in Genetic 
Epidemiology (S.A.G.E.)[221]. The GENIBD function was used to generate IBD sharing 
distributions, the output file indicating the probability of each pair sharing 0, 1 or 2 alleles 
IBD. This file was then used for trait analysis using the SIBPAL function. The output file 
generated indicated significance for each predictor in the analysis and the direction of 
association, the latter being determined by the t statistic. 
  
HLA region analyses 
     HLA class II loci are multiallelic; as such the methods described for coding genetic data 
in SPSS for regressions could not be used. Analyses were carried out using stata version 10 
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(www.stata.com) specifying a multiplicative model, and using routines available from 
www-gene.cimr.cam.ac.uk/clayton/software/stata to test for deviations from HWE. 
Linear regression was used for pulmonary function (FEV1, FEV1/ FVC and KCO) and 
logistic regression for emphysema, adjusting for smoking, age and gender. Locus 
associations were tested first. The alleles were then categorised within the regression to 
obtain individual allelic associations, in each case setting the most frequent allele as the 
comparator against which the likelihood ratio was calculated and grouping at the 1% 
frequency level. Further detail is given in Chapter 6. 
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Chapter 3: Phenotypic associations of TNFα and TNFA in 
AATD 
 
3.1 Aims of this chapter 
This chapter will detail the COPD phenotypes observed in AATD and the phenotypic 
associations TNFA variation, and of circulating and sputum TNFα levels in such 
subjects. Independent effects of TNFA variants on circulating and airway levels of TNFα 
will then be described. 
 
The introduction, methods and results for TNFA and TNFα will be presented in sub-
sections specific to genetic association, and protein associations with clinical phenotype, 
prior to an analysis of protein level associations with genotype which utilises results from 
both preceding sub-sections, prior to an overall conclusion for the chapter. Much of the 
data presented here has been published in a peer reviewed journal (Appendix 7). 
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3.2 TNFA 
 
3.2.1 Introduction 
      TNFA, which encodes TNFα, is located on chromosome 6p21.3, and is situated within 
the HLA class III region, illustrated in Figure 3.1. TNFA is composed of 4 exons arranged 
over approximately 3kb of DNA[222], as shown in Figure 3.2. Regulation of TNFα 
production at the transcriptional level is controlled by several regulatory sequences at the 
5’ end of the gene, including sequences for the activator proteins 1 and 2 sites and a cyclic 
adenosine monophosphate (cAMP) responsive element[223]. The 3’ untranslated region 
also contains a sequence which affects mRNA stability and therefore subsequent 
translation efficiency[223]. SNPs affecting these sequences have the potential to alter the 
production of TNFα, which if present in excess might drive the inflammation seen in 
COPD. 
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Figure 3.1: The HLA region 
This is a simplified diagram of the HLA region on chromosome 6p21. Detail of key genes 
in each class is shown, with class III expanded.  
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Promoter region 
rs361525 
G-238A 
rs1799964 
T-1031C 
5’ 3’ 
A851G 
rs3093662 
Exons 
rs1800629 
G-308A 
 
Figure 3.2: The structure of TNFA  
The structure of the gene is shown, together with the SNPs studied in this chapter. The 
original SNP descriptors are shown beneath the current reference SNP numbers, for ease 
of comparison with prior published work.
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TNFA in COPD and AATD 
     TNFA has been investigated in several COPD phenotypes[72, 105-107, 224, 225], 
predominantly with selected SNP work[105-107, 224, 225], though one study used tag 
SNPs to screen the whole gene for association[72]. These studies have defined their cases 
by FEV1 and FEV1/FVC diagnosed COPD[72, 105, 224], presence of emphysema[106, 
225] and chronic bronchitis[107]. The associations have been poorly replicated, perhaps 
because of these differences in patient characterisation, or because of low numbers of 
patients in each study. LD with HLA alleles[226] and racial variation may also have 
contributed[227]. If an association is actually due to an allele with which it exhibits a 
degree of LD some studies may show the association and others, perhaps where the 
population have a different degree of LD, may not.  Similarly racial differences may affect 
the distribution of SNP genotypes, a fact which prompted the genotyping of four racial 
groups in the studies underying HapMap. A recent meta-analysis concluded that a 
promoter region SNP (rs1800629, G-308A) is significantly associated with COPD[228], but 
the validity of this may be questioned as it pooled results from studies that defined their 
COPD subjects using differing criteria.  
     In AATD there is significant variation in the clinical phenotype. Both familial and 
non-familial studies suggest that, as in usual COPD, other genetic influences may be 
important in determining clinical features[194, 195, 197, 199], but no studies have 
examined the role of candidate genes in the full range of COPD phenotypes previously 
associated with TNFA polymorphisms.  Furthermore, the interaction between AAT and 
TNFα might magnify any effect of TNFA polymorphisms in AATD. Epistatic effects 
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explicable by cytokine interactions, such as this, are also seen in asthma when multiple 
polymorphisms in genes involved in the Th2 immune response magnify the risk of asthma 
phenotypes[229]. For instance, both interleukin-13 (IL13) and interleukin-4 (IL4),  
produced by Th2 cells, are capable of inducing B lymphocytes to produce IgE after 
allergen exposure and share a common receptor component, interleukin-4 -receptor alpha 
(IL4Rα)[229]. The presence of associated alleles of single SNPs with asthma phenotypes 
(such as bronchial hyperresponsiveness) in IL4RA and IL13 together in an individual was 
found to increase the risk of asthma relative to either associated allele being present 
alone[229]. 
 
3.2.2 Methods 
Subjects 
      Four hundred and twenty four unrelated UK Caucasian subjects with the PiZZ 
genotype of AATD were studied in the initial case-control study. Although phenotypic 
information and blood had been stored on a further 20 subjects, the samples of blood on 
these subjects were so small as to yield insufficient DNA for genotyping of all SNPs and 
were therefore excluded from further analyses. Subjects’ characteristics, with additional 
stratification by the phenotypes described in chapter 2 (section 2.1 and Table 2.1) are 
shown in Table 3.1. The frequency and degree of phenotypic overlap for the qualitative 
phenotypes is illustrated in Figure 3.3. It should be noted that only 82% of subjects 
underwent a CT to formally diagnose emphysema, and as such the number of subjects for 
whom CT derived diagnostic information is available is less than that for lung function. 
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Similarly annual lung function data with 4 data points over 3 years, providing data for 
annual decline, was only available for a sub-set of subjects, so the number for this analysis 
is again smaller. 
     Subjects with emphysema had worse lung function and greater smoke exposure 
compared to those without emphysema (all p<0.001). There was no difference in smoke 
exposure, lung function or UZVI between those with and without bronchiectasis, though 
affected subjects were older (p<0.001). Bronchiectatics had more severe lower zone 
emphysema, (p=0.026), than those without bronchiectasis. Subjects with chronic 
bronchitis had lower FEV1 (p=0.013) but no other demographic or clinical feature differed 
from those without bronchitis. There were no gender differences between those with and 
without each of the qualitative phenotypes.  
     Seventy two sibling pairs were studied as a replication dataset; samples suitable for 
DNA extraction were only available on 52 pairs, thus comparison of genotypes was only 
possible in this smaller group. The characteristics of the siblings are shown in Table 3.2. 
Significant differences were observed between index and non-index siblings in that index 
siblings tended to have worse lung function and a higher incidence and severity of 
emphysema. There was no difference in the incidence of chronic bronchitis between 
siblings. 
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Emphysema Bronchiectasis Chronic bronchitis  Whole group 
n=424 Yes n=279 No n=70 Yes n=83 No n=266 Yes n=159 No n=265 
% of subjects of male 
gender 
59.91 64.16 54.29 57.83 63.67 64.78 57.03 
Age in years 50.01 (0.52) 51.76 (0.78) 41.52 
(33.77-49.27) 
54.18 (1.03) 48.90 (0.63) 50.79 (0.77) 49.48 (0.69) 
Pack years 14.00 
(2.35-25.65) 
17.50 
(7.65-27.35) 
0 
(0-4.18) 
14.63 
(4.33-25.93) 
13.50 
(1.40-24.60) 
14.63 
(2.55-26.71) 
12.75 
(0.75-24.75) 
FEV1 %predicted 37.15 
(18.30-56.04) 
32.08 
(18.94-45.22) 
102.88 
(80.93-124.83) 
36.64 
(14.59-58.69) 
35.54 
(17.39-53.69) 
32.76 
(15.49-50.03) 
38.17 
(14.18-62.16) 
FEV1/FVC 38.40 
(25.95-50.85) 
35.00 
(26.00-44.00) 
73.60 
(63.10-84.10) 
40.10 
(24.35-55.85) 
37.50 
(25.00-48.00) 
37.85 
(26.85-48.85) 
39.40 
(26.40-52.40) 
KCO %predicted 69.82 (1.18) 63.18 (1.38) 98.66 (2.55) 67.85 (2.75) 70.57 (1.54) 67.62 (2.31) 71.34 (1.89) 
UZVI 31.09 (1.05) 32.71 (1.02) 2.31 (0.39) 33.45 (1.89) 30.63 (1.27) 32.98 (1.69) 29.88 (1.36) 
LZVI 44.59 (1.21) 46.78 (1.14) 5.85 (1.01) 54.15 
(39.50-68.80) 
47.95 
(32.15-63.75) 
48.85 
(34.60-63.10) 
49.50 
(31.90-67.10) 
FEF25-75 (l) 0.38 
(0.18-0.58) 
- - - - - - 
 
Table 3.1: Clinical features of the AATD case-control dataset 
Data is presented as mean (standard error of the mean) or median (interquartile range) dependent on its distribution. 
FEV1 = forced expiratory volume in one second, FVC = forced vital capacity, KCO = gas transfer corrected for alveolar volume, FEF25-75 
= forced expiratory flow between 25 and 75% of total, UZVI = upper zone voxel index, LZVI = lower zone voxel index.
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Figure 3.3: Phenotypic overlap and frequency of qualitative phenotypes and in the AATD 
case-control dataset 
The Venn diagram shows the number of subjects with each of the three qualitative 
phenotypes studied, and the degree of overlap between them. The bar chart shows the 
proportion of each phenotype within the group (%).  
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  Index Non-index p value 
Gender (% male) 59.68 53.18 NS 
Age in years 47.91 (1.20) 46.00(1.22) NS 
Smoking  in pack years 12.50 (1.5-23.00) 8.50 (0-18.50) NS 
FEV1 %pred 31.00 (21.00-55.00) 68.00 (46.00-107.00) <0.001 
FEV1/FVC % 37.00 (30.0-47.0) 59.00 (43.00-75.00) <0.001 
KCO %pred 69.10 (3.21) 82.70 (2.51) 0.023 
Chronic bronchitis (%) 46.20 42.60 NS 
Emphysema (%) 82.50 55.70 0.001 
UZVI % voxels <-910HU 35.35 (23.32-47.39) 16.02 (5.32-26.72) <0.001 
LZVI % voxels <-910HU 53.90 (40.45-67.35) 27.92 (12.80-43.05) <0.001 
 
Table 3.2: Characteristics of the familial replication dataset 
Data is presented as mean (standard error of the mean) or median (interquartile range) 
dependent on its distribution. 
FEV1 = forced expiratory volume in one second, FVC = forced vital capacity, KCO = gas 
transfer corrected for alveolar volume, UZVI = upper zone voxel index, LZVI = lower 
zone voxel index, NS= non-significant 
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TNFA genotyping 
     Tag SNPs to cover TNFA were chosen using the algorithm described in section 2.3.2 
and published data pertaining to TNFA variation in UK Caucasian subjects[218]. This 
resource was chosen as coverage of TNFA was relatively poor in HapMap at the time of 
commencement of the studies herein, and the population in this resource was the most 
closely geographically matched group for the subjects studied in this thesis. Population 
matching is important as TNFA lies within the HLA region, which is known to show 
geographical variation[217]. The number of SNPs captured is shown in Table 2.4 and their 
position relative to TNFA structure is shown in Figure 3.1.  
     All tags were genotyped using TaqMan® genotyping technologies. This uses primers 
designed and supplied by Applied Biosystems (ABI), based on the sequence surrounding 
the SNP of interest. The exact primer sequence, therefore, remains the property of the 
company, hence only context sequences used for design can be given in this thesis. After 
primers have been designed and optimised by ABI for a particular SNP it will be listed on 
their website (using the reference SNP number) to indicate that a pre-designed genotyping 
assay is available. Assays for other SNPs can be designed upon request, using sequence 
data supplied by the customer. For the tags chosen within TNFA, assays had already 
been designed by ABI (www.appliedbiosystems.com), so no further sequence data was 
necessary. The context sequence associated with the primers for each tag is shown in 
Table 3.3. 
     The PCR reactions were set up on 384 well plates (Greiner Bio-one, UK), using 4 blanks 
as negative controls per plate. For each plate 1050µl of genotyping master mix (supplied 
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ready mixed, containing dNTPs, MgCl2 and Taq polymerase and optimised for use with 
TaqMan® genotyping assays by Applied Biosystems, UK), 70µl of genotyping assay at a 
20x concentration (ABI, UK) and 35µl of MillQ water were mixed in an opaque eppendorf 
(Alpha labs, UK), since the assay is light sensitive. For assays supplied at a 40x 
concentration the amount of assay was halved and the amount of water correspondingly 
increased, such that the total volume was unchanged.  
     A volume of 2.25µl of DNA at 20ng/µl was pipetted into each well of a 384 well plate, 
leaving 4 wells free to act as blanks, to which the same volume of MillQ water was added 
in order to standardise the reaction volume. The master mix (2.75µl) was then added to 
each well of the plate, the plate sealed with an optically clear seal (Alpha Labs, UK), and 
covered with foil in order to protect the light sensitve genotyping assay. The plate was 
then centrifuged at 1000rpm for 1 minute to ensure that all reagents were at the bottom of 
the plate and once completed the plates were placed in a thermal cycler (MJ Research 
(PTC-225) UK) and PCR performed under the following conditions: 
  50°C  2 minutes 
  95°C 10 minutes 
  92°C 15 seconds 
  60°C 1 minute 
40 cycles 
After completion of the PCR the plates were again covered with foil to prevent 
degradation of the light sensitive assay and stored at 4°C until they could be read. This 
step was carried out using an ABI-7900HT (ABI, UK), which is able to read the 
fluorescent signals emitted by the VIC and FAM markers within each assay. For each tag 
ABI supplied information indicating which allele the VIC and FAM markers detect, such 
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that this can be specified prior to reading the plate. The instrument collects fluorescence 
data on the samples which are analysed using SDS software (version 2.2.2, ABI, UK). The 
software presents the results as a scatterplot. There are four potential clusters of points, 
which correspond to the two homozygous genotypes, heterozygotes or no amplification. 
Parameters may be set to indicate cut-off values for allocation of genotypes within the 
software, and was set at 95% for the studies contained herein (as recommended by the 
manufacturers). Each plot was reviewed for the position and relative signal quality of 
samples where a genotype could not be allocated by the software, and a genotype assigned 
manually if possible. If the signal quality was <80% or the position was such that the 
genotype was unclear such samples were reanalysed. 
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SNP  Context sequence Design strand 
rs1800269 GAGGCAATAGGTTTTGAGGGGCATG[A/G]GGACGGGGTTCAGCCTCCAGGGTCC Reverse 
rs361525 GGCCCAGAAGACCCCCCTCGGAATC[A/G]GAGCAGGGAGGATGGGGAGTGTGAG Reverse 
rs1799964 GGAAGCAAAGGAGAAGCTGAGAAGA[C/T]GAAGGAAAAGTCAGGGTCTGGAGGG Reverse 
rs3093662 TTGAATGCCTGGAAGGTGAATACAC[A/G]GATGAATGGAGAGAGAAAACCAGAC Reverse 
 
Table 3.3: TNFA sequences for primer design 
The 2 alleles of each SNP are highlighted in blue,within square brackets, at the point where it appears within the primer sequence. 
Statistical analysis 
     Each tag SNP genotype was assessed for its contribution to COPD phenotypes by 
regression analysis. In the case-control dataset phenotypic associations of each SNP 
genotype were sought using the qualitative phenotypes of emphysema, bronchiectasis and 
chronic bronchitis, and quantitative analyses using FEV1, KCO and HRCT densitometry. 
Associations seen were then sought in the familial replication dataset. 
 
3.2.3 Results 
Case control dataset 
     Genotyping was successful, on average, in 95.3% (n=404) of cases. An example of the 
genotyping plots is shown in Figure 3.4 for rs1799964. All SNPs were in Hardy Weinberg 
equilibrium (all p>0.05 for deviation from HWE). Allele and genotype frequencies are 
shown in Table 3.4. The dataset had 80% power to detect an OR of between 1.62 and 2.26 
of developing a given disease phenotype (Table 3.5), this being calculated retrospectively 
based on the genotype frequencies obtained. Lower power was exhibited where the minor 
allele frequency was low. 
     In the regression analyses the influence of age, gender and smoking on each phenotype 
was sought prior to addition of genetic data. In the logisitic regression models for 
qualitative phenotypes, age was a significant predictor of both emphysema and 
bronchiectasis (both p<0.0001), whilst pack years smoked was associated with 
emphysema (p<0.0001). No demographic or clinical features predicted the development of 
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chronic bronchitis. In the linear regressions both FEV1 and FEV1/FVC required log 
transformation due to their non-normal distribution. Age, gender and smoking were 
significant predictors of logFEV1, logFEV1/FVC, KCO, UZVI and LZVI (all p<0.05). 
Gender was the only significant predictor of FEV1 decline (p=0.03). This aspect of the 
regressions is summarised in Table 3.6. 
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Figure 3.4: TaqMan® genotyping plot for TNFA rs1799964 
CC homozygotes give the strongest signal along the X axis, whilst TT homozygotes have a 
strong signal from the fluorophore allocated to Y axis. Heterozygotes emit signal from 
both markers, thus lie between the other groups. Three clear groups are visualised for this 
SNP. A cut off of 95% was chosen on the software, with subsequent manual allocations 
based on the appearance of the plot. The plot was generated using SDS version 2.2.2 (ABI, 
UK).
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SNP All AATD Chronic 
bronchitis  
Emphysema Bronchiectasis 
rs1800629 [G/A] 
A allele 
GG 
GA 
AA 
 
21.91  
61.63 (249)  
32.92 (133)  
5.45 (22)  
 
24.84 
56.60 (90) 
37.75 (60) 
5.66 (9) 
 
21.85 
62.22 (168) 
31.85 (86) 
5.96 (16) 
 
26.58 
54.43 (43) 
37.97 (30) 
7.59 (6) 
rs361525 [G/A] 
A allele 
GG 
GA 
AA 
 
8.54 
83.67 (338) 
15.56 (63) 
0.74 (3) 
 
11.64 
77.99 (124) 
20.75 (33) 
1.31 (2) 
 
8.52 
84.07 (227) 
14.81 (40) 
1.11 (3) 
 
5.13 
91.03 (71) 
7.69 (6) 
1.28 (1) 
rs1799964 [T/C] 
C allele 
TT 
TC 
CC 
 
25.62 
57.32 (231) 
34.49 (139) 
8.19 (33) 
 
26.89 
55.34 (88) 
35.85 (57) 
8.80 (14) 
 
25.19 
57.78 (156) 
34.07 (92) 
8.15 (22) 
 
26.58 
55.70 (44) 
35.44 (28) 
8.86 (7) 
rs3093662 [A/G] 
G allele 
AA 
AG 
GG 
 
8.81 
82.63 (333) 
17.12 (69) 
0.25 (1) 
 
11.39 
77.36 (123) 
22.64 (36) 
- 
 
7.99 
84.39 (227) 
15.24 (41) 
0.37 (1) 
 
4.49 
91.02 (71) 
8.97 (7) 
- 
 
Table 3.4: Allele and genotype frequencies of TNFA tag SNPs in the case control dataset 
SNP alleles are listed [major, minor] and the minor allele frequency given as a percentage, 
together with all genotype frequencies, where the raw data is also shown in parentheses. 
Statistically significant differences contributing to a COPD phenotype were ascertained 
by regression and are detailed in the text (section 3.2.3).
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SNP Phenotype Minimum odds ratio detectable with 80% 
power 
Emphysema 1.83 
Bronchiectasis 1.82 
rs1800629 
Chronic bronchitis 1.62 
Emphysema 2.26 
Bronchiectasis 2.18 
rs361525 
Chronic bronchitis 2.05 
Emphysema 1.79 
Bronchiectasis 1.75 
rs1799974 
Chronic bronchitis 1.58 
Emphysema 2.16 
Bronchiectasis 2.17 
rs3093662 
Chronic bronchitis 2.00 
 
Table 3.5: Power of the case-control dataset to detect differences in phenotypes for TNFA 
tag SNPs 
The table shows the odds ratio of developing each phenotype, prior to adjustment for 
covariates, calculated using the formulae detailed in Appendix 4. 
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Regression 
type 
Phenotype Predictor B SE 
(B) 
r2 
change 
p value 
Age 0.094 0.016 NA <0.0001 
Gender - - - NS 
Emphysema 
Pack years  0.095 0.017 NA <0.0001 
Age 0.05 0.013 NA <0.0001 
Gender - - - NS 
Bronchiectasis 
Pack years  - - - NS 
Age - - - NS 
Gender - - - NS 
Logistic 
 
Chronic 
bronchitis 
Pack years  - - - NS 
Age -0.003 0.001 0.015 0.006 
Gender -0.086 0.025 0.024 0.001 
logFEV1 
Pack years  -0.007 0.001 0.153 <0.0001 
Age -0.004 0.001 0.066 <0.0001 
Gender -0.082 0.016 0.077 <0.0001 
logFEV1/FVC 
Pack years  -0.004 0.001 0.074 <0.0001 
Age -0.625 0.103 0.077 <0.0001 
Gender -2.602 2.294 0.012 0.029 
KCO 
Pack years  -0.387 0.078 0.046 <0.0001 
Age 0.514 0.092 0.090 <0.0001 
Gender 8.896 1.961 0.082 0.016 
UZVI 
Pack years  0.192 0.065 0.019 <0.0001 
Age 0.813 0.099 0.170 <0.0001 
Gender 5.968 2.11 0.043 <0.0001 
LZVI 
Pack years  0.445 0.070 0.084 <0.0001 
Age - - - NS 
Gender -0.702 0.336 0.032 0.030 
Linear 
 
FEV1 decline 
Pack years  - - - NS 
 
Table 3.6: Clinical predictors of phenotypes used in regression models 
The table shows the regression models constructed and the predictors assessed. B is the 
regression coefficient and represents the change in the outcome variable if the predictor is 
increased by 1. In all logistic regressions the phenotype was coded 1 if present and 0 if 
absent, thus a positive B value indicates an increased risk of developing the phenotype. 
Gender was coded male=1 and female=0 in all regressions, thus a positive value indicates 
an increased risk of developing a phenotype (logistic models) or an increase in the 
quantitative outcome variable (linear models). Where the significance of the F change was 
>0.05 this is shown as non-significant (NS), and no regression coefficient is given as a 
result. The level of r2 change in the linear regressions indicates the amount of variability of 
the measure explicable by variation in the predictor, such that if r2 change =0.084 then 
the amount of variability explicable is 8.4%. FEV1 decline was calculated using for each 
individual using raw data, but a log value of this figure was used for the regressions, as the 
distribution of decline within the group was non-normal. NS= not applicable. 
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     Genetic data was added to the regression models by forced entry subsequent to 
adjustment for clinical covariates; in each case the genotype was coded 0, 1 or 2 and 
analysed as a categorical variable, such that each genotype was treated independently. 
This is effectively a general model. A second model was constructed to assess allelic effects, 
with the number of minor alleles present being coded 0, 1 or 2 in a quantitative manner. 
This is equivalent to a co-dominant model.  
     A significant difference in allele and genotype frequency was seen between subjects 
with and without chronic bronchitis for rs361525 (both p=0.01), with the A allele 
conferring an OR of 1.99 (95% confidence interval (CI) 1.18-3.67) in the general model 
regression analysis. No other tag SNPs predicted this phenotype.  
     There were no tag SNP associations with emphysema, bronchiectasis, lung function or 
emphysema severity (as measured by UZVI and LZVI), all models showing p>0.05 for the 
step where genetic data was added.  
 
When haplotype analysis was performed, no haplotypes were observed for analysis; the 
LD plot is shown in Figure 3.5. 
 
Familial dataset 
The hypothesis that rs361525 is associated with chronic bronchitis could not be tested in 
the replication dataset because this phenotype did not differ significantly between family 
members (Table 3.2). 
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 Figure 3.5: Linkage disequilibrium plot for TNFA tag SNPs 
The linkage disequilibrium plot shows the r2 values between pairs of SNPs, identified by 
following the lines formed by the blocks within the plot, such that the value between 
rs1799964 and rs1800629 is 59, and that between rs1799964 and rs361525 is 84. The 
software displays the r2 value as a whole number by default, such that these figures are 
actually 0.59 and 0.84 respectively. Higher values are indicative of greater LD, since the 
SNP alleles are correlating more closely. The Haploview software highlights any pairs or 
groups of SNPs whose r2 values indicate significant LD (p<0.05). No haplotype blocks 
were observed in Haploview for further analysis, as shown above. 
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3.3 TNFα 
 
3.3.1 Introduction 
TNFα in COPD 
     Chronic obstructive pulmonary disease is associated with an abnormal inflammatory 
response within the lungs and the circulation (section 1.1.3). Tumour necrosis factor-α 
(TNFα) is an inflammatory cytokine which is elevated in the sputum[230], bronchial 
biopsies[231] and circulation[232] of  COPD subjects. It is central to the inflammatory 
cascade in COPD (Figure 1.5), and probably also influences co-morbidities such as 
vascular disease and osteoporosis, as shown in Figures 3.6 and 3.7. A murine model also 
confirms a role for TNFα in COPD pathophysiology, with TNFα receptor (TNFAR) 
knock out mice failing to develop the inflammatory response in the lung typical of COPD 
after either short or long term cigarette smoke exposure[49]. This was the rationale for 
testing of anti-TNFα therapy in COPD[23]. However, a clinical trial of a drug with this 
action (infliximab), already in use in other inflammatory conditions, did not show any 
significant effect on symptoms or lung function when given regularly intravenously over 
two years[23]. A subgroup of cachectic subjects, however, showed an improvement in 
exercise capacity (as measured by the six minute walk test) after infliximab 
treatment[23], perhaps lending support to the theory that phenotypic subgroups within 
COPD respond differently to treatment, and should be considered as different disease 
entitities.  
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Figure 3.6: The TNFα mediated inflammatory cascade 
Cigarette smoking is associated with greater gene expression of TNFα  [200] and 
subsequent systemic inflammation. Increased adiposity also contributes to TNFα and 
interleukin-6 (IL6) production, both of which activate nuclear factor kappa beta (NFκβ), 
leading to insulin resistance, dyslipidaemia and atherogenesis. The latter is enhanced by 
the activity of MMPs, which is increased by TNFα. Raised glucose levels also affect gene 
expression, predominantly in adipose tissue, elevating inflammatory cytokine levels 
further.
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Figure 3.7: The role of TNFα in osteoporosis 
TNFα both upregulates receptor activator for the NFκβ ligand (RANKL) and enhances 
osteoclast differentiation. This promotes bone resorption by osteoclasts, causing an 
imbalance between this and bone formation by osteoblasts, ultimately resulting in 
osteoporosis. 
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TNFα in AATD 
     Alpha one antitrypsin (AAT) and TNFα show a degree of interaction[202], such that 
TNFα release is suppressed by AAT in vitro[202] and in animal models[233]. This is 
thought to occur because AAT inhibits thrombin and plasmin activity, which prevents 
proteinase activated receptor-1 activation, a process which stimulates TNFα release[202] 
(Figure 3.8). In AATD this suppression would be reduced thus any TNFα effects are likely 
to be more pronounced, perhaps contributing to the observation that inflammation is 
more marked in AATD than usual COPD[234]. The relationship of TNFα levels to clinical 
phenotype has not been reported in AATD. 
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Figure 3.8: The mechanism by which AAT suppresses TNFα release in the lung  
Cigarette smoke increases the permeability of the alveolus, such that protein leakage 
occurs. In the lung thrombin and plasmin cause release of TNFα from macrophages, 
acting via proteinase activated receptor-1, a process which is blocked by AAT. 
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3.3.2 Methods 
Subjects 
     The subjects on whom circulating and airway levels of TNFα were measured comprised 
all those in the case-control dataset described in section 3.2.2 with appropriate stored 
samples available. Plasma concentrations were measured on all PiZZ subjects for whom a 
sample was available (n=237), though this was less than the number genotyped, as some 
genotyped subjects did not have a stored plasma sample (n=97). Sputum concentrations 
were measured in patients with chronic bronchitis (the only group who can spontaneously 
expectorate sputum when stable; even subjects without lung disease may do so in the 
presence of clinical features of infection). The number of suitable samples was, therefore, 
fewer than plasma (n=60). Many factors influence airway inflammation in COPD 
including bacterial colonisation[235] and cachexia[232] so any study of airway 
inflammatory markers requires matching of subjects for these features. In this study a 
subset of subjects were matched for age, gender, FEV1, body mass index (BMI) and 
bacterial colonisation status (section 2.2.6).  
 
Quantitation of TNFα 
     TNFα concentrations were measured using a pre-validated high sensitivity (HS) 
commercially available ELISA kit (R&D systems, UK). Circulating TNFα concentrations 
were measured using stored plasma samples, and airway concentrations using stored 
sputum sol phase samples. Blood samples were collected from stable subjects in EDTA 
tubes (Greiner Bio-one, UK) and centrifuged at 3000rpm at 4°C for 15 minutes prior to 
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storage of plasma in aliquots of 200µl at -80°C. Sputum samples, again from stable 
subjects, had been centrifuged at 2000rpm at 4°C for 90 minutes and the resultant sol 
phase stored in aliquots of 50-200µl at -80°C. 
     All solutions required for the ELISA were provided in the kit. The plates provided are 
pre-coated by the manufacturer with an antibody specific to TNFα. A standard curve was 
set up by serial dilution of the standard provided (concentration 32pg/ml) in the calibrator 
diluent to 16, 8, 4, 2, 1 and 0.5pg/ml. Standards and samples were run in duplicate on 96 
well plates. Fifty µl of assay diluent and 200µl of plasma or standard was added to each 
well, and the plate incubated at room temperature (~18°C) for 3 hours. It was then 
washed 6 times using 400µl wash buffer per well for each wash. Two hundred µl of TNFα 
HS conjugate was then added to each well, followed by incubation for 2 hours and 
washing as before. Fifty µl of substrate solution was added next, followed by an hour of 
incubation. Amplifier solution (50µl ) was then added prior to a final 30 minute incubation 
period, again at room temperature. Before reading the plate, 50µl of stop solution was 
applied to each well. Colour readings were taken at 490nm, with wavelength correction set 
to 650nm, using a microplate reader (Biotek plate reader with Gen5 software, both 
Northstar Scientific, UK) and compared to the standard curve. 
     Sputum sol phase samples had higher TNFα concentrations, and hence required 
dilution to obtain an accurate reading within the range of the standard curve. Samples 
were diluted using the calibrator diluent from the kit to 1:50, and a volume of 200µl of this 
dilution added to each well of the plate, in a similar manner to the plasma. If the result fell 
outside the range of the standard curve at this dilution the measurement was repeated at 
lower or higher concentrations as needed.  
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Statistical analysis 
    Plasma and sputum concentrations of TNFα were compared with demographic and 
clinical features. Phenotypic associations of circulating TNFα levels were sought in order 
to ascertain any associations thats presence should be corrected for in subsequent 
regression models involving genetic data.  
 
3.3.3 Results 
Clinical associations of circulating TNFα  
     Plasma TNFα levels were obtained on 230 subjects out of the total case-control cohort 
of 424. There was no significant difference in plasma level between male and female 
subjects, nor did it vary with smoke exposure. Older subjects tended to have higher TNFα 
levels, as shown by the correlation in Figure 3.9 (p=0.029, r=0.145). Plasma TNFα showed 
no significant correlations with FEV1, KCO or lung function decline, nor were there any 
significant differences between those with and without emphysema, chronic bronchitis or 
bronchiectasis (Table 3.7). 
 
Clinical associations of airway TNFα  
     Sputum TNFα levels were measured on 58 subjects, showing a mean of 31.14pM with a 
standard error of 9.84, reflecting the wide range (0.06-390.00pM). No samples were 
available from subjects of the AA genotype for analysis. 
     Three subjects whose values lay more than 3 standard deviations from the mean were 
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excluded from further analysis because examination of their clinical records showed that 
samples had been obtained at the time of an infective exacerbation. Exacerbations are 
associated with increased airway inflammation[234], such that inclusion of these samples 
would have biased the results.  
     There was no significant difference in sputum level between male and female subjects, 
nor did it vary with age, smoke exposure, FEV1 or KCO (all p>0.1). There was no 
correlation between sputum and plasma TNFα levels (p=0.836). Contemporaneous 
quantitative sputum microbiology was available in 35 subjects; of whom 51% were 
colonised with recognised airway pathogens. Sputum TNFα tended to be higher in 
samples colonised with bacteria (mean 43.78pM; SE=23.91pM v 14.99pM; SE=5.21pM), 
although the difference was not statistically significant (p=0.310).   There was no 
correlation with bacterial numbers in colonised subjects (p=0.991).  
     The analysis was repeated in a subset of subjects matched for age, gender and severity 
of COPD (see also section 1.1.1 and Table 1.1), comprising 11 male subjects, with normal 
body mass index, mean age of 53.09 years (SE=1.16) and FEV1 23.65%predicted 
(SE=2.19). One subject, whose concentration was vastly different from the rest of the 
cohort (594pM), was excluded as the stored sample had been obtained whilst he was 
participating in a clinical trial. Again, there was a wide range of TNFα concentrations, 
with a mean of 67.12pM (range 0.20-389.00pM). There was no difference in sputum TNFα 
between those with and without stable state bacterial colonisation of the airway 
(p=0.441).    
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Figure 3.9: Plasma TNFα correlates with age 
The graph shows levels of circulating TNFα for each subject relative to their age. There 
was a weak but positive correlation (r=0.145, p=0.029) indicating a general increase in 
older subjects. Since the data was non-parametric the correlation line has been omitted 
from the graph. 
 
 Plasma TNFα  (pM) 
All subjects 0.061 (0.051-0.071) 
Phenotype Affected Unaffected 
Emphysema 0.079 (0.061-0.098) 0.065 (0.005) 
Bronchiectasis 0.065 (0.045-0.085) 0.061 (0.044-0.079) 
Chronic bronchitis 0.062 (0.040-0.082) 0.061 (0.040-0.081) 
 
Table 3.7: Plasma TNFα levels in AATD subjects 
The table shows mean (standard error of the mean) or median (interquartile range) plasma 
TNFα dependent on its distribution. The mean circulating level of TNFα was 0.061pM in 
the cohort; the data is then substratified into groups affected or unaffected by the 3 
phenotypes listed in the first column (emphysema, bronchiectasis or chronic bronchitis), 
all of which are defined in section 1.1.1 and the first two illustrated in figures 1.2 and 1.3. 
There were no significant differences between subjects with and without these phenotypes 
(all p>0.05). 
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3.4 Associations between TNFA and TNFα 
      
3.4.1 Introduction 
     A functional effect for a SNP may be inferred if an association of genotype and protein 
level is seen, together with a phenotypic association[236]. The analyses in the preceding 
sections (TNFA and TNFα associations with phenotype in AATD) highlight many factors 
that need to be considered when assessing whether genotype-phenotype associations are 
reflective of a causative association mediated by the protein product.  
 
3.4.2 Methods   
     Differences in circulating and airway levels of TNFα reported in section 3.3.3 were 
sought for associated genotypes identified in section 3.2.3, controlling for associated 
clinical features by regression and matching of subjects respectively. Since only rs361525 
was associated with any phenotype, this was the only SNP studied here. 
 
3.4.3 Results 
Circulating TNFα stratified by genotype 
      Plasma TNFα levels stratified for rs361525 genotype are shown in Figure 3.10. There 
was a trend suggesting a higher level in those with at least one A allele, indicating it may 
have an effect on circulating levels of the protein. This might imply that circulating TNFα 
levels are important in pathogenesis, since this allele was associated with the chronic 
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bronchitis phenotype. However, since age was a significant predictor of plasma TNFα 
(section 3.3.3), a regression model to control for age prior to seeking genetic association 
with protein levels was constructed. The distribution of plasma TNFα concentrations 
deviated sufficiently from normality (Kolmogorov-Smirnov statistic 0.203, p<0.0001) 
such that regression models to assess the influence of genotype, corrected for age, could 
not be constructed prior to data transformation. Using log values the regression model did 
not show any significant effect of rs361525 genotype on plasma TNFα, either in the whole 
group, or in those with chronic bronchitis (associated with the SNP in the case control 
dataset). Although there were 4 cases whose standard residuals lay more than 3 standard 
deviations from the mean (indicating outliers), none influenced the model unduly 
(maximum Cooks distance 0.115). The regression results are summarised in Table 3.8. 
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Figure 3.10: Plasma TNFα stratified for rs361525 genotype 
The bar chart shows the mean (SE) of circulating TNFα levels for each of the three 
observed genotypes of rs361525 in AATD subjects. Although levels appear higher in 
subjects with one or more A alleles the difference was not statistically significant. 
 
 
 
Predictor B SE (B) r2 change p value 
rs361525 A allele 0.056 0.052 0.005 0.285 
Age 0.003 0.002 0.013 0.087 
 
Table 3.8: Linear regression results assessing independent predictors of plasma TNFα 
The table shows the regression coefficient and change in r2 value observed with addition of 
each predictor. Neither achieved statistical significance. 
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 Sputum TNFα stratified by genotype 
      Neither gender, age, smoke exposure or any other recorded demographic feature were 
associated with sputum TNFα levels in this study (section3.3.3). Since no feature affected 
the outcome measure (sputum TNFα level) no adjustment by regression modelling was 
needed and as such the levels were compared directly between those with and without the 
associated allele of rs361525. However, since prior studies have shown several features 
associated with airway inflammation (sections 1.1.3 and 3.3.2) the statistics for association 
of sputum TNFα levels were carried out in the matched subset described in the methods 
(section 3.3.2), as well as the larger group. 
     Sputum TNFα levels were markedly higher in those with the A allele of rs361525, the 
difference being more marked in the matched subset, as shown in Table 3.9 and Figures 
3.11 and 3.12. Although all subjects in the smaller matched group had significant numbers 
of airway bacteria (i.e. diagnostic of airway bacterial colonisation), four subjects had only 
those deemed mixed normal flora, rather than potential pathogens, leaving 3 of each 
genotype matched for pathogen colonisation status. Since this factor might influence 
airway inflammation it was appropriate to sub-stratify the results for this feature. 
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 rs361525 genotype  
AG  GG 
p 
value 
All subjects (AG, n=11; GG, n=43) 100.02 
(45.76) 
18.33 
(6.85) 
0.028 
Matched subjects (AG, n=4;GG, n=6) 165.11 
(76.12) 
1.80 (0.69) 0.011 
Matched subjects with airway 
pathogens  
(AG & GG, n=3) 
90.14 (18.65) 0.54 (0.30) 0.050 
 
Table 3.9: Sputum TNFα between subjects stratified for rs361525 genotype 
The mean concentration (SE) in pM for each group is shown in the table. In all 
comparisons the levels are significantly higher in subjects with the A allele. 
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Figure 3.11: Sputum TNFα stratified for rs361525 genotype in AATD subjects  
The bar chart shows the mean (SE) sputum concentrations of TNFα in the unmatched 
AATD cohort (all subjects); the difference is significant (p=0.028). 
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Figure 3.12: Scatterplot of sputum TNFα concentrations stratified for rs361525 genotype in 
subjects matched for age, gender, BMI and FEV1 
Sputum TNFα concentrations are shown as log values for ease of visualisation on the 
graph, since the raw values differed so widely between the genotypes. The difference is 
statistically significant (p=0.01). 
 138
3.5 Discussion 
     The results presented in this chapter suggest an association between the A allele of 
rs361525, a SNP in the promoter region of TNFA, and chronic bronchitis in AATD. 
Furthermore, a functional effect of the SNP is suggested by the observation of higher 
airway levels of TNFα in subjects with the A allele. The presence of an association of 
genotype with protein levels, localised to the airway, and an airway related phenotype 
strongly suggests that this polymorphism has a role in the pathophysiology of chronic 
bronchitis.  
          Chronic bronchitis is a feature of approximately 40% of the AATD subjects studied 
here, and was not predicted by any demographic feature in the regression models (unlike 
other COPD phenotypes) suggesting that genetic or other unidentified environmental 
influences might be important in its pathogenesis. Its’ importance as a phenotypic 
outcome measure has been recognised by other COPD genetic association studies[99, 107], 
perhaps for this reason. Clinically it is an important phenotype to ascertain, as it is 
associated with more frequent exacerbations [237], which in turn are associated with a 
tendency to disease progression [238, 239]. In some patients, difficulty in expectorating 
may also occur, leading to increased cough. Mucolytic therapy may be more beneficial in 
the presence of a productive cough[8], facilitating airway clearance and reducing 
exacerbation frequency [240]. Association of chronic bronchitis with both TNFA 
genotype and airway TNFα levels suggests that treatment strategies aimed at blocking 
TNFα effects might be of benefit in such patients. Anti-TNFα therapy is available, and 
has undergone clinical trials in COPD[23], but was not assessed specifically in subjects 
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with chronic bronchitis despite the recognised importance of TNFα in the 
pathophysiology [231]. Furthermore, response to anti-TNFα treatment may be dependent 
on TNFA genotype [26], perhaps indicating a need for further clinical trials directed to 
clinical sub-phenotype or genotype.  
     Although there is a degree of overlap of COPD phenotypes, these results are specific to 
chronic bronchitis, concurring with previous work on TNFα in airways disease[231]. 
TNFα is known to be elevated in the sputum[230] and bronchial biopsies[231] of subjects 
with COPD, and is generally accepted to be important in the pathogenesis of both 
pulmonary and systemic features of COPD[241]. Such an association is lacking for 
presence or severity of parenchymal disease, defined by emphysema on HRCT. This 
suggests different genetic factors influence the development of each clinical sub-phenotype 
and supports the view that inadequate patient characterisation may underlie poor 
replication of previous COPD genetic association studies. It is also of interest that the 
influence of age and smoke exposure differed between COPD phenotypes in the regression 
models, further emphasising that the pathophysiology of individual phenotypes has a 
different basis.  
     Despite the genetic association observed, there was no difference in circulating TNFα 
between sub-phenotypes. It was not possible to test differences in airway TNFα between 
sub-phenotypes, as only those with chronic bronchitis produce sputum for testing. This is 
an inherent problem in studies of airways disease; whilst sputum induction may allow 
collection of airway secretions from healthy individuals factors relating to the process of 
sputum induction could confound results[242]. 
     Genetic association with another promoter region SNP (rs1800629, G-308A) in TNFA 
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is accepted as important in COPD, following a supportive meta-analysis[228]. However, 
previous studies included in the meta-analysis have defined their cases using FEV1 and 
FEV1/FVC [72, 105, 224], CT diagnosed and pulmonary function diagnosed 
emphysema[106, 225] and chronic bronchitis[107]. It is, therefore, debatable whether such 
studies can be merged in a single analysis of their outcome, as they may include different, 
albeit related, disease phenotypes. Furthermore many of the supportive publications 
included studied less than 100 subjects with a COPD phenotype [106, 107, 224, 225], and 
as such are small for determining genetic association work and may produce false positive 
results. It will be of importance to study this SNP, or at least the region in which it is 
located, in the large genome wide association studies in COPD underway at present, with 
particular reference to the bronchitis phenotype.  
     The rs361525 (G-238A) SNP has been less comprehensively studied in COPD. One 
previous study has tagged TNFA[72] but failed to find an association. However, subjects 
included a family cohort with airflow obstruction, and cases with emphysema; no previous 
studies in COPD have looked for association of chronic bronchitis with rs361525. Another 
study by the same group in subjects with AATD tagged several candidate genes and found 
associations with lung function for three SNPs in TNFA, including one in LD with 
rs361525[236]. Interaction of TNFα with AAT may make the relationship exclusive to 
those with AATD or alternatively the specificity of the phenotypic association might 
explain the lack of previous association of this SNP in COPD.  
     The rs361525 SNP is located in the promoter region of TNFA and has been studied 
extensively in many different disease states, although little evidence exists for a functional 
effect. Cellular studies of TNFA promoter region SNPs suggest that the A allele of 
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rs361525 increases gene transcription[243]. Conversely gene expression in patients with 
psoriasis (a disease with which the A allele of rs361525 is strongly associated[244]) appears 
reduced[245]. Further functional work clarifying the role of the rs361525 SNP would be 
indicated if fine mapping of the region surrounding it confirmed it to be the functional 
variant associated with chronic bronchitis, rather than merely a polymorphism in LD 
with another such SNP. Such studies are expensive, and alternative surrogate support for 
a functional effect may be gained by assessing TNFα levels[236], which was the strategy 
chosen for the studies in this chapter.  
    The data did not show an association between rs361525 genotype and plasma TNFα 
levels. This may be because of the specific association with airways disease since airway 
and plasma inflammatory markers do not correlate in COPD [52], as confirmed here. It 
was only possible to obtain airway secretion samples from a relatively small cohort for 
measurement of airway TNFα, the results show a significant difference between those 
with and without the associated allele, and no variation with any other clinical feature.  
Whilst it is appropriate to view the results with caution because of the small sample size 
for airway TNFα measurements, they support a functional effect of the A allele in airways 
disease. Further study involving a larger cohort of patients is therefore indicated. 
     The genetic association results reported here do not include adjustment for multiple 
statistical testing as such corrections (for instance the Bonferroni) appear overly 
conservative in genetic association studies[68], and hence are generally inappropriate. 
This is particularly true when several theories are being tested, as in this study in which 
the hypothesis was that each SNP could be driving any of three qualitative COPD 
phenotypes, or affecting disease severity via several quantitative phenotypes. Statistical 
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significance is usually accepted if it reaches the level needed for a genome wide study 
(generally considered to be p≤5 x 10-5[68]), or by replication in an independent population. 
The studies reported in this thesis have considered the latter approach, using a small 
familial dataset to act as a replication group. However, within this dataset there was no 
difference in the prevalence of chronic bronchitis between family members.  As such it was 
not possible to test the hypothesis of association with this phenotype in this replication 
cohort.  These problems are inherent in studying rare conditions, such as AATD, as 
recruitment of datasets powered for genome wide significance using healthy AATD 
controls is currently impossible, because of the high rates of disease phenotypes (Figure 
3.3). International collaborations to create larger datasets could help overcome this 
problem although geographical variation of genes, particularly those within the HLA 
region such as TNFA, may be a further confounding factor [217].       
 
3.6 Conclusions 
     This study suggests an association between rs361525 (G-238A) and chronic bronchitis 
in AATD, but requires further independent replication. No functional effect of the SNP 
was demonstrated in plasma, and plasma TNFα did not differentiate between COPD 
phenotypes or correlate with disease severity. A functional effect in the airway is 
suggested by the difference in sputum TNFα levels seen between those carrying the 
associated allele and those without, but must be viewed with caution because of the small 
sample size. 
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Chapter 4: The role of selected genes which encode 
proteins relating to inflammation in the respiratory 
phenotype of AATD 
 
4.1 Introduction 
     Inflammation is more marked in AATD than usual COPD[234], and whilst the 
interaction between AAT and TNFα[202] (see also section 3.3.1) may contribute to this, 
polymers resulting from the PiZ mutation are also thought to be pro-inflammatory[246], 
though the mechanisms underlying this are not yet fully elucidated. This suggests that 
inflammation will be present in all PiZZ subjects, including those with no clinical evidence 
of disease and who do not smoke. In this situation an additive effect of different variations 
in a series of pro-inflammatory proteins, or inhibitors of inflammation, resulting from 
genetic polymorphism, could be clinically important.  
     A number of genes relating to inflammation have associations in usual COPD (section 
1.1.4); for the studies contained in this chapter 3 genes, each of which have at least 4 prior 
studies supporting a role in usual COPD, were examined for association with clinical 
phenotype in the cohort of PiZZ subjects described in chapters 2 and 3. These genes are 
Surfactant protein B (SFTPB), transforming growth factor β (TGFB) and Group specific 
component (GC), which is also known as Vitamin D binding protein. These genes, their 
protein products and prior evidence for a role in COPD will be discussed in sub-sections of 
this introduction, prior to results on each gene in turn. 
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     Data presented here has been published in a peer reviewed journal (Appendix 7). 
 
4.1.1 Surfactant protein B 
     The surfactant protein B gene (SFTPB) lies on chromosome 2p12 and is composed of 
11 exons spread over approximately 10kb of DNA, with an 823 nucleotide 3’ untranslated 
region[247]. The protein it encodes (SFTPB) is derived from extensive proteolytic 
digestion of a 381 residue precursor within alveolar type II cells, to form a final protein 79 
residues in size[248]. As a consequence of this, intronic polymorphisms resulting in 
changes in protein function, associated with disease, are relatively well recognised and 
described[249].  
     Surfactant protein B is thought to inhibit pulmonary inflammation by reducing nitric 
oxide release from alveolar macrophages[250] and reducing L selectin expression, with a 
consequent reduction in neutrophil migration to the lungs[251]. The role of SFTPB in 
COPD pathogenesis has not been widely studied, but low levels are observed in animals 
with emphysema[252]. Mathematical models of emphysema [253] suggest that surfactant 
related changes in surface tension would contribute to disease although this has yet to be 
studied in vivo. Pathways relating to this protein may be of even greater interest in AAT 
deficient subjects with COPD because surfactant proteins interact with AAT to decrease 
anti-elastase activity[254] which could be critical in AATD as anti-elastase activity is 
already profoundly reduced.  
     Variation within SFTPB has been positively associated with COPD in Hispanic 
subjects compared to smokers with normal spirometry, such that the C allele of rs1130866 
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(Thr131Ile) conferred an OR of 3.65 of disease [133]. This is a high OR of disease for a 
single SNP, given that COPD is a disease where many genetic factors are thought to 
influence outcome, and it is of note that the 95% confidence interval for the OR was very 
wide (1.19-12.12), possibly because of relatively low numbers of cases in the study 
(n=94)[133]. The same polymorphism was associated with emphysema[72] and a flanking 
microsatellite with exercise capacity[78] in the NETT cohort. In the first of these 
studies[72] the SNP was studied in a case-control group, and replication attempted in a 
familial group. In the case control study it was associated with emphysema in the presence 
of a gene by smoking interaction term, and replicated in those of the family group with 
severe disease, but not in those with milder disease. It is of note that the defining 
characteristics of the cases in the 2 groups differed slightly, though it is likely both had 
emphysema, data pertaining to this specific phenotype was not reported for the familial 
group. The second of these studies was performed by the same research group, utilising 
different phenotypic data from the case-control dataset, and the same familial replication 
group [78]. It is perhaps not surprising, therefore, that the results were largely concordant 
with the earlier study. A German study, examining only microsatellite lengths, found a 
significant association with respiratory failure in COPD (OR=4.9), though no association 
with COPD per se[132]. Again this was a relatively small study, comprising 118 subjects 
with COPD, an identical number of matched control subjects and 110 population based 
control subjects. However only 24 of the subjects with COPD also had respiratory failure, 
which is reflected in the wide 95% confidence interval reported (1.76-13.60)[132].  
     The functional SNP in this gene (rs1130866, Thr131Ile) has been studied in AATD 
more recently, and was not associated with lung function[236]. No phenotypic data other 
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than lung function was reported, and the mean FEV1 (%predicted) was 65.9%, indicating 
that most subjects had only mild COPD according to British standards (Table 1.1). 
Although the studies supporting a role for SFTPB in COPD have some weaknesses their 
results suggest that if the gene is of importance it may be so in defining those with more 
severe lung disease, reflected by the association seen with this phenotype in the study by 
Hersh et al[72] and with respiratory failure[132]. The phenotypic data available in the UK 
AATD population, reported in this thesis, is of sufficient detail to ascertain if the lack of 
association seen in the first study of this gene in AATD[236] is truly reflective of its role in 
disease or simply reflects the relatively mild disease seen in the population studied. 
 
4.1.2 Transforming growth factor β 
     The transforming growth factor β gene (TGFB) lies on chromosome 19q13, and is 
composed of 7 exons with 6 very large introns, giving a total gene size of approximately 
23kb[255]. The final protein, TGFβ1, consists of 112 amino acids from the C terminal end 
of the precursor, formed into 2 polypeptide chains linked by disulphide bridges[256].  Mice 
who are unable to activate latent TGFβ1 develop emphysema, suggesting that disordered 
activation of TGFβ1 relates to the pathogenesis of COPD[257]. This occurs via alterated 
expression of MMP12, such that increased proteolysis occurs because of increased levels of 
its protein product (MMP12), which is a matrix metalloprotease (MMP)[257]. The role of 
MMPs in emphysema pathogenesis is discussed in the introduction and in chapter 5 
(sections 1.1.3 and 5.1). TGFβ1 also regulates extra-cellular matrix production, cell 
growth and differentiation, tissue repair and some immune responses [258], many of which 
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are thought to be important in COPD pathogenesis. It is capable of conversion of naïve T 
cells into both regulatory T cells (Treg), and pro-inflammatory Th17 cells, with a shift to 
the latter being observed in the presence of IL6[259] - a cytokine known to be important 
in COPD[260]. Retinoic acid, a vitamin A metabolite, regulates this process such that it 
promotes anti-inflammatory change[259], and provides some of the rationale for clinical 
trials of drugs targeting these pathways in COPD by reducing the inflammation driving 
the disease process (section 1.1.3)[261]. 
     Three SNPs in TGFB (rs2241712, rs1800469 and rs1982073) were associated with 
severe COPD in the NETT cohort[108], two (rs2241712 and rs1800469) being linked to 
subjective measures of dyspnoea (though not objective measures of exercise capacity) in a 
later study by the same group[78]. Amongst these, functional roles are known for 
rs1800469 (C-509T), which enhances promoter function, thus increasing levels of 
TGFβ1[262], whilst rs1982073 (T869C) leads to an amino acid substitution (Leu10Pro) 
and is associated with higher levels of mRNA and protein[263]. The direction of 
association in prior work suggests a potential protective role for TGFβ1: a case-control 
study examining rs1982073 in subjects with COPD, resistant smokers and healthy 
controls found the T allele less commonly in COPD subjects[135]. This association was 
replicated in a larger (1390 subjects) European study[134]. Although an animal model 
(described in paragraph 1 of this section) suggests this association has pathogenetic 
credibility[257] some clinical studies contradict this hypothesis, showing that TGFβ1 is 
highly expressed in COPD airways[264, 265], and that this correlates with lung 
function[265] suggesting that the protein may contributes to pathophysiology. 
     Two SNPs in the region surrounding TGFB have also been associated with COPD - 
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rs2241718 and rs6957[108]. These SNPs lie in a protein coding region, and it is not yet 
known whether their association simply reflects proximity to an associated SNP in TGFB, 
whether one of them is the major associated variant in the area (such that those in TGFB 
are only associated because of their proximity) or represent independently associated 
variants, in addition to those reported in TGFB. Both rs2241718 and rs6957 lie in the 
coiled-coil domain-containing protein 97 gene (CCDC97), at the 3’ end of TGFB. 
Although it is known that this gene codes for a protein its function and hence any possible 
role in respiratory pathology is unknown. However, because of the previously published 
association with COPD [108] it was felt that this gene should be studied alongside TGFB 
for the studies contained in this chapter. The version of HapMap used to choose tag SNPs 
for this study (build 36)[71] showed that the block containing the promoter of TGFB also 
spans some of the adjacent hypothetical protein coding gene MGC4093, and as such this 
gene has been examined in the same way as TGFB, in the studies reported in this chapter 
in order to aid ascertainment of the true associated variant(s) in the region.  
 
4.1.3 Group specific component 
     The Group-specific component gene (GC), lies on chromosome 4q12, is approximately 
42kb in size, and is comprised of 13 exons, 1 of which is entirely untranslated, and 2 only 
partially translated[266]. Its protein product, Gc globulin (GC), also known as Vitamin D 
binding protein, is a precursor of macrophage activating factor[267] and enhances the 
neutrophil chemotactic  properties of C5 derived peptides[268]. This is consistent with a 
role for GC in COPD pathogenesis, since activated macrophages and neutrophilic 
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inflammation are believed to be important in COPD pathogenesis (section 1.1.3). The 
latter process is prevented by neutrophil elastase (NE) inhibitors[269], suggesting a 
relationship between GC dependent inflammation and proteolytic pathways, which could 
be of importance in AATD. It is thought that this is because NE cleaves the GC binding 
site on neutrophils, such that GC is freed into the circulation resulting in more neutrophil 
chemotaxis[269].  
     The GC2 allele (rs4588), resulting from a non-synonymous SNP, is protective against 
COPD in Caucasians[110, 111]conferring an OR of 0.5-0.7 of disease in heterozygotes 
(varying depending which allele it is combined with)[110] and an OR of 0.17[111] to 
0.5[110] in homozygotes. This is consistent with the fact that only 10% of this form of the 
protein can be converted to macrophage activating factor[270], though it is not known to 
alter neutrophil chemotaxis[111]. The GC1F allele was linked to an increased risk of 
developing airflow obstruction, emphysema and a rapid decline of FEV1 in Japanese 
subjects[109, 136], but studies in Caucasians have varied in their results[102, 110, 111]. It 
is also of note that GC variants have been associated with diffuse panbronchiolitis[109], a 
condition seen almost exclusively in Japan, which leads to bronchiectasis[271]. 
 
4.2 Aims of this chapter 
This chapter describes specific phenotypic associations of variation in SFTPB, TGFB, its 
surrounding region, and GC. Associations were sought with the COPD phenotypes 
described in chapter 2, with the addition of a measure of pulmonary function relevant to 
small airways disease for TGFB (and surrounding region), and of airway bacterial 
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colonisation for GC because of its potential influence on host defences. Data pertaining to 
frequency and type of airway bacterial colonisation in the study population is therefore 
presented here, prior to this analysis. 
 
4.3 Methods 
The subjects studied have been described in chapter 3 (section 3.2.2), consisting of a case-
control population of 424 subjects and a familial replication dataset of 52 sibling pairs. 
Tag SNPs to cover SFTPB, TGFB, GC, MGC4093 and CCDC97 were chosen using 
HapMap, as described in chapter 2 (section 2.3.2). The latter 2 genes lie immediately 
adjacent to TGFB in a region where association with COPD has been reported[108]; the 
rationale for studying them has been described in sections 1.1.4 and 4.1.2. All tags were 
genotyped using TaqMan® genotyping technologies on an ABI7900HT, using the 
methods described in chapter 3 (section 3.2.2). The locations of tags within the genes are 
shown in Figure 4.1, and their context sequences in Table 4.1.  
 
Each tag was examined for qualitative and quantitative phenotypic associations as 
before, with additional analyses for small airways disease for the TGFB region SNPs, 
using FEF25-75, and airway bacterial colonisation for GC SNPs. FEF25-75 is a measure 
of pulmonary function most specific to small airways disease, found in COPD (section 
1.1.1). It is of particular relevance to study for TGFB since its protein product (TGFβ1) is 
highly expressed in the small airways of subjects with COPD[264], suggesting a sub-
phenotype in which this gene/protein is of most relevance. Similarly since GC is known to 
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have a role in defence of the airway, by means of neutrophil recruitment[268], and is 
associated with DPB[109], a condition in which airway infection is of particular 
prognostic importance[271], it was relevant to examine the phenotype of airway bacterial 
colonisation (section 2.2.6) for this gene alone. 
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Figure 4.1: Location of tag SNPs within SFTPB, the TGFB region and GC 
(c) GC 
(b) TGFB region 
(a) SFTPB 
In each picture the mauve blocks represent exons, the promoter is represented by a grey 
pentagon, other regulatory regions or non-coding areas by pink blocks and introns by a 
black line. In each diagram the 3’ end is on the left of the page. All SNPs are denoted by 
their reference SNP number, with additional decriptors added only where these are 
commonly used in past literature.  
rs2298849 rs222023 
(a) 
(b) 
(c) 
rs2118177 rs1130866 
Thr131Ile 
CCDC97 TGFB MGC4093 
rs11083616 rs1800469 
C-509T 
rs4803455 
rs11466338 
rs8110090 
rs8179181 
rs10417924 
rs8109167 
rs8109627 
rs222029 
rs1491718 
rs2070741 
rs705117 
rs222035 
rs11466345 
rs3733359 
rs1352844 
rs3755967 
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Gene SNP Context sequence Design 
strand 
rs2118177 CTTTGTCCAGAGGCGACTCCTAACC[C/T]TTAGCAGGCTCTGCCCTAACTTACA Reverse SFTPB 
rs1130866 AGGAGGTGAGCTTGCAGCCCTCACA[A/G]TCTGGTTCTGGAAGTAGTCGATGAC Reverse 
rs8109167 CAGAAGCCTTCTGAACAAGACACAC[G/T]GTGAAAACCATGAAGGAAAAAAAAG Forward 
rs8109627 GAATAGATCAGAATTTAGTAGATGT[C/T]AGAAGTGGCATTTCAGATTGGTAGG Reverse 
CCDC97 
rs10417924 AGCTAACACGTGCTGGGGACACACA[C/T]AGACAAGACCATCCATACCAAACAG Reverse 
rs8179181 GTGGAGCTGCAGGCAGGAGAGACGC[A/G]TCAGGGGCAGGGAGGGGCTACCACC Reverse 
rs11466345 CCTCAGCCTCCCAAAGTGCTGGGATTACGGG[T/C]GTGAGCTACCATACCTGGCCTCTCTTAG
GAC 
Reverse 
rs811090 CCCAGAGACAGGACCAAAATATTTT[A/G]AGCAAGGGAGGAATAAGGTCAGATG Reverse 
rs11466338 GATGGCGCTAAGATCTGGTGGTGAAGGAGCC[T/C]GGGAGCAGGGCTGATTTTCTGGCA  Reverse 
rs4803455 CCTGAATTCTCAGTAACTTAGAAGT[A/C]ATTTCTAATGATTCCGGCTGGGCAC Forward 
TGFB 
rs1800469 GAGGAGGGGGCAACAGGACACCTGA[A/G]GGATGGAAGGGTCAGGAGGCAGACA Forward 
MGC4093 rs11083616 AGAAAAGAAAAAAAGAAAATGCACC[A/G]AGTACTAACTAAATCCCAGATGCTA Forward 
rs2070741 TGCTCAACAGACGCATATAAACTCA[T/G]GCTATTTTAATATTTATGCCAAAAA Forward 
rs705117 TAGTTATGTCACAGTTCTATTTGCA[C/T]GGTGTAAAAAATTCCATGTTTCATT Reverse 
rs3755967 TTGTGGTCTCATTATTTCTGGATAT[C/T]AAGTACCTCAGACCTATAACTTTGT Reverse 
rs222035 GCTTCAAACTATTTGTGAAATATTT[G/T]TATGCCATCATTATGCATACACATC Reverse 
rs222023 TTTTTTTTTAAAGATTCTCTTTAGG[A/G]CTCATCAGATTAATGTCACCTGTTT Forward 
rs1491718 GCTGTTAAACTAATACAAGAAAACA[C/T]AGGGGAAAAGCTCCATGATGTTGGT Reverse 
rs222029 TTCACAAGGCTTGCATTCTATATTT[A/G]TTACAATAAGCAAATGAACAACCAG Reverse 
rs1352844 GTAGTGTTTCTCAGAACCTTTAGGA[C/T]GACAAAGGCATGAATTGTGAAACCA Reverse 
rs2298849 AAACACATTACTATTATGAATAATA[A/G]TGTACGAATTAGGTGAGGCTGTTAA Reverse 
GC 
rs3733359 AGAGAGTCTTGCAGCACCTCCTCTCTCCT[G/A]TAGGTGACCATGTAAAAGTGGTAGCC Forward 
Table 4.1: Tag SNP sequences for primer design in SFTPB, TGFB region and GC 
The two possible alleles of each SNP are highlighted in blue between square brackets indicating the position of the SNP within the gene.
4.4 Results 
4.4.1 SFTPB 
     Initially the genotyping success rate was 85.7%, which was unacceptably low, but the 
plots suggested that this was because of many failures on the plates (Figure 4.2). The 
plates had been aliquoted entirely by hand, a potentially error prone technique given the 
small volumes and large number of samples per plate. When a robotic system (Biomek 
2000, UK) was used for DNA aliquoting the success rate improved to over 95% (n=413). 
Both SNPs were in Hardy Weinberg equilibrium (p=0.18 and 0.22 for deviation from 
HWE). Allele and genotype frequencies are shown in Table 4.2.  
     The case-control dataset had 80% power to detect a risk allele OR of 1.71-1.83 of 
developing each phenotype prior to adjustment for covariates, as shown in Table 4.3. This 
is equivalent for a protective allele of 1/(risk OR), in this case a protective variant with 
OR 0.54-0.56. There were no allelic associations of either tag with any phenotype, but 
minor allele homozygotes (CC) of rs2118177 exhibited a lower risk of COPD (defined as 
FEV1/FVC<0.7 with FEV1<80% predicted) in the general regression model for this 
phenotype, producing an OR of 0.28 (95% CI 0.11-0.73) for this phenotype (p=0.01, 
Figure 4.3). This OR is for the minor allele homozygote only, and was obtained after 
adjustment for covariates. No allele OR was significant. Quantitative analyses in the case-
control dataset were non-significant (p>0.1). Quantitative analysis of genotypes in the 
replication dataset showed a significant association of FEV1 with the same SNP 
genotype, the t statistic indicating that FEV1 tended to be higher (t=2.96, p=0.002) 
which is consistent with the result in the case-control group. 
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 When haplotype analysis was performed no haplotype was observed (Figure 4.4).
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Figure 4.2: Example of TaqMan® plot with high failure rate for SFTPB rs2188177 
The plot (SDS version 2.2.2, ABI, UK) shows clustering of failed samples adjacent to the 
negative controls suggesting that there was no DNA present in the wells. Use of a robotic 
aliquoting system improved this, indicating that human error in repeated aliquoting of 
small volumes may have been the cause. 
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 SNP All AATD Chronic bronchitis  Emphysema Bronchiectasis 
rs2118177 [T/C] 
C allele 
TT 
TC 
CC 
 
36.92 
38.26 (158) 
49.63 (205) 
12.11 (50) 
 
33.02 
42.14 (67) 
49.69 (79) 
8.18 (13) 
 
35.71 
38.83 (106) 
51.65 (141) 
9.52 (27) 
 
32.23 
43.42 (33) 
48.69 (37) 
7.89 (6) 
rs1130866 [A/G] 
G allele 
AA 
AG 
GG 
 
49.76 
23.73 (98)  
53.03 (219) 
23.25 (96) 
 
54.09 
18.86 (30) 
54.08 (86) 
27.04 (43) 
 
49.08 
24.91 (68) 
52.01 (142) 
23.08 (63) 
 
45.39 
30.26 (23) 
48.68 (37) 
21.05 (16) 
 
 Table 4.2: Allele and genotype frequencies of SFTPB tag SNPs 
SNP alleles are listed [major, minor] and the minor allele frequency given as a percentage, 
together with all genotype frequencies as a percentage, with the raw value in brackets. 
 
 
 
SNP Phenotype Minimum odds ratio detectable with 80% 
power 
Emphysema 1.81 
Bronchiectasis 1.76 
rs2118177 
Chronic 
bronchitis 
1.57 
Emphysema 1.86 
Bronchiectasis 1.74 
rs1130866 
Chronic 
bronchitis 
1.54 
 
Table 4.3: Power of the SFTPB studies to detect qualitative phenotypes in the case-control 
dataset  
Power calculations were carried out as before (Appendix 4), and the ORs shown are prior 
to adjustment for covariates. 
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Figure 4.3: Distribution of rs2118177 genotypes in subjects with and without COPD 
The CC genotype, being the minor allele homozygote, was less common in those with 
COPD, suggesting a protective effect of this genotype. The difference in genotype 
frequency was statistically significant, with p=0.01 in the regression model after 
adjustment for smoking, gender and age. 
 
 
Figure 4.4: Linkage disequilibrium plot for SFTPB tag SNPs 
No haplotype block was observed in Haploview for further analysis, as shown by the low 
r2 value (17) between the 2 SNPs in this LD plot. See Figure 3.5 for further information 
about interpretation of LD plots. 
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4.4.2 TGFB region 
     Genotyping was successful in 93.2% of cases (n=395). All SNPs were in HWE (p>0.05). 
Two cluster plots were observed for several TGFB SNPs (Figure 4.5) indicating absence of 
the minor allele homozygote. As a consequence power lessened, such that for the least 
common minor allele (rs8110090) the study had 80% power to detect an OR of 2.96 in the 
worst affected phenotypic analysis, compared to the best OR of 1.55 achieved with 
rs4803455. Allele and genotype frequencies are shown in Table 4.4, and power prior to 
adjustment for covariates in Table 4.5. 
     There were no allelic or genotypic associations with any qualitative phenotype in the 
case-control dataset. One SNP was associated with FEV1 in the quantitative analyses 
(rs4803455, p=0.043), with a trend towards association being observed for the same SNP 
with FEV1/FVC (p=0.076). SNPs tagging the haplotype blocks upstream of rs4803455 
also showed a trend towards an association with FEV1/FVC although this also failed to 
reach significance (rs1800469, p=0.052; rs11083616, p=0.100). Abnormalities of this alone 
may occur with small airways disease, and the lung function measure most specific to this 
phenotype (FEF25-75) was associated with rs1800469 (p=0.017). The most associated 
SNP genotype was the TT genotype of rs1800469; the difference in FEF25-75 observed is 
illustrated in Figure 4.6. Significant tag SNP associations, and supporting trends, from the 
regressions are shown in Table 4.6.  
 
 160
In the replication dataset quantitative analyses using FEV1/FVC were not significant 
(p>0.05), but there was insufficient information available pertaining to FEF25-75 to 
assess this phenotype. 
 
Haplotype analysis revealed one haplotype block, which showed no qualitative 
phenotypic associations. It is of note that the 3 SNPs (rs4803455, rs1800469 and 
rs11083616) showing associations and trends with FEV1/FVC and FEF25-75 tended to 
form a haplotype (Figure 4.7), but the Haploview software did not show significant 
correlations between these SNPs (p>0.05) so the group was not analysed as a block.  
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Figure 4.5: Examples of two cluster TaqMan® plot for rs8110090 & rs1146638 in TGFB 
Two cluster plots were seen for two SNPs within TGFB, examples of the plots from SDS 
(version 2.2.2, ABI, UK) being shown above. 
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Gene SNP All AATD Chronic 
bronchitis  
Emphysema Bronchiectasis 
rs8109167 [G/T] 
T allele 
GG 
GT 
TT 
 
20.00  
63.44 (251) 
32.91 (130) 
3.54 (14) 
 
21.48 
61.07 (91) 
34.90 (52) 
4.03 (6) 
 
21.27 
62.42 (167) 
32.84 (88) 
4.85 (13) 
 
19.18 
65.75 (48) 
30.14 (22) 
4.11 (3) 
rs8109627 [T/C] 
C allele 
TT 
TC 
CC 
 
31.01 
47.34 (187) 
43.29 (171) 
9.37 (37) 
 
29.28 
45.64 (68) 
44.97 (67) 
9.39 (14) 
 
29.86 
47.69 (128) 
44.62 (120) 
7.46 (20) 
 
29.45 
49.32 (36) 
42.47 (31) 
8.22 (6) 
CCDC97 
rs10417924 [C/T] 
T allele 
CC 
CT 
TT 
 
19.12 
65.06 (257) 
31.65 (125) 
3.29 (13) 
 
17.45 
68.46 (102) 
28.19 (42) 
3.36 (5) 
 
16.60 
68.28 (183) 
30.22 (81) 
1.49 (4) 
 
19.18 
64.38 (47) 
32.88 (24) 
2.74 (2) 
rs8179181 [G/A] 
A allele 
GG 
GA 
AA 
 
23.80 
56.96 (225) 
38.48 (152) 
4.56 (18) 
 
24.49 
57.72 (86) 
37.58 (56) 
4.70 (7) 
 
26.87 
48.13 (129) 
50.00 (134) 
1.87 (5) 
 
24.66 
56.16 (41) 
38.36 (28) 
5.48 (4) 
rs11466345[A/G] 
G allele 
AA 
AG 
GG 
 
9.75 
81.01 (320) 
18.48 (73) 
0.51 (2) 
 
11.07 
78.52 (117) 
20.81 (31) 
0.67 (1) 
 
10.07 
79.85 (214) 
20.15 (54) 
- 
 
9.59 
82.19 (60) 
16.44 (12) 
1.37 (1) 
rs8110090 [A/G] 
G allele 
AA 
AG 
GG 
 
5.32 
89.36 (353) 
10.63 (42) 
- 
 
5.37 
89.26 (133) 
10.74 (16) 
- 
 
4.29 
91.42 (245) 
8.58 (23) 
- 
 
6.16 
87.67 (64) 
12.33 (9) 
- 
rs11466338[A/G] 
G allele 
AA 
AG 
GG 
 
8.48 
83.04 (328) 
16.96 (67) 
- 
 
7.72 
84.78 (126) 
15.44 (23) 
- 
 
7.09 
85.82 (230) 
14.18 (38) 
- 
 
7.54 
84.93 (62) 
15.07 (11) 
- 
TGFB 
rs4803455 [A/C] 
C allele 
AA 
AC 
CC 
 
42.53 
33.42 (132) 
48.10 (190) 
18.48 (73) 
 
43.29 
32.21 (48) 
48.99 (73) 
18.89 (28) 
 
41.60 
35.45 (95) 
45.90 (123) 
18.66 (50) 
 
43.84 
32.88 (24) 
46.58 (34) 
20.55 (15) 
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rs1800469 [C/T] 
T allele 
CC 
CT 
TT 
 
26.96 
52.91 (209) 
40.25 (159) 
6.84 (27) 
 
27.18 
52.35 (78) 
40.94 (61) 
6.71 (10) 
 
22.01 
60.82 (163) 
34.43 (92) 
4.85 (13) 
 
26.03 
54.79 (40) 
38.36 (28) 
6.85 (5) 
MGC4093 rs11083616[A/G] 
G allele 
AA 
AG 
GG 
 
32.78 
44.57 (176) 
45.32 (179) 
10.13 (40) 
 
34.23 
42.28 (63) 
46.98 (70) 
10.74 (16) 
 
30.78 
47.76 (128) 
42.91 (115) 
9.33 (25) 
 
33.56 
42.47 (31) 
47.95 (35) 
9.59 (7) 
 
Table 4.4: Allele and genotype frequencies of TGFB region tag SNPs 
SNP alleles are listed [major, minor] and the minor allele frequency given as a percentage, 
together with all genotype frequencies as a percentage, the raw number being given in 
brackets. 
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SNP Phenotype Minimum odds ratio detectable with 
80% power 
Emphysema 1.86 
Bronchiectasis 1.86 
rs8109167 
Chronic bronchitis 1.62 
Emphysema 1.77 
Bronchiectasis 1.72 
rs8109627 
Chronic bronchitis 1.53 
Emphysema 1.92 
Bronchiectasis 1.84 
rs10417924 
Chronic bronchitis 1.67 
Emphysema 1.83 
Bronchiectasis 1.83 
rs8179181 
Chronic bronchitis 1.61 
Emphysema 2.23 
Bronchiectasis 2.32 
rs11466345 
Chronic bronchitis 1.85 
Emphysema 2.96 
Bronchiectasis 2.60 
rs8110090 
Chronic bronchitis 2.24 
Emphysema 2.50 
Bronchiectasis 2.40 
rs11466338 
Chronic bronchitis 2.03 
Emphysema 1.79 
Bronchiectasis 1.74 
rs4803455 
Chronic bronchitis 1.55 
Emphysema 1.87 
Bronchiectasis 1.76 
rs1800469 
Chronic bronchitis 1.58 
Emphysema 1.77 
Bronchiectasis 1.71 
rs11083616 
Chronic bronchitis 1.53 
 
Table 4.5: Power of the TGFB region studies to detect qualitative phenotypes in the case-
control dataset  
Power calculations were carried out as before (Appendix 4), and the ORs shown are prior 
to adjustment for covariates. 
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  Tag SNP Phenotype B SE (B) r2 
change 
p value 
logFEV1  0.037 0.018 0.009 0.043 * rs4803455 
logFEV1/FVC 0.022 0.012 0.007 0.076 
logFEV1/FVC -0.041 0.033 0.007 0.052 § rs1800469 
FEF25-75 -1.501 0.629 0.041 0.019 
* rs11083616 logFEV1/FVC 0.20 0.013 0.006 0.100 
 
Table 4.6: TGFB region tag SNP associations in linear regression models 
The table shows the regression parameters models from those models where p≤0.1 Co-
dominant models are denoted *, in each case the heterozygote was coded 1, and the minor 
allele homozygote 2, such that when the B value is positive it indicates a higher level of 
the outcome variable in minor allele homozygotes. § indicates a recessive model. 
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Figure 4.6: FEF25-75 relates to rs1800469 genotype 
The bar chart shows the mean (SE) prior to adjustment for covariates, stratified by 
genotype. The minor allele homozygote is shown separately as this genotype was only 
significant in a recessive model. The difference is significant, with p=0.019 in the 
regression model. 
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Figure 4.7: Linkage disequilibrium plot for tag SNPs in the TGFB region 
This output from Haploview shows the r2 values between SNPs, and identified one 
haplotype block containing all tags within CCDC97 and 2 within TGFB. The 3 tags 
showing a tendency to association with small airways disease (rs4803455, rs1800469 and 
rs11083616) have a propensity to form a haplotype, as can be seen from the r2 values, and 
colour of the blocks, although this was not statistically significant. 
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4.4.3 GC 
     Genotyping was successful in 90.1% of cases (n=382). This is a little lower than some of 
the other genes contained in this thesis, although above the acceptable threshold of 90%. 
This occurred predominantly because of initial problems with the assay for rs705117, 
which required alterations of the PCR reaction mixture before adequate genotype 
discrimination was achieved. This process is summarised in Figure 4.8. Despite this 
improvement, a genotype could not be confidently allocated in 42 cases for this SNP. All 
SNPs were in Hardy Weinberg equilibrium (p>0.05 for deviation from HWE), except 
rs3755967 (p=0.04), which was therefore excluded from further anlayses. Allele and 
genotype frequencies are shown in Table 4.7. In the qualitative analyses the mean OR the 
study had 80% power to detect was 2.01; full details of power are shown in Table 4.8. 
     One SNP (rs2070741) showed both allele and genotype association with bronchiectasis, 
with the minor allele [C] conferring an OR of 1.80, as shown in Table 4.9. A second SNP 
showed an association with the same phenotype in the minor allele homozygote, but its 
significance was lost in an allelic analysis (Table 4.9). No other associations were seen with 
the qualitative or quantitative phenotypes described earlier (p>0.1 in regression models).      
     Further analyses were undertaken based on the existence of bacterial colonisation of 
the airway (section 2.2.6), to give an indication of the mechanism behind the phenotypic 
association. One hundred sputum samples were analysed; the frequency of colonisation 
and bacterial species identified are shown in Table 4.10. Some examples of the growth 
plates used are shown in Figure 4.9. Subjects with airway colonisation exhibited no 
significant clinical differences from those without (Table 4.11), but the phenotype was 
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more likely to occur in carriers of the C allele of rs2070741. The allele conferred an OR of 
3.83 for this phenotype (p=0.04). There was insufficient data relating to bronchiectasis 
and bacterial colonisation in the family dataset to test replication. 
     Three haplotype blocks were observed in the case-control dataset (Figure 4.10), but 
none showed any qualitative phenotypic associations (all p>0.1 in each analysis). 
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 (b)  Double amount of fluorescent assay (a)  Original PCR reaction 
 
 
(c)  Increased PCR cycles to 50, with assay amount from (b) 
 
Figure 4.8: TaqMan® plots for selected rs705117 genotyping reactions 
(a) No genotypic groups could be distinguished by fluorescence signals in the original PCR 
reaction (b) Increasing the amount of fluorophore allowed genotypic groups to be 
distinguished by the software, but there was a linear pattern; clear clusters were not seen 
until the PCR cycles were also extended (c).  
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SNP All AATD Chronic bronchitis  Emphysema Bronchiectasis 
rs2070741 [A/C] 
C allele 
AA 
AC 
CC 
 
9.29 
81.41 (311) 
18.11 (69) 
0.52 (2) 
 
8.78 
83.11 (123) 
16.22 (24) 
0.68 (1) 
 
9.55 
81.65 (218) 
17.77 (47) 
0.75 (2) 
 
14.00 
74.67 (56) 
22.67 (17) 
2.67 (2) 
rs705117 [T/C] 
C allele 
TT 
TC 
CC 
 
17.54 
68.85 (263) 
27.23 (104) 
3.93 (15) 
 
16.89 
70.95 (105) 
24.33 (36) 
4.73 (7) 
 
17.23 
70.04 (187) 
25.47 (68) 
4.49 (12) 
 
17.33 
69.33 (52) 
26.67 (20) 
4.00 (3) 
rs3755967 [C/T] 
T allele 
CC 
CT 
TT 
 
27.62 
50.26 (192) 
44.24 (169) 
5.50 (21) 
 
28.04 
51.35 (76) 
41.22 (61) 
7.43 (11) 
 
29.03 
47.19 (167) 
47.57 (127) 
5.24 (14) 
 
28.00 
49.33 (37) 
45.33 (34) 
5.33 (4) 
rs222035 [G/T] 
G allele 
GG 
GT 
TT 
 
42.93 
33.25 (127) 
47.64 (182) 
19.12 (73) 
 
44.59 
34.46 (51) 
42.14 (62) 
23.65 (35) 
 
44.76 
32.21 (86) 
46.07 (123) 
21.72 (58) 
 
46.00 
36.00 (27) 
36.00 (27) 
28.00 (21) 
rs222023 [G/A] 
A allele 
GG 
GA 
AA 
 
5.89 
88.74 (339) 
10.73 (41) 
0.52 (2) 
 
4.05 
92.57 (137) 
6.76 (10) 
0.68 (1) 
 
5.43 
89.89 (240) 
9.36 (25) 
0.75 (2) 
 
7.33 
88.00 (66) 
9.33 (7) 
2.67 (2) 
rs1491718 [T/C] 
C allele 
TT 
TC 
CC 
 
13.22 
75.13 (287) 
23.30 (89) 
1.57 (6) 
 
13.18 
74.32 (110) 
25.00 (37) 
0.68 (1) 
 
12.55 
76.40 (204) 
22.10 (59) 
1.50 (4) 
 
13.33 
74.67 (56) 
24.00 (18) 
1.35 (1) 
rs222029 [A/G] 
G allele 
AA 
AG 
GG 
 
18.32 
67.02 (256) 
29.32 (112) 
3.67 (14) 
 
16.22 
71.62 (106) 
24.32 (36) 
4.05 (6) 
 
17.98 
67.79 (181) 
28.46 (76) 
3.91 (10) 
 
20.40 
61.84 
31.53 
2.63 
rs1352844 [C/T] 
T allele 
CC 
CT 
TT 
 
12.83 
75.13 (287) 
24.08 (92) 
0.79 (3) 
 
11.15 
77.71 (115) 
22.30 (33) 
- 
 
13.30 
73.78 (197) 
25.84 (69) 
0.37 (1) 
 
15.33 
70.67 (53) 
28.00 (21) 
1.35 (1) 
rs2298849 [C/T] 
T allele 
CC 
 
19.50 
64.92 (248) 
 
17.23 
69.59 (103) 
 
20.22 
63.67 (170) 
 
24.00 
54.67 (41) 
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CT 
TT 
31.15 (119) 
3.93 (15) 
26.35 (39) 
4.05 (6) 
32.21 (86) 
4.12 (11) 
42.67 (32) 
2.70 (2) 
rs3733359 [G/A] 
A allele 
GG 
GA 
AA 
 
9.55 
82.03 (313) 
17.02 (65) 
1.05 (4) 
 
9.80 
81.38 (120) 
18.24 (27) 
0.68 (1) 
 
8.80 
83.15 (222) 
16.10 (43) 
0.75 (2) 
 
8.67 
82.67 (62) 
17.33 (13) 
- 
 
Table 4.7: Allele and genotype frequencies of GC tag SNPs 
SNP alleles are listed [major, minor] and the minor allele frequency given as a percentage, 
together with all genotype frequencies as a percentage, with the raw value in brackets. 
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 SNP Phenotype Minimum odds ratio detectable with 80% 
power 
Emphysema 2.22 
Bronchiectasis 2.33 
rs2070741 
Chronic bronchitis 1.89 
Emphysema 2.13 
Bronchiectasis 2.13 
rs705117 
Chronic bronchitis 1.82 
Emphysema 1.82 
Bronchiectasis 1.75 
rs3755967 
Chronic bronchitis 1.56 
Emphysema 1.77 
Bronchiectasis 1.70 
rs222035 
Chronic bronchitis 1.54 
Emphysema 2.93 
Bronchiectasis 2.92 
rs222023 
Chronic bronchitis 2.08 
Emphysema 2.05 
Bronchiectasis 2.05 
rs1491718 
Chronic bronchitis 1.76 
Emphysema 2.00 
Bronchiectasis 1.91 
rs222029 
Chronic bronchitis 1.64 
Emphysema 2.21 
Bronchiectasis 2.05 
rs1352844 
Chronic bronchitis 1.74 
Emphysema 2.06 
Bronchiectasis 1.90 
rs2298849 
Chronic bronchitis 1.61 
Emphysema 2.06 
Bronchiectasis 2.18 
rs3733359 
Chronic bronchitis 1.90 
 
Table 4.8: Power of the GC studies to detect qualitative phenotypes in the case-control 
dataset  
Power calculations were carried out as before (Appendix 4), and the ORs shown are prior 
to adjustment for covariates. 
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  Minor allele 
homozygote 
Minor 
allele 
Allele 
OR 
95% CI 
rs2070741 [A/C] 0.031 0.046 1.80 1.02-3.19 
rs2298849 [C/T] 0.013 NS - - 
 
Table 4.9: GC tag SNP associations with bronchiectasis 
The table shows the p values for associated SNPs only. SNPs are listed showing 
[major/minor] alleles, together with the OR of bronchiectasis conferred by genotypes 
containing the minor allele. 
 
 Frequency (n) 
Not colonised 30 
Mixed normal flora 20 
Haemophilus influenzae 23 
Moraxella catarrhalis 11 
Haemophilus 
parahaemolyticus 
8 
Staphylococcus aureus 6 
Pseudomonas aeruginosa 5 
Streptococcus pneumoniae 4 
Haemophilus parainfluenzae 3 
Pseudomonas species 2 
Proteus mirabilis 2 
Enterobacteriaceae 2 
Haemophilus haemolyticus 1 
Klebsiella oxytoca 1 
Haemophilus species 1 
 Bacterial numbers  in cfu/ml 8.0x107  
(1.2 x107-1.3 x109) 
 
Table 4.10: Microbiology of stable state sputum samples in AATD subjects 
The majority of subjects had at least one bacterial species in the airway, with only 30 
samples having none present. 
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(a) 
(b) 
 
 
 
(c) 
Figure 4.9: Sputum culture plates 
(a) Pseudomonas colonies: small, white colonies, shown on primary plate and a subsequent 
dilution and a specific cetrimide plate (b). P.aeruginosa appears green and will fluoresce 
under UV light when grown on this medium. 
(c) Staphylococcus aureus colonies: larger, yellow colonies, with dilution across the plate  
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 Airway bacterial colonisation No colonisation  
Age in years 51.37 (47.24-55.31) 50.74 (42.48-59.05) 
Smoking in pack years 16.00 (5.70-26.30) 18.00 (11.00-22.00) 
FEV1%predicted 32.71 (21.14-56.18) 28.15 (19.57-38.21) 
FEV1/FVC % 37.70 (26.10-47.00) 33.00 (25.00-45.00) 
KCO %predicted 66.31 (3.32) 56.57 (5.07) 
Bronchiectasis % 35.56 34.78 
Emphysema % 86.67 86.96 
UZVI % voxels <-910HU 30.96 (2.53) 44.50 (4.53) 
LZVI % voxels <-910HU 49.80 (29.68-59.43) 59.40 (52.10-65.50) 
 
Table 4.11: Characteristics of subjects with and without airway bacterial colonisation  
Data is shown as mean (SE) and median (IQR), as described in chapter 2 (section 2.3.1). 
There were no statistically significant differences. 
 
 
 
Figure 4.10: Linkage disequilibrium plot for GC tag SNPs 
The output above from Haploview, using r2 values as before, shows that 3 haplotype 
blocks were observed. No phenotypic associations were seen with any of these blocks. 
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4.5 Discussion 
     The results presented in this chapter illustrate the concept that detailed phenotypic 
information is key when examining genetic associations, since SFTPB, the TGFB region 
and GC show different phenotypic associations from one another, yet have all been 
associated with the broader diagnosis of COPD in previous published work. It is 
interesting that the associations seen are consistent with their protein products’ putative 
roles in pathogenesis, though further studies would be needed to endorse this. However 
the strength of these associations and the degree of confidence in the results is also 
variable, and will now be discussed. 
    The association of rs2118177 SNP in SFTPB with COPD, defined by lung function, in 
the case-control dataset and with FEV1 in the family dataset indicate a potential 
protective effect of the minor allele homozygote. It is an intronic SNP of no known 
function that tags the promoter region of the gene in HapMap[71], though coverage here 
is relatively sparse. In usual COPD this SNP has been associated with exacerbation 
frequency[113]; a number of SNPs within the gene were associated with this outcome 
(defined by health care utilisation only) in a study population comprising participants in 
NETT. The most associated SNP was in the promoter region of the gene (rs3024791, 
p=0.007) but rs2118177 showed a weaker association. This phenotype has not been 
examined in other studies, so the result should be viewed with caution until it has been 
replicated. Other genetic association studies derived from NETT have not examined this 
SNP [19, 72, 78] and the only similar study in AATD did not genotype this SFTPB SNP 
[236].  The AAT genetic modifier study only genotyped rs1130866 (Thr131Ile), since this 
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had previously been the most associated SNP in SFTPB with COPD, and was only able 
to examine association with spirometric measures[236]. These two facts might explain the 
lack of association seen.  
     Evidence from the study reported in this chapter alone would be insufficient to justify 
the expense of fine mapping the haplotype block to find the actual disease associated 
variation, but should encourage further study of the role of surfactant proteins in 
emphysema and AATD, since a genetic association implies a role for the protein product 
in pathogenesis.  Current evidence would suggest that it is most likely to be involved in 
parenchymal disease, since levels are low in an animal model of emphysema[252] and 
mathematical models suggest that the effect of this in the lung would be to alter alveolar 
surface tension in such a way that emphysema could result[253]. We were unable to prove 
such an association here, perhaps because the number included in the analyses based on a 
CT diagnosis of emphysema was lower, as CT data was not available on all subjects. If 
SFTPB contributes to emphysema it might show potential in treating the condition, 
especially as preparations of surfactant suitable for delivery to the lung are already in 
use[272]. 
     In the TGFB region 3 tag SNPs showed a tendency to associate with lung function, 
consistent with small airways disease in the case-control dataset. However, since FEF25-
75 (the lung function measure most specific for small airways disease) was not available in 
the familial dataset, it was not possible to replicate the association. The associations with 
other lung function measures were tested in the familial dataset but showed no 
association. The most associated SNP was rs1800469 (C-509T) in which the T allele 
elevates circulating TGFβl by increasing gene transcription[262]; this suggests that the 
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protein contributes to small airways disease, and is consistent with prior clinical work 
examining small airway biopsies which show elevated levels of the protein product 
(TGFβ1) in this location[264]. In usual COPD genetic association work on rs1800469 has 
shown conflicting results - in American Caucasian subjects the T allele has been associated 
with both COPD[108] and increased dyspnoea[78], but C allele containing haplotypes are 
also associated with COPD in European Caucasians[134] and in Chinese subjects[273]. If 
the association is specific to small airways disease, as our results suggest, then inadequate 
phenotyping might explain these inconsistencies. It is also possible that the true 
association is with a SNP in LD with rs1800469. The two SNPs tagging haplotype blocks 
adjacent to rs1800469 (rs4803455 and rs11083616) were associated with FEV1 and showed 
a slight trend to association with FEV1/FVC respectively, both being phenotypes 
consistent with early disease, and the haplotype analysis suggested that these tended to 
form a block with rs1800469 (Figure 4.8) though this did not reach statistical significance. 
The rs4803455 SNP is an intronic SNP in TGFB of no known functional consequence, and 
with no known disease associations. rs11083616 is an intronic SNP, again with no known 
functional consequence, and lies in MGC4093, a gene which codes for a hypothetical 
protein. Expression of MGC4093 is increased in the small airway epithelium of smokers 
compared to those who have never smoked[274], and correlated with emphysema severity 
in subjects in NETT[275]. This suggests a role for the protein in small airway disease, and 
emphysema, such that genetic variation might also be associated with disease. This gene, 
its putative protein product, and their roles in COPD are, therefore, worthy of further 
study. Since TGFβ1 is a multifunctional protein, if a specific association were proven with 
TGFB it is unlikely to be a target for drug design, as blocking or altering its actions would 
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probably have widespread, potentially harmful effects. 
     Two GC SNPs showed association with bronchiectasis and/or bacterial colonisation of 
the airway in the case-control dataset. Information pertaining to these phenotypes was 
not available in the familial replication dataset, so the association could not be replicated. 
Both are intronic SNPs of no known function, do not tag known functional variants, and 
were at low frequency in the cases studied. The latter fact in particular means that the 
result must be viewed with caution as the possibility of false positive results is higher in 
small datasets. However, given that GC is involved in both neutrophil chemotaxis and 
macrophage activation, by enhancement of the chemotactic properties of complement 
derived peptides[268] and because it is a precursor of macrophage activating factor[267], 
the observation of an apparent genetic association with airway defence against infection is 
interesting. Airway bacterial colonisation is associated with increased pulmonary 
inflammation[235], and with an increased frequency of exacerbations[276], both of which 
may influence disease progression. The cause of bronchiectasis in AATD is unknown; 
though it tends to co-locate with emphysema in the majority of subjects, a bronchiectasis 
predominant phenotype is also recognised[22]. This genetic association generates a 
hypothesis that structural damage to the airway from repeated exacerbations, after 
bacterial colonisation of the airway, could lead to bronchiectasis. It will therefore also be 
of importance to examine the role of GC polymorphisms in bronchiectasis unrelated to 
AATD, and to study the protein’s role further in airway disease.   
    The level of p-value to determine significance in genetic studies is controversial, as 
discussed previously (section 3.5). The studies herein adopted the well recognised strategy 
of replication in an independent dataset. Unfortunately there was insufficient phenotypic 
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data to test for replication of all observed associations in TGFB and GC in the family 
dataset, thus the association in SFTPB is the only one that can be viewed with 
confidence. In diseases where a number of genes influence outcome, as is likely to be the 
case with COPD, each polymorphism may confer only a small increased risk of disease, 
thus large numbers are needed to detect differences between populations. In this respect 
the studies in this thesis are limited, and underpowered. Power was a particular issue with 
the studies contained in this chapter where many tag SNPs exhibited low minor allele 
frequencies. This means that an effect cannot be excluded in all SNPs, except where the 
allele effect size exceeds that reported in Table 4.8. These are somewhat higher than many 
of the OR’s now being reported in other complex diseases with multiple genetic 
associations, which may be as low as 1.1[277]. The level of OR more typically observed 
when the association is within a locus whose protein product is deemed 
pathophysiologically important, such as the thyroid stimulating hormone receptor gene in 
Grave’s disease, is closer to 1.5[278]. Nevertheless it does not diminish the significance of 
the result for rs2118177, within SFTPB, since this has replicated in both datasets. 
   
 
4.6 Conclusions 
Variation within the haplotype block tagged by rs2218177 in SFTPB is associated with 
COPD in AATD. Variation within the TGFB region and within GC associates with small 
airways disease and bronchiectasis respectively, but these results require verification in an 
independent patient population. 
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Chapter 5: The role of MMPs 
 
5.1 Introduction 
     Matrix Metalloproteinases (MMP’s) compromise a structurally and functionally related 
group of twenty proteolytic enzymes, which are capable of degrading components of the 
extracellular matrix[39]. The functions of some of those thought to be important in COPD 
are summarised in Table 5.1. It is this potential for destruction which is thought to 
contribute to the pathogenesis of COPD, consistent with the protease-antiprotease theme 
discussed in Chapter 1 (section 1.1.3)). Many clinical studies have reported the presence of 
MMPs in the lung, with elevated levels in subjects with COPD[279, 280], supporting this 
concept. 
     MMPs are synthesised as proenzymes which are maintained in an inactive form by 
interaction of a zinc residue in their catalytic domain with a cysteine residue within the 
proenzyme domain, as shown in Figure 5.1. Macrophages secrete many MMPs, including 
MMP1, MMP3, MMP7 and MMP12[39]. A separate group, known as membrane type 
MMPs, are localised to the cell surface (MMP14-17). The production of both MMP types is 
highly regulated at the transcriptional level by a variety of growth factors and 
cytokines[39]. A further two macrophage derived MMPs (MMP8 and MMP9) are not as 
well regulated, being stored in the granules of neutrophils for rapid release[39]. 
Subsequent MMP activity is regulated by tissue inhibitors of metalloproteases (TIMPs). 
Although all TIMP’s are capable of inhibiting any MMP their affinity for each MMP 
varies[281].  
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  Interstitial 
collagens 
Basement membrane components Elastin 
MMP1 III, I, II Laminin, entactin, proteoglycan - 
MMP3 - Laminin, entactin, proteoglycan, pepsinised type IV 
collagen 
+ 
MMP9 Gelatin Types IV and V collagen, entactin, proteoglycan ++ 
MMP12 - Laminin, entactin, proteoglycan, pepsinised type IV 
collagen 
++++ 
 
Table 5.1: Activity of selected MMP against components of the extracellular matrix 
The table shows some of the MMPs most widely studied in relation to COPD, delineating 
their substrates in 3 columns. The first two list interstitial collagens and basement 
membrane components that the given MMP is capable of degrading. The third column 
indicates relative activity levels against elastin by the use of + and - signs, such that a 
single + indicates some activity, further + signs indicates higher activity and - no activity. 
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 Catalytic zinc ion 
Cysteine residue within 
proenzyme domain 
 
Figure 5.1: The structure of an MMP molecule 
The picture shows the structure of MMP9, used as an example of the molecular structure 
of MMPs. All MMPs have a catalytic domain, highlighted here in pink and a proenzyme 
domain, shown in blue. Within these areas the zinc and cysteine residues that interact to 
keep the molecule in inactive conformation have been labelled.  
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     MMP’s are logical candidate genes for association with COPD, and have been the 
subject of a number of genetic studies, as outlined in Chapter 1 (section 1.1.4). MMPs 
have been mapped to chromosomes 11, 14, 16, 20 and 22 with several (including MMP1, 
MMP3 and MMP12) being clustered on the long arm of chromosome 11[282]. This area 
was linked to both FEV1 and KCO in a European familial genetic association study in 
AATD[203]. For this reason this cluster of MMPs, rather than any other previously 
associated MMP, was chosen for the studies contained in this chapter. 
  
5.1.1 MMP1, MMP3 and MMP12 
     MMP1, MMP3 and MMP12 lie adjacent to one another on chromosome 11q22-23.    
MMP1 is approximately 17kb in size[283] and is comprised of 10 exons and 11 large 
introns. MMP1, also known as collagenase, is capable of breaking down type I, II and III 
collagen, which are ubiquitous in the connective tissues of the body, including the lung. 
MMP3 is similar in structure to MMP1, such that their protein products share over half 
their amino acid sequences, suggesting a common evolutionary origin[284]. MMP3 is also 
known as stromelysin, and digests proteoglycan, laminin and type IV collagen[285] which 
also contribute to the extracellular matrix in the lung. MMP12 is somewhat smaller, 
being 1.8kb in length, but codes for a similar sized protein (470 amino acids). It is known 
as macrophage metalloelastase, is produced by alveolar macrophages and is capable of 
degrading elastin[286]. 
     In usual COPD a SNP in the promoter region of MMP1 (rs1799750) was implicated in 
upper zone dominant emphysema[19] and in decline of FEV1[77], as detailed in chapter 1 
 185
(section 1.1.4).  The rs1799750 SNP increases gene expression by creation of an extra 
transcription factor binding site (ETS)[287]. An animal model in which transgenic mice 
overexpress MMP1, results in the presence of  emphysema [288]. The SNP associations 
seen must, however, be viewed with caution as neither has been replicated. The NETT 
genetics study[19] attempted replication of the association of rs1779750 with emphysema 
zone by examining both surgically and medically treated groups, but found no association 
in the latter. When the entire NETT cohort were compared to healthy subjects from the 
normative aging study no association with emphysema was seen, nor was there association 
in a family cohort with COPD[72]. No other studies have examined rs1799750 in relation 
to lung function decline. A SNP in MMP12 (rs652438) was also implicated in lung 
function decline in the LHS, but only as part of a haplotype with rs1799750 (MMP1)[77]. 
Animal studies here show that MMP12 null mice are protected against smoke related lung 
injury[289], thus making it a good candidate gene. Again, however, the association 
described in usual COPD has not been replicated, and should be viewed with caution. 
Important interactions of AAT and MMP12 have also been observed in in vitro studies, 
where smoke exposed macrophages fail to secrete MMP12 in the presence of AAT[202] 
providing further rationale for the study of this gene in subjects with AATD. Unlike 
MMP1 and MMP12, MMP3 had not previously been associated with COPD at the start 
of this project, nor are there are any specific animal models or in vitro work regarding its 
protein product in respiratory disease. However, MMP3 lies between MMP1 and 
MMP12, thus is still within the region of the linkage peak in AATD[203] and was worthy 
of further association analysis in AATD. Subsequent to the completion of this project a 
large genome wide study in usual COPD has reported association of a SNP within MMP3 
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(rs615098) with a quantitative emphysema phenotype [73]. 
 
5.2 Aims of this chapter 
This chapter describes associations of MMP1, MMP3 and MMP12 with lung function 
and lung function decline in AATD, and forms a follow up study after the report of 
linkage of FEV1 and KCO to this region in AATD[203]. It, therefore, aims to provide 
initial evidence of replication of this association, and narrow the size of the block 
containing the associated variant(s) such that further fine mapping might be planned if 
appropriate. 
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5.3 Methods 
     The subjects studied have been described in Chapter 3 and comprise the unrelated case-
control dataset only (n=424), since some members of the familial dataset had participated 
in the linkage study that reported an association which this study aims to replicate[203]. 
Specific phenotypes relating to lung function, lung function decline and emphysema zone 
were chosen because of prior evidence in AATD[203] and usual COPD[19, 77]. The group 
assessed for decline of lung function showed no difference in any demographic or clinical 
feature from the whole group (described in Chapter 3), except that they had smoked 
slightly more (median 18.75 v 14.00 pack years, p=0.030). Clinical characteristics of the 
genotyped decline group are shown in Table 5.2. Non-genetic influences upon decline of 
lung function have been assessed further and are described in Chapter 7, significant 
independent predictors being included in the regression models herein. Emphysema zone 
was analysed as a quantitative phenotype, defined as UZVI-LZVI in the presence of a 
visual appearance and densitometry consistent with emphysema. 
     Tag SNPs covering the 3 genes were chosen using HapMap, and genotyped using 
TaqMan® genotyping technologies, as described previously (Chapter 3, section 3.2.2). The 
location of tags is shown in Figure 5.2, and the context sequences for primer design in 
Table 5.3. One tag in MMP12 (rs476185) failed design, probably due to a high GC content 
in the region. No other tags were available within the frequency limits (MAF>5%) thus 
this haplotype block could not be genotyped. 
     Haplotypes were identified in Haploview, and analyses of association with continuous 
outcome variables carried out in SPSS. This was done by coding each observed haplotype 
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as described in Chapter 2 (section 2.3.2) and using this code in the regression models for 
lung function and lung function decline. 
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 Decline group 
n=110 
Gender (% male) 66.36 
Age  in years 51.48 (0.92) 
Pack years 18.75 (9.01-28.49) 
FEV1 %predicted 35.01(18.25-51.77) 
FEV1/FVC 37.30(27.10-48.40) 
KCO %predicted 68.09 (2.12) 
UZVI 32.84 (1.69) 
LZVI 52.10(38.53-65.68) 
Decline of FEV1 in ml/yr -42.00 (-87.00-3.00) 
Decline of KCO in 
[mmol/min/kPa/l]/yr 
-0.03 (0.004) 
 
Table 5.2: Clinical characteristics of genotyped subjects for decline of lung function 
The table shows demographic features, lung function and HRCT densitometry measures 
in the group assessed for decline of lung function. Data is shown as mean (SEM) or median 
(IQR) dependent on its distribution. FEV1 decline was non-normally distributed and 
required log transformation prior to subsequent linear regression modelling. KCO decline 
was normally distributed, and as such could be used in its raw form for subsequent 
regressions. The group showed no difference in any demographic or clinical feature from 
the whole cohort (Table 3.1), except that they had smoked slightly more (p=0.03). 
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Figure 5.2: Location of tag SNPs in MMP1, MMP3 and MMP12 
The diagram shows the structure of the 3 MMPs on chromosome 11 chosen for further study. The mauve blocks represent exons, the 
promoter is represented by a grey pentagon, other regulatory regions by pink blocks and introns by a black line. All SNPs are denoted by 
their reference SNP number. 
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Gene SNP Context sequence Design 
strand 
rs470747 TTTGCTAAACATGTGCACTCTGAAA[A/G]TCATTACAGAAAATACACAATGAGG Reverse 
rs7125062 AAAAAAAGCAAGAAAAGTTTCCATC[C/T]AATTTCTGGTAATCTCTGGCAGATA Forward 
rs7125320 ACCATTGTATAGCATACAAATAAAA[G/T]AGGCATAAGTAACTTTAAGAACATA Reverse 
rs996999 GGAAAACACAAAAAGCCTTCCTTTT[C/T]TTTAATTTCCACATAAGTTTATGAC Forward 
rs470358  ACTAAAAATTTACATTATTGTCACA[C/T]GCAATGCAGCATTTACCTGGACTAA Forward 
rs3213460 AGTGATGGCTTCCCAGCCTCTTGCT[A/G]CTCCAATATCCCAGCTAGGAAGCTC Forward 
MMP1 
rs5031036  TATCGCTAATGGCTGTTTNATTTGAAATACATATAAAGACCACCAGGCCCTTGTCCGTAA 
[T/C]GTTTTTCCCCATACTCACCATATATGGCTTGGATGCCATCAATGTCATCCTGAGCTAGC 
Forward 
rs650108 GAGGTGACAAGTGGGTGAGGTTAGA[A/G]GTAGCCCTTGAAAATCATATAGTAG Reverse 
rs3025066 TGTTTGTCATGTGCATATTGATCCA[C/T]CAGTAAGTAAATTACTTGATTAAAT Reverse 
rs476762  AAATGTGGGAAAAGGCAGCACCAGA[A/T]CTAAATGATTCCAAGCTCAGAAGAA Forward 
MMP3 
rs678815  ATTTCTCTAGCTTGCTGAAATAATG[C/G]CAAATTTTATAATATGATACTAGCA Forward 
rs652438  GGGATAATTTGGCTCTGGTCTTAAA[C/T]TGCTAATTAACCAGTATTTGTCATC Forward 
rs632009  CCTCATCTGTATAATGAAGATAATA[C/T]CTGTGTCACCTGCCACACAGGGTTC Reverse 
rs11225442 GTCTTTTCGTAAGCCCAAATATAAG[A/G]CTATCATTAAGTTTCAGGTACTGTG Forward 
MMP12 
rs17368659  TTACCACAATACTTCATTTTTGCTA[G/T]CACAATTGGAAAATGGATCATTTCA Forward 
  
Table 5.3: Context sequences for primer design in MMP1, MMP3 and MMP12 
The two possible alleles of each SNP are highlighted in blue between square brackets indicating the position of the SNP within the gene.
5.4 Results 
     Adequate genotype discrimination could not be achieved in AATD subjects for 
rs5031036 thus it could not be assessed further. No other tags were available for this block 
within the required allele frequency limits - that is, no other SNPs with MAF>5% were 
tagged by rs5031036. The genotyping success rate in the remaining SNPs was 92.5%. All 
SNPs were in HWE, except rs476762 (MMP3, p<0.01), which was excluded from further 
analyses. The allele and genotype frequencies of successfully genotyped SNPs are shown in 
Table 5.4. 
      In the dominant quantitative models of lung function, two SNPs (rs470358 and 
rs678815) were independent predictors of baseline KCO. The minor allele (T) of rs470358 
in MMP1 showed a protective effect in the regression model (B=6.130, p=0.025), the B 
value indicating that KCO is 6.13% higher in those carrying at least one T allele. The 
major allele (G) of rs678815 in MMP3 was associated with a protective effect on KCO of 
similar magnitude (B=7.766, p=0.025). The B value from the regression shows that 
subjects who did not have the G allele exhibited KCO 7.77% lower on average than those 
with at least one copy of it. Mean KCO stratified for presence of these alleles is shown in 
Figure 5.3.  
      There were no genetic associations with FEV1, FEV1/FVC or emphysema zone (all 
p>0.1). In the models to assess decline no SNP genotype predicted FEV1 or KCO decline 
(all p>0.1).  
     One haplotype was observed in Haploview (Figure 5.4), which showed no associations 
(all p>0.1) with the quantitative phenotypes above.  
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 Genotype frequency % (n) Gene Tag SNP 
Major allele 
homozygote 
Heterozygote Minor allele 
homozygote 
MAF 
(%) 
rs470747 [G,A] 40.55 (159) 50.39 (198) 9.06 (36) 34.25 
rs7125062 [T,C] 50.29 (197) 42.77 (168) 6.94 (28) 28.32 
rs7125320 [C,T] 83.75 (328) 14.95 (58) 1.27 (5) 8.82 
rs996999 [C,T] 64.65 (253) 30.21 (118) 5.14 (20) 20.24 
rs470358 [C,T] 34.40 (135) 50.71 (199) 14.89 (58) 40.25 
MMP1 
 
rs3213460 [G,A] 63.82 (250) 34.13 (134) 2.05 (8) 19.11 
rs650108 [A,G] 55.06 (216) 40.17 (157) 4.78 (19) 24.86 
rs3025066 [G,A] 85.52 (335) 13.45 (52) 1.03 (4) 7.76 
rs476762 [T,A] 72.97 (286) 19.77 (77) 7.27 (28) 17.15 
MMP3 
rs678815 [G,C] 27.80 (109) 52.12 (204) 20.08 (79) 46.14 
rs652438 [G,A] 87.89 (345) 12.11 (47) - 6.06 
rs632009 [T,C] 44.97 (176) 42.59 (167) 12.43 (49) 33.73 
rs11225442 
[G,A] 
74.01 (290) 23.16 (91) 2.82 (11) 14.41 
MMP12 
rs17368659 
[G,T] 
77.38 (303) 21.31 (84) 1.31 (5) 11.97 
  
Table 5.4: MMP1, MMP3 and MMP12 allele frequencies 
The table shows the tag SNPs within the MMP cluster that were successfully genotyped. 
SNPs are listed as [major allele, minor allele], with the incidence of each genotype shown 
as a percentage, the raw data being in brackets, and the minor allele frequency (MAF) in 
the final column. 
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Figure 5.3: KCO stratified for associated MMP SNP genotype 
The graph shows the mean and standard error of KCO from the regression models after 
adjustment for age, gender and smoking. The difference in KCO was significant for both 
SNPs, in each case p=0.025. 
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Figure 5.4: Linkage disequilibrium plot for MMP1, MMP3 and MMP12 
The LD plot shows the r2 values generated in Haploview. One haplotype block was 
identified, which did not show any significant phenotypic association. 
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5.5 Discussion  
     The main factor prompting the investigation of the 3 MMPs reported in this chapter 
was a linkage study in AATD, which suggested that the region of chromosome 11 
containing them contained a protective variant[203]. Many of the siblings in the UK 
familial dataset participated in this study, which is why associations were not assessed in 
this group again. Two protective variants were identified in the unrelated dataset reported 
here; the T allele of rs470358 (MMP1) and the G allele of rs678815 (MMP3), both being 
associated with higher KCO. The results presented in this chapter, therefore, support prior 
work. Both SNPs are located in intronic regions of their respective genes and neither has 
an identified functional role.  
     Previous work in usual COPD implicated a SNP in the promoter region of MMP1 
(rs1799750) in UZDE[19]. In this study two tags cover the promoter region of MMP1, one 
of which is rs470358, though since rs1799750 allele frequencies were not reported in 
HapMap for this SNP the HapMap software did not report that it was tagged by 
rs470358. However, given that the MAF in previous studies has been greater than 5% it is 
likely that it is. Nevertheless we were unable to confirm association with emphysema 
zone, defined using the difference between LZVI and UZVI in an individual. This may 
have been because there were lower numbers of subjects in the CT based analyses since not 
all subjects underwent a local quantitative scan. In AATD emphysema zone relates to 
lung function with FEV1 tending to reflect LZDE better than UZDE and KCO the 
converse (i.e. reflecting UZDE better than LZDE)[18]. Thus the results for KCO are 
consistent with a tendency to protection from UZDE in those with the associated alleles. 
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This would also be in agreement with the association seen in NETT of rs1799750 with 
UZDE.  
     The results of this chapter did not show any associations within MMP12, but it should 
be noted that variation within MMP12 alone has not usually been reported with any 
phenotype in either COPD or AATD previously, rather only as part of a haplotype. A 
SNP in MMP12 (rs652438) was implicated in lung function decline in the LHS, but only 
as part of a haplotype with rs1799750[77]. Another study on two mixed European 
populations showed an enhanced risk of COPD in individuals with a haplotype of two 
MMP12 SNPs (rs652438 and rs2276109)[164]. Our results do not show any haplotypes 
containing tags within MMP1 and MMP12 or any significant haplotypes within 
MMP12, though rs470747 and rs470358 approached significance as a pair (Figure 5.4). 
This might be because the population studied herein (although of the same racial group to 
the LHS, and indeed European) come from a different geographical region. The LHS was 
carried out in Denmark, and although the population there is predominantly Caucasian, 
as in the UK, the racial ancestry may differ. A similar difference might occur between a 
UK and a mixed mainland European population. This is because in recorded history the 
UK has been invaded by Danish Vikings, Nordic Vikings and Romans amongst others. 
Thus the UK population’s genetic make up will reflect this[290], unlike Denmark, where 
the influences are different. HapMap exemplifies the differences in LD that occur between 
racial groups, though it has not studied racial ancestry within Caucasians. It is, therefore, 
possible that differences between the Caucasian cohorts might account for differences in 
haplotypes observed in the 2 populations. High degrees of geographical variation have 
been observed on both the long and short arm of chromosome 11 in a large genome-wide 
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study in the UK[217]. We might speculate that this is due to differences in the ancestry of 
populations residing in each area of the UK – for instance, areas in the South-East might 
show more markers of Danish Viking ancestry than those in the North-West, because of 
the site of Viking invasion in the South-East and relatively slow spread of the invading 
population North and West. This highlights the importance of geographical 
standardisation, as well as replication in different racial groups, when considering genetic 
associations with complex disease. 
MMP3 had not previously been associated with COPD when this project started. 
However, recently a genome-wide study has reported association of a SNP (rs615098) very 
close to the MMP3 promoter region with a quantitative emphysema phenotype[79]. 
Although the association did not replicate in the second population tested it remained 
significant at genome wide level in a meta-analysis of the two groups. This type of meta-
analysis is relatively new and remains a little controversial in the field so will require 
further replication. There are no specific animal models or in vitro work regarding its 
protein product (MMP3) in COPD. A mouse model of inflammatory lung injury, 
performed by instilling a chemotactic cytokine into the trachea, showed less lung injury in 
MMP3 deficient mice than their normal counterparts[291]. This may indirectly support a 
role for the protein in inflammatory diseases of the lung, including COPD. A recent 
Japanese study identified a functional polymorphism in the MMP3 promoter, associated 
with  increased serum MMP3[292], supporting the existence of genetic variants that could 
change the risk of diseases where MMP3 plays a role. Elevated pulmonary levels of other 
MMPs have been observed in emphysema[279, 293] and may contribute to disease 
pathogenesis via increased proteolytic damage to the lung parenchyma. It is conceivable 
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that this is the same for MMP3, though the only study to report airway levels (in sputum) 
thus far found no difference between subjects with COPD and healthy controls[294]. 
However, the study was small and further investigation is warranted, which should 
include examining levels of the protein in airway biopsies, resected specimens of lung 
parenchyma, or airway secretions in subjects with and without COPD.     
     Genetic association implies a role for the protein product in pathogenesis, and hence a 
rationale for treatment. Our results suggest that treatments targeting MMPs might be 
appropriate in AATD. Endogenous anti-proteases (TIMPs) given to patients as a 
recombinant protein, or by gene therapy, and synthetic MMP inhibitors have been 
considered[295]. However, recombinant proteins are not yet cost effective and gene 
delivery is unlikely to produce enough protein to be effective[295]. A small study of a 
synthetic MMP inhibitor in asthma showed some promise in reducing pulmonary 
inflammation [34] but no trials have been conducted in COPD. Due to the associations of 
MMP genes with phenotype in COPD and AATD, such drugs might be of benefit in 
subjects with both conditions. However, the observation that pulmonary inflammation is 
more marked in AATD than usual COPD [234] might make the efficacy of the 
intervention more easily detectable in this group. 
     
 
5.6 Conclusions 
Variation within MMP1 and MMP3 is associated with KCO, a marker of parenchymal 
disease, in AATD. These results support a family based linkage study in AATD, and 
whilst not true replication, go some way to confirming the importance of the region. 
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Chapter 6: The role of HLA type 
6.1 Introduction 
     Most previous work on COPD pathogenesis has concentrated on the role of proteases, 
oxidants and inflammation, as discussed in Chapter 1 (section 1.1.3). However, an 
autoimmune component to disease pathogenesis has also been proposed, in part because 
inflammation in the lungs persists after smoking cessation. This indicates a pathogenic 
process initiated by smoking but one that is subsequently self-perpetuating, which could 
be via an autoimmune process. Support for autoimmunity comes from the observation 
that a similar inflammatory cytokine and cellular profile ocuur in autoimmune conditions, 
such as RA, and COPD[296].  
     Characteristic features of autoimmune diseases include the presence of autoantibodies 
or autoreactive T lymphocytes, reproducibility in animals (or indeed in man) after 
transfer of either of these moieties and lymphocytic infiltration of the target organ[297]. 
These features are present in patients with COPD, and in particular in patients with 
emphysema.  Elevated  anti-elastin antibodies have been observed in the circulation of 
patients with emphysema[205] as well as autoantibodies to pulmonary epithelium[298] 
and the vascular endothelium[299]. Results from animal models also support an 
autoimmune basis to disease development:  the transfer of pathogenic CD4+ T cells from 
rats with emphysema and anti-endothelial cell antibodies results in the development of 
emphysema in healthy animals [206] and  mice injected with elastin peptides  develop 
both anti-elastin antibodies and a bronchoalveolar lavage (BAL) fluid profile similar to 
that seen in COPD[279, 300]. In addition a lymphocytic infiltrate in the lung has been 
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reported, with pulmonary CD4+ and CD8+ T cell numbers associated with worsening 
disease [11, 301].  Furthermore, oligoclonal T cell populations have been demonstrated in 
the lung, suggesting accumulation due to antigenic stimulation [302, 303]. Thus far the 
most likely stimulus in COPD is an anti-elastin autoantibody[205, 300], but it remains 
possible that other antibodies against self antigens play a role, or that cigarette smoke 
itself is the main factor [303]. Finally, evidence of clustering of organ specific autoimmune 
diseases within individuals with COPD unrelated to smoking[304] may suggest a common 
genetic basis to disease development.  
     A number of loci exhibit association with autoimmune diseases, many of the most well 
replicated of which are in the HLA region[217]. The HLA region is located on 
chromosome 6p21, and is one of the most gene dense, polymorphic and LD rich regions in 
the human genome [305, 306]. It can be subdivided into class I, II and III regions (Figure 
3.3). Molecules encoded by class I genes are involved in presentation of endogenous 
antigens, as well as those derived by intracellular processing of viruses, to CD8+ T cells, 
whilst those encoded by class II present exogenous antigens to CD4+ T cells[306]. The 
class III region contains other immune response genes, such as TNFA. Autoimmune 
diseases, such as type 1 diabetes have a complex pattern of HLA association, the strongest 
evidence being for class II alleles, with strong predisposing effects being seen for HLA-
DRB1*04[307]. Associations with HLA class I and III are also well known, though 
though there is significant LD between these areas and class II so it can be difficult to 
ascertain if a single locus or combination of these is responsible for disease association 
[308, 309]. Attempts have been made to dissect these effects in other autoimmune 
diseases. In diabetes, for instance, both HLA class I and class II alleles are associated with 
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disease but analysis shows that after taking account of HLA class II effects the influence 
upon disease from class I is smaller[310]. This suggests that HLA class II is the most 
important part of the region in autoimmune disease. 
     Genetic association of COPD with the HLA region, specifically HLA class I, has been 
reported in two studies [204, 311]. However, these studies considered different sub-
phenotypes of COPD - FEV1[204] and chronic bronchitis[311] and results lacked 
consistency. Polymorphisms in TNFA, part of the HLA class III region, have also been 
associated with COPD phenotypes [105, 107], but association with class II has not been 
reported, despite the high degree of LD between HLA class II and TNFA[312]. The 
association with TNFA, togther with the evidence of autoimmunity described above, 
suggests that investigation of genetic association studies of HLA class II in COPD may be 
fruitful. Furthermore, cells from subjects with COPD exhibit an attenuated inflammatory 
response when blocking HLA class II in vitro suggesting an HLA class II dependent 
inflammatory pathway[205]. This leads to the hypothesis that HLA class II type might 
influence the development of emphysema. 
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6.2 Aims of this chapter 
     This chapter compares HLA class II genotype frequencies between AATD patients 
with and without emphysema, and assesses HLA class II association with lung function. 
It also describes phenotypic associations of anti-elastin antibodies in AATD, and assesses 
differences in anti-elastin antibody levels between genotypes with and without associated 
HLA class II alleles. This provides an indication of whether anti-elastin mediated 
pathways are dependent on or unrelated to genetic factors in the HLA class II region. 
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6.3 Methods 
6.3.1 Subjects 
     Subjects were taken from the cohort previously described (Chapters 2 and 3)and 
comprised all subjects whose DNA samples (extracted by DNA precipitation, as 
previously described) exceeded 100ng/µl and was of sufficient volume to allow HLA class 
II typing. HLA phototyping requires DNA at this concentration, unlike TaqMan® based 
genotyping methods, which work well at lower DNA concentrations (down to 4ng/µl). This 
resulted in a total of 322 subjects suitable for study.  
     The characteristics of the subjects are shown in Table 6.1.  
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 Whole group 
n=322 
Emphysema 
n=219 
No emphysema  
n=48 
Age in years 50.86 (0.74) 52.33 (0.77) 41.19 (33.53-48.86) 
% of group of 
male gender 
58.19 63.24 43.18 
Pack years 13.75 (0.03-24.00) 16.00 (5.47-26.53) 0 (0-4.38) 
FEV1 
%predicted 
36.45 (23.56-60.00) 32.44 (19.93-44.95) 102.44 (80.81-124.04) 
FEV1/FVC 29.33 (56.63) 34.75 (26.33-43.18) 72.30 (2.32) 
KCO %predicted 66.10 (54.60-85.95) 63.65 (51.95-73.35) 98.18 (3.11) 
UZVI 31.75 (15.60-45.93) 33.00 (18.80-47.20) 2.61 (0.44) 
LZVI 49.65 (30.62-61.90) 53.00 (39.93-66.06) 6.99 (0.66) 
 
Table 6.1: Characteristics of subjects studied for HLA class II type 
Data is shown as mean (SEM) or median (IQR) dependent on its distribution. 
Age, gender, smoke exposure, lung function and CT densitometry differed significantly 
between emphysematous and non-emphysematous subjects (all p<0.0001 except gender 
p=0.012). Only 82% of subjects had a CT scan to diagnose emphysema, hence the number 
listed for the whole group exceeds the sum of the numbers of subjects with and without 
emphysema. 
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6.3.2 HLA class II typing 
     This was performed primarily by the phototyping method[216], with additional typing 
using commercial kits for samples which failed by this method. All the methods used 
contain internal control bands. 
Phototyping 
     This technique uses PCR with sequence specific primers to identify class II alleles at a 
resolution equivalent to serological typing. Forty two reactions are required to assign a 
class II type for DRB1, DQB1 and DQA1, the results grouping into 13 DRB1 types, 8 
DQB1 and 8 DQA1 types. The pattern of bands visible on subsequent gel electrophoresis 
identifies the HLA type because each allele will generate bands of a known size in specific 
reactions, as shown in Table 6.3. Two control bands are also seen, showing that the PCR 
was successful - the PCR product in this band is an amplified part of intron 3 of DRB1 
and a dimer derived from it. Where the control bands were not seen it suggested that 
amplification had not occurred and it was repeated. All primers have a melting point 
between 58-62°C, to enable them to be run in the same thermal cycling conditions (see 
section 2.2.3). The primers used are listed in Table 6.3.  
     In the PCR reactions required for HLA typing many different alleles are being sought, 
and a large number of primers are used in different combinations to amplify them[216]. 
The combinations were therefore mixed in advance and stored. Primers were purchased as 
crude nucleotides (Sigma, UK) and the amount required for dilution calculated using the 
following formulae 
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                 Primer amount (µM) =         Primer OD x 100 
                                                        1.5A +0.71C +1.2G +0.84T 
 
A, C, G and T are the number of times adenine, cytosine, thymine and guanine 
respectively appear in the primer sequence.  
 
Primer amount (µl/ml) = Required working primer concentration x 1000 
                                                                   Primer amount (µM ) 
 
The amount of primer was calculated using the first formula, and the primer dilutions 
were then made at the required concentration[216] using the second formula to indicate 
the total volume of primer(s) required, the amount being made up to 1ml with MillQ 
water for later use. Primer plates were aliquoted in batches, using 5µl of the primer mixes 
and then 10µl mineral oil (Sigma, UK) over this in each well (to prevent evaporation 
during PCR), as shown in Figure 6.1, such that two subjects could be typed per 96 well 
plate. 
     For each DNA sample to be amplified 300µl TDMH (Appendix 3), 169µl MillQ water, 
9µl DNA and 2.25µl Taq polymerase (Bioline, UK) were mixed in a 1.5ml eppendorf 
(Alpha labs, UK) by vortexing, and 8µl of this mixture added to each of the 42 wells 
needed for a the chosen HLA class II loci. This was then sealed with a transparent lid 
(Greiner bio-one, UK) and centrifuged at 1000rpm for 1 minute prior to cycling under the 
following conditions: 
 96°C 1 minute 
 96°C 20 seconds 
 70°C 45 seconds 
 72°C 25 seconds 
5 cycles 
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Thirteen µl of PCR product per well were run on a 1% agarose gel made with 0.5xTBE 
and 0.024µl ethidium bromide/ml (see also section 2.2.4). Each gel was produced from 
500ml of TBE and 0.5g of agarose and allowed 6 individuals to be typed at the 3 loci being 
studied in this chapter and was electophoresed for 15 minutes at 350 Volts, 300 Amps and 
150 Watts. Gels were photographed using UV light in a ‘G-box’ (Syngene, UK) and 
assigned a type accordingly (Appendix 6). 
 
 20°C 5 minutes 
 72°C 90 seconds 
 55°C 60 seconds 
 96°C 30 seconds 
 72°C 30 seconds 
 65°C 50 seconds 
 96°C 25 seconds 
21 cycles 
4 cycles 
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 Alleles amplified Forward primer/s (5’-3’) Reverse primer/s (5’-3’) Size (bp) 
0101/2/4 TTGTGGCAGCTTAAGTTTGAA CCGCCTCTGCTCCAGGAG 194 
0103 TTGTGGCAGCTTAAGTTTGAA CCCGCTCGTCTTCCAGGAT 195 
1501-5 TCCTGTGGCAGCCTAAGAG CCACCGCGGCCCGCGC 206 
1601-6 TCCTGTGGCAGCCTAAGAG CTCCGTCACCGCCCGGT 137 
03011/12/2/3/4/5, 1107 GTTTCTTGGAGTACTCTACGTC GTCCACCCGGCCCCGCT 211 
0301/4 GACGGAGCGGGTGCGGTA CTGCACTGTGAAGCTCTCCA 216 
0302/5, 1302/3, 1109/20, 1402/3/9/13/19 TACTTCCATAACCAGGAGGAGA CTGCACTGTGAAGCTCTCAC 188 
0401-22, 1410, 1122 GTTTCTTGGAGCAGGTTAAACA (i)CTGCACTGTGAAGCTCTCAC 
(ii)CTGCACTGTGAAGCTCTCCA 
259 
0701 CCTGTGGCAGGGTAAGTATA CCCGTAGTTGTGTCTGCACAC 231 
0801-11, 1415 AGTACTCTACGGGTGAGTGTT (i)CTGCAGTAGGTGTCCACCAG 
(ii)TGTTCCAGTACTCGGCGCT 
162 
213 
0901 GTTTCTTGAAGCAGGATAAGTTT CCCGTAGTTGTGTCTGCACAC 235 
1001 CGGTTGCTGGAAAGACGCG CTGCACTGTGAAGCTCTCAC 203 
1101-21 (i)GTTTCTTGGAGTACTCTACGTC 
(ii)TTCTTGGAGTACTCTACGGG 
CTGGCTGTTCCAGTCCTCCT 174 
176 
1201/2/3 AGTACTCTACGGGTGAGTGTT CTGTTCCAGGACTCGGCGA 163 
1301/2/4/8/15-17/19/20/22, 1416,  
1102/3/11/14/16/20/21 
(i)GTTTCTTGGAGTACTCTACGT 
(ii)TTCTTGGAGTACTCTACGGG 
TCCACCGCGGCCCGCTC 210 
1301/2/4/8/9/16/20, 1116/20, 1416 GTTCCTGGACAGATACTTCC (i)TCCACCGCGGCCCGCTC 
(ii)CCACCGCGGCCGCGC 
152 
1301/2/10/15/16, 1116/20, 1419/20 TACTTCCATAACCAGGAGGAGA (i)CCCGCTCGTCTTCCAGGAT 
(ii)TCCACCGCGGCCCGCTT 
129 
138 
1305/6/10, 1109, 1419/21 TACTTCCATAACCAGGAGGAGA (i)ACCGCGGCCCGCCTGCG 
(ii)TCCACCGCGGCCCGCTT 
136 
138 
1303/10, 1419/21 GTTTCTTGGAGTACTCTACGTC TCCACCGCGGCCCGCTT 210 
DRB1 
1303/4/12/21, 1413 GTTTCTTGGAGTACTCTACGTC TGTTCCAGTACTCGGCCT 170 
 210 
1305/7/11/14/18/21, 
1101/4/6/9/10/(11)/12/15 
GTTTCTTGGAGTACTCTACGTC CCCGCCTGTCTTCCAGGAA 200 
1301/2/5-9/10/11/14-16/18/19/20/22,  
1402/3/6/9/12/14/17/19-21, 0301-5 
GTTTCTTGGAGTACTCTACGTC CTGTTCCAGTACTCGGCATC 171 
1401/3-5/7/8/10-12/14/15/18, 1318, 0809, 
1117 
GTTCCTGGACAGATACTTCC 
GTTCCTGGAGAGATACTTCC 
(i)TCTGCAATAGGTGTCCACCT 
(ii)CTGCAGTAGGTGTCCACCAG 
164 
165 
1401/7/16 GTTTCTTGGAGTACTCTACGTC CTGTTCCAGTGCTCCGCAG 171 
1402-3/6/9/12/13/17, 1318, (1418/19/21),  
(0301/2/3/5) 
TACTTCCATAACCAGGAGGAGA (i)CTGCAGTAGGTGTCCACCAG 
(ii)CCGCCTCTGCTCCAGGAG 
129 
151 
0305 GCTACTTCACCAACGGGACC TGCACACCGTGTCCAACT 195 
02 GTGCGTCTTGTGAGCAGAAG CGTGCGGAGCTCCAACTG 198 
04 GCTACTTCACCAACGGGACC TGGTAGTTGTGTCTGCATACG 208 
05 ACGGAGCGCGTGCGGGG CCCGCGGTACGCCACCTC 207 
0601-3 (i)TTTCGTGCTCCAGTTTAAGGC 
(ii)GACGTGGGGGTGTACCGC 
CCGCGGAACGCCACCTC 249 
140 
0603-9 GGAGCGCGTGCGTCTTGTA (i)TGCACACCGTGTCCAACTC 
(ii)TGCACACCCTGTCCACCG 
176 
0301/4 GACGGAGCGCGTGCGTTA CGTGCGGAGCTCCAACTG 207 
0302 GTGCGTCTTGTGACCAGATA CTGTTCCAGTACTCGGCG 119 
DQB1 
03032 GACGGAGCGCGTGCGTCT CTGTTCCAGTACTCGGCGT 129 
0101/4 CATGAATTTGATGGAGATGAGG ATGATGTTCAAGTTGTGTTTTGC 149 
0102/3 CATGAATTTGATGGAGATGAGC ATGATGTTCAAGTTGTGTTTTGC 149 
0201 ACGGTCCCTCTGGCCAGTT CAGGATGTTCAAGTTATGTTTTA
G 
173 
03011/12 TTCACTCGTCAGCTGACCAT CAAATTGCGGGTCAAATCTTCT 183 
0302 TTCACTCGTCAGCTGACCAC CAAATTGCGGGTCAAATCTTCT 183 
0401 ACCCATGAATTTGATGGAGAC CACATACCATTGGTAGCAGCA 194 
DQA1 
0501/2 ACGGTGCCTCTGGCCAGTA AGTTGGAGCGTTTAATCAGAC 189 
 211 
0601 ACGGTCCCTCTGGCCAGTT GGTCAAATCTAAATTGTCTGAGA 191 
Control Part of intron 3 of DRB1 TGCCAAGTGGAGCACCCAA GCATCTTGCTCTGTGCAGAT 796 
 
 
Table 6.2: Primers used for HLA class II typing 
All primers were used at a concentration of 3.4mM. Where more than one primer was used in a mix this is denoted by (i) for the first primer 
(ii) for the second. 
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 1 2 3 4 5 6 7 8 9 10 11 12 
A 0101/2/4 0701 1301/2/10/15/16, 
1116/20, 1419/20 
1402-
3/6/9/12/13/17, 
1318  
02 0101/4 A1 A2 A3 A4 A5 A6 
B 0103 0801-11, 1415 1305/6/10, 1109, 
1419/21 
 04 0102/3 B1 B2 B3 B4 B5 B6 
C 1501-5 0901 1303/10, 1419/21  05 0201 C1 C2 C3 C4 C5 C6 
D 1601-6 1001 1303/4/12/21, 1413  0601-3 03011/12 D1 D2 D3 D4 D5 D6 
E 03011/12/2/3/4/5, 
1107 
1101-21 1305/7/11/14/18/21, 
1101/4/6/9/10/(11)/12/
15 
 0603-9 0302 E1 E2 E3 E4 E5 E6 
F 0301/4 1201/2/3 1301/2/5-9/10/11/14-
16/18/19/20/22,  
1402/3/6/9/12/14/17/1
9-21, 0301-5 
 0301/4 0401 F1 F2 F3 F4 F5 F6 
G 0302/5, 1302/3, 
1109/20, 
1402/3/9/13/19 
1301/2/4/8/15-
17/19/20/22, 1416,  
1102/3/11/14/16/20/21 
1401/3-5/7/8/10-
12/14/15/18, 1318, 
0809, 1117 
 0302 0501/2 G1 G2 G3 G4 G5 G6 
H 0401-22, 1410, 
1122 
1301/2/4/8/9/16/20, 
1116/20, 1416 
1401/7/16 0305 03032 0601 H1 H2 H3 H4 H5 H6 
                                                                                     
Figure 6.1: Primer locations in 96 well plate for HLA Class II typing 
The diagram shows the positions of primers for alleles at the 3 loci within HLA class II; DRB1 alleles are in the grey boxes, DQB1 in pink 
and DQA1 in blue. Setting up in this way allowed repetition of the primer pattern in the second half of the plate (columns 7-12), as 
indicated by the well locations listed from columns 1-6 in these columns, such that 2 subjects could be typed on each plate. 
 
Dynal 
     It is possible for phototyping to fail at any of the 3 class II loci if the allele present is 
not one adequately identified by the primer mixes, or if control bands cannot be 
adequately visualised in some reactions, despite repeated attempts. This necessitates more 
high resolution typing methods with different primer mixes, such as those made by 
commercial providers such as Dynal. In the studies reported here no phototyping failed at 
the DQA1 locus, thus Dynal was only necessary for DRB1 and DQB1. 
 
DRB1 
     Samples where a DRB1 type could not be allocated by phototyping were analysed 
using a DRB1 specific high resolution PCR kit (SSP UniTray, Dynal, Invitrogen, UK). A 
DRB1 type is assigned using 96 reactions, the primers for which are pre-aliquoted into 
plates by the suppliers. For each DNA sample to be amplified 1 vial (580µl) of the PCR 
buffer provided in the kit, 9.3µl Taq polymerase (Bioline, UK), 268µl MillQ water and 80µl 
DNA (at a concentration of 75-125ng/µl) were mixed in a sterile 1.5ml eppendorf (Alpha 
labs, UK), with 8µl of the mixture being aliquoted into each well of the plate. Ten µl of 
mineral oil (Sigma, UK) was added to each well, prior to sealing with a transparent lid 
(Greiner Bio-one, UK), centrifuging at 1000rpm for 1 minute and thermal cycling as 
follows: 
 96°C 1 minute 
 96°C 25 seconds 
 70°C 50 seconds 5 cycles 
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 72°C 25 seconds 
96°C 25 seconds 
 65°C 50 seconds 
 72°C 45 seconds 
21 cycles 
 96°C 25 seconds 
 55°C 60 seconds 
 72°C 120 seconds 
4 cycles 
 
Thirteen µl of each PCR product was run on a 1% agarose gel as before (sections 2.2.4 and 
6.3.2, phototyping). Gels were photographed and applied to a worksheet provided with 
the kit (Appendix 6) and results interpreted according to the manufacturer’s instructions. 
 
DQB1 
     Samples where a DQB1 type could not be allocated by phototyping were analysed 
using specific low resolution PCR kits (AllSet, Dynal, Invitrogen, UK). A strip of 8 PCR 
tubes was used, containing primers aliquoted by the suppliers. Fewer primers were 
required than for DRB1 typing because the DQB1 locus exbibits fewer alleles[313]. For 
each DNA sample to be amplified 19.0µl of DNA (at 50ng/µl), 80µl of the provided PCR 
buffer and 0.80µl Taq polymerase (Bioline, UK) were mixed, and 10µl dispensed into each 
primer tube, followed by 10µl of mineral oil (Sigma, UK), sealing with a strip of lids 
provided, centrifuging at 1000rpm for 1 minute and thermal cycling as follows: 
 96°C 90 seconds 
 96°C 15 seconds 
10 cycles 
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 65°C 1 minute 
  
96°C 10 seconds 
 61°C 50 seconds 
 72°C 30 seconds 
20 cycles 
 
Samples were run on a 1% agarose gel using the same volumes and conditions as 
previously, photographed, applied to a worksheet (Appendix 6) and interpreted according 
to the manufacturer’s instructions. 
 
6.3.3 Statistical analysis of genetic association 
     Hardy-Weinberg equilibrium was checked for the HLA-DRB1, HLA-DQB1 and HLA-
DQA1 loci using an add-on package to the stata programme (available from 
www.gene.cimr.cam.ac.uk/clayton/software/stata). Linear regression models were 
constructed using FEV1, FEV/FVC and KCO, adjusting for smoke exposure, gender and 
age where these were significant predictors of the outcome variable. A logistic regression 
model to compare subjects with and without emphysema was constructed in a similar 
manner. Since not all subjects had a CT scan the number included in the lung function 
models was greater than in the emphysema model (n=306 v 248). The regression models 
initially included all the alleles for a given locus to obtain a p-value for the association of 
the locus. For each locus the model with covariates and genotypes was compared to a 
model with just covariates via a likelihood ratio test. The alleles were then categorised 
within the regression to obtain individual allelic associations, in each case setting the most 
frequent allele as the comparator against which the likelihood ratio was calculated. In 
 216
each model alleles were grouped at the 1% frequency level, such that HLA-DRB1*09 and 
HLA-DRB1*10 were combined. 
 
6.3.4 Anti-elastin antibody ELISA 
     Anti-elastin antibodies were measured in 172 stored serum samples, prepared by 
collection of blood from subjects at the time of their baseline clinical assessment in plain 
tubes (Greiner Bio-one, UK), which was allowed to clot prior to centrifuging at 3000rpm 
for 15 minutes. The resultant supernatant was stored in aliquots of 200µl at -80°C in a 
freezer. A smaller number of subjects had serum stored at their baseline assessment than 
those that had DNA stored, such that the number of samples genotyped exceeded the 
number on which it was possible to measure the autoantibody. The method for this assay 
was adapted from that published by Lee et al[205]. 
     Soluble human lung elastin (Sigma, UK) was diluted to 25µg/ml in a 0.01% solution of 
bovine soluble albumin (BSA; Sigma, UK) in phosphate buffered saline (PBS, Appendix 
3). The addition of BSA to the solution aided solubilisation of the elastin. Forty µl of this 
solution was added to each of 96 wells of a maxisorb plate (Nunc, UK), which allow 
optimal binding of protein to the plate surface. The outer wells of the plate (i.e. the first 
and last column and row) were not used because of the risk of excess evaporation from 
these during subsequent 37°C incubations, which could confound results. The elastin was 
left to bind to the plate by incubation overnight at 4°C. The following morning a 0.01% 
solution of BSA (prepared as before) was added to the plate, and incubated at 37°C for 2 
hours. The plate was then washed using PBS with 0.05% Tween (Sigma, UK) to remove 
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unbound elastin, using a 3 wash cycle with 400µl of the washing solution per well. 
     Serum samples were diluted in PBS to a 1:500 dilution. One hundred µl of each sample, 
run in duplicate as with previous ELISAs (section 2.2.5), was added to the wells of each 
plate. Plates were then incubated at 37°C for 2 hours. During this stage any anti-elastin 
antibodies present, bound to the elastin on the plate. Plates were then washed as before, 
to remove any unbound substances, prior to addition of 40µl of anti-human IgG (Sigma, 
UK) diluted to 1:40000 in PBS, and a further incubation at 37°C for 2 hours. After 
another wash 200µl of tetramethylbenzidine (Sigma, UK) was added to each well to allow 
the colour change necessary to detect the antibody level (Section 2.2.5), and the plate 
incubated at room temperature for 20 minutes. The reaction was stopped by addition of 
sulphuric acid, prior to reading at 490nm, with wavelength correction set to 570nm, using 
a standard microplate reader (Biotek plate reader with Gen5 software, both Northstar 
Scientific, UK).  
     The standard curve was generated by serial dilution of a pooled plasma sample from 
healthy volunteers from 1:100 to 1:1600. The patient samples could then be measured 
relative to the top standard, which was given an arbitrary value of 100 international 
units.  
     The ELISA was validated in three ways. Firstly the coefficient of variation was 
calculated using a plate made up only of standards at the given concentration, such that 
there were 10 repeats at each concentration. This step ensured that the assay was 
performing consistently, giving the same result for each sample of the same concentration. 
Secondly a check of the sensitivity of the assay to small changes in concentration was 
performed using a plate set up with 4 columns made up using 50µl standard plus 50µl of 
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the 1:800 dilution in each well of the first column, and 50µl standard plus 50µl of the 
1:1600 dilution in each well of the next 2 columns. These columns allowed calculation of 
spike recovery, which is the difference between observed and expected concentration 
expressed as a percentage of the expected value. Finally, to ensure assay specificity for 
anti-elastin antibodies, 2 columns were set up using a 1:40000 dilution of an anti-CD11 
antibody, rather than the anti-human IgG. This step confirmed assay specificity for anti-
human IgG antibodies to the elastin bound to the plate. 
 
6.3.5 Statistical analysis of anti-elastin antibody levels      
     Anti-elastin antibody levels were compared to clinical variables using standard 
statistical methods outlined in chapter 2, prior to comparison between genotypes at 
associated loci using the Kruskal-Wallis test. 
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6.4 Results 
6.4.1 HLA class II association with clinical features 
     Genotyping was successful in 95.3% of cases. Examples of the gels obtained by 
phototyping and Dynal methods are shown in Figures 6.2-6.4. Allele frequencies are 
shown in Table 6.3. The HLA-DRB1, HLA-DQB1 and HLA-DQA1 loci were in Hardy-
Weinberg equilibrium in both emphysematous and non-emphysematous patients (all 
p>0.05). 
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A        B         C         D        E         F        G        H         I 
 
(a) DRB1 typing 
25 sets of primers are used 
for this locus. This example 
shows bands below the 
controls in lanes E, F and H 
on the top row, the first two 
corresponding to DRB1*03 
and the last to DRB1*04. 
 
(b) DQB1 typing 
Bands are seen in lanes A 
and G corresponding to 
DQB1*02 and DQB1*0302 
respectively. 
 
(c) DQA1 typing 
Bands are seen in lanes D 
and G corresponding to 
DQA1*0301 and DQA1*0501 
respectively. 
Figure 6.2: Examples of gels from HLA phototyping 
Forty two wells are required for one subject to obtain a class II type at the DRB1, DQB1 
and DQA1 loci by this method. This series of pictures shows the gel as it runs from the 
well at the top of each row in the picture towards the bottom. Larger PCR products move 
more slowly through the gel, thus the control band appears first since it is much bigger 
than those that identify alleles (see Table 6.3 and Appendix 6 for further information). 
The above example, from a single subject, shows the following classical haplotypes. 
 
DRB1*03 DQB1*02 DQA1*0501 
DRB1*0401-22 DQB1*0302 DQA1*03011/12 
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 1               2                3                 4                5               6           
7               8                9                10               11              12           
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B 
C 
D 
E 
F 
G 
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A 
B 
C 
D 
E 
F 
G 
H 
Figure 6.3: Examples of gels from high resolution DRB1 typing 
This requires 96 wells to obtain a single subject’s DRB1 type. The largest 1-2 bands in 
each lane are the control bands. The typing sheet (appendix 6) indicates the well numbers 
and sizes for each type. The resultant type is DRB1*010101-03 and DRB1*040101/02. 
This kit also identifies alleles at the DRB3, DRB4 and DRB5 loci, which were not required 
for the studies herein.  
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     A         B         C          D         E        F         G        H          
 
Figure 6.4: Example gel from low resolution DQB1 typing 
This requires 8 wells, similar to phototyping, to obtain a DQB1 type, but the required 
DNA concentration is lower. The above example shows bands in lanes B, C and H, 
corresponding to DQB1*050101-0504 and *030302-3/0306/0315/0317, as indicated by the 
interpretation sheets in Appendix 6. 
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 Locus Allele All patients Emphysema No emphysema
*01 12.8 (78)  13.2 (55)  15.6 (14)  
*03 17.0 (104)  16.7 (70)  20.0 (18)  
*04 16.6 (101)  15.8 (66)  21.1 (19)  
*07 12.8 (78)  12.0 (50)  13.3 (12)  
*08 2.6 (16)  2.9 (12)  1.1 (1)  
*09 0.2 (1)  0.2 (1)  0 
*10 0.8 (5)  0.7 (3)  0 
*11 6.4 (39)  6.7 (28)  5.6 (5) 
*12 2.3 (14)  2.2 (9)  3.3  (3) 
*13 12.0 (73)  13.6 (57)  5.6 (5)  
*14 3.6 (22)  3.1 (13)  2.2 (2) 
*15 11.8 (72)  12.0 (50)  12.2 (11)  
HLA-DRB1 
*16 1.1 (7)  1.0 (4)  0 
*02 20.0 (122)  18.4 (77) 24.4 (22)  
*0301 14.6 (89)  15.1 (63) 16.7 (15)  
*0302 9.0 (55)  8.4 (35) 11.1 (10)  
*03032 4.6 (28)  4.5 (19) 3.3 (3)  
*04 3.0 (18)  3.3 (14)  1.1 (1) 
*05 19.3 (118)  18.9 (79) 17.8 (16)  
HLA-DQB1 
*0601-9 29.5 (180)  31.3 (131)  25.6 (23)  
*0101 16.4 (100)  16.5 (69)  15.6 (14)  
*0102/3 23.3 (142)  24.4 (102)  17.8 (16)  
*0201 10.7 (65)  10.0 (42)  8.9 (8)  
*0301 19.4 (118)  18.7 (78)  23.3 (21)  
*0401 2.5 (15)  2.6 (11)  1.1 (1)  
*0501 27.2 (166)  27.3 (114)  33.3 (30)  
HLA-DQA1 
*0601 0.6 (4)  0.5 (2)  0 
 
Table 6.3: HLA Class II allele frequencies according to respiratory phenotype 
The table shows the allele frequency of each allele within the HLA-DRB1, HLA-DQB1 
and HLA-DQA1 loci, shown as a percentage with the raw numbers in parentheses.  
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     No locus associations were observed with emphysema, however pulmonary function 
showed association at the HLA-DQA1 locus with KCO (p=0.034) and trends towards 
association with FEV1 and FEV1/FVC (Table 6.4, p=0.08 and 0.07 respectively). Since 
parenchymal disease (i.e. emphysema) is generally best represented by KCO, with FEV1 
and FEV1/FVC impaired later in the disease process[149] these results are suggestive of an 
association with this phenotype, perhaps not detectable in the CT based analysis because 
of lower numbers in this group. 
     The allelic associations were examined next, and are detailed in Table 6.4. The most 
associated allele was HLA-DQA1*0301, which predicted lower FEV1 and FEV1/FVC as 
shown by the negative regression coefficients (p=0.003 and 0.005 respectively), and tended 
to associate with lower KCO (trend; p=0.063). It is of note that the associations with 
FEV1 and FEV1/FVC would remain significant even after a Bonferroni correction for 
multiple statistical testing, which may be too conservative when considering areas of high 
LD, such as the HLA region. HLA-DRB1*04, which was in LD with HLA-DQA1*0301 
(r2=0.92, p<0.0001) in this dataset (this relationship being consistent with current 
knowledge of regional LD[313]) showed association in the same direction with FEV1/FVC 
(p=0.046) and a trend to association with FEV1 and KCO (p=0.075 and 0.098 
respectively). These were the only 2 alleles that showed evidence, or suggested evidence, of 
association with more than one measure of pulmonary function. 
     DQB1*02 and DQB1*03032 showed association with higher KCO and lower FEV1 
respectively (p=0.014 and 0.035 respectively). Neither showed association with other 
features of pulmonary function. Alleles with which DQB1*02 is commonly in LD, such as 
DRB1*03[313], showed no association with any feature of pulmonary function. This is 
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also the case for DQB1*03032, and might indicate a DQB1*02 or DQB1*03032 specific 
effect, or a false positive result at these alleles. The latter is perhaps more likely, given the 
lack of suggestion of association in the locus analysis for DQB1.  
     Since a locus association was observed with KCO, and both DQA1*0601 and 
DQA1*0101 associate with this feature (p=0.011 and 0.015 respectively) these results 
deserve some further consideration. Alleles with which DQA1*0601 and DQA1*0101 are 
commonly in LD, such as DRB1*01, showed no association with any feature of disease. 
Both alleles associate with lower KCO, but the confidence interval for the regression 
coefficient for DQA1*0601 is very wide (Table 6.4), indicative of low numbers of subjects 
carrying this allele (Table 6.3). This result must, therefore, be viewed with great caution, 
as it may represent a false positive. The number of subjects carrying the DQA1*0101 allele 
was much greater, so the same cannot be said of this allele, and it remains possible that 
this allele is having an effect on risk of disease. On balance, however, the strength of effect 
at DQA1*0301 and consistency of effect through measures of pulmonary function, and 
with an allele with which it is commonly in LD (DRB1*04) makes this a more likely 
candidate at the DQA1 locus. 
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 Locus/Allele Phenotype Regression coefficient 95% confidence interval p value 
FEV1/FVC - - 0.416 
FEV1 - - 0.122 
DRB1 
KCO - - 0.437 
FEV1/FVC - - 0.245 
FEV1 - - 0.085 
DQB1 
KCO - - 0.191 
FEV1/FVC - - 0.070 
FEV1 - - 0.080 
DQA1 
KCO - - 0.034 
FEV1/FVC -0.06 -0.09 - -0.02 0.005 
FEV1 -0.09 -0.15 - -0.03 0.003 
DQA1*0301 
KCO -4.96 -10.19 - 0.27 0.063 
FEV1/FVC  -0.05 -0.09 - -0.0008 0.046 
FEV1 -0.06 -0.12 - 0.01 0.075 
DRB1*04 
KCO  -5.32 -11.64 - 0.99 0.098 
DRB1*13 KCO -6.54 -14.07 - 0.99 0.088 
DQB1*02 KCO 6.98 1.45 - 12.50 0.014 
DQB1*03032 FEV1 -0.10 -0.20 - -0.01 0.035 
DQA1*0101 KCO -7.11 -12.59 - -1.63 0.011 
DQA1*0601 KCO -27.37 -49.49 - -5.26 0.015 
 
Table 6.4: Association analyses for HLA class II and pulmonary function 
     For the three class II loci, the p values for likelihood ratio test results, with 13 degrees 
of freedom for HLA-DRB1 and 8 for HLA-DQB1 and HLA-DQA1 are shown for each 
measure of pulmonary function. Details from the regressions are shown for alleles where 
p≤0.1 only without adjustment for multiple statistical testing; after a Bonferroni 
correction for the number of alleles tested the p value for significance at HLA-DRB1 
should be 0.004, and at HLA-DQB1 or HLA-DQA1 it should be 0.006. Results significant 
at p<0.05 are shown in bold type. 
     The only alleles to show consistent effects across several pulmonary function 
parameters were DQA1*0301 and DRB1*04, which were in LD with one another (r2=0.92, 
p<0.0001). Furthermore HLA-DQA1*0301 would remain significantly associated with 
FEV1/FVC and FEV1 after a Bonferroni correction. The lack of consistent effects across 
pulmonary function measures for this and other alleles below DRB1*04 in the table may 
mean these are less likely to be true associations, though further study will be required. 
The wide 95% CI of DQA1*0601 reflects its low frequency within the group, and further 
reduces the confidence that this is a true association.  
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6.4.2 Anti-elastin antibody associations with clinical features 
     Anti-elastin antibody levels were obtained from samples contemporaneous to the 
clinical assessment for all 172 subjects, the mean value being shown in Table 6.5. The 
coefficient of variation for the assay over the working range was 7.13 - 9.47%. At the 
lowest concentration of the standard (6.25IU) it was higher (21.16%). Samples with anti-
elastin antibody concentrations at this level were repeated at appropriate dilutions to 
ensure a result was obtained within the most reliable range of the assay. The spike 
recovery was 87.34%, and assay specificity for anti-human IgG was confirmed by a zero 
reading in the columns where control anti-CD11 antibody had been used. 
     No difference in level was seen between genders, and the level did not vary significantly 
with age (p=0.64 and 0.74 respectively). Antibody level did not differ between those who 
had never smoked and those who had (p=0.07, Figure 6.5), nor did they differ between 
those with normal FEV1/FVC, normal FEV1 or normal KCO and those where these 
parameters were abnormal (p= 0.09, 0.22 and 0.26 respectively). However there was a 
statistically significant correlation between antibody levels and FEV1/FVC, p=0.03, 
Figure 6.6). However, if those who had never smoked or those with a normal FEV1/FVC 
were excluded the significance of the relationship was lost (p=0.84 and 0.20 respectively). 
This suggests that the data is being influenced predominantly by these subjects. The level 
did not vary between emphysematous and non-emphysematous subjects (p=0.074, Table 
6.5), nor did it correlate with any other feature of lung function (all p>0.05). 
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 Mean (SE) anti-elastin antibody titre (IU) 
All subjects 39.54 (7.54) 
Emphysema 29.30 (6.06) 
No emphysema 51.12 (17.33) 
p value 0.074 
 
Table 6.5: Anti-elastin antibody levels in the AATD subjects 
The table shows the mean anti-elastin antibody level in the AATD group, stratified by 
presence of emphysema. The differences were not statistically significant. 
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Figure 6.5: Anti-elastin antibody levels do not differ between those that have and have not 
smoked 
The histogram shows the mean anti-elastin antibody level, with error bars representing 
SEM, stratified by smoke exposure. The difference was not statistically significant 
(p=0.068). 
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Figure 6.6: Anti-elastin antibody levels correlate with FEV1/FVC 
The graph shows anti-elastin antibody levels, with each point representing an individual. 
Less airflow obstruction was observed in those with high anti-elastin antibody levels 
(r=0.16, p=0.03). The trendline has been omitted due to non-normal data distribution. 
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6.4.3 HLA class II associations with anti-elastin antibody levels 
      Anti-elastin autoantibody levels were compared between genotypes of phenotypically 
associated alleles only, in order to assess if anti-elastin autoimmunity was driving the 
phenotypic association with HLA type. This would indicate a potential mechanism for the 
observed genetic association.  
     Antibody levels were associated with HLA-DQA1*0301 and HLA DRB1*04 genotype 
(p=0.027 and 0.024 respectively), such that they were higher in those homozygous for the 
associated alleles. For the HLA-DRB1*04 allele the mean (SEM) antibody level was 
109.65 (38.96) IU/ml, whilst in heterozygotes it was 36.99 (15.63) IU/ml and in those with 
no HLA-DRB1*04 alleles 38.73 (8.77) IU/ml. For the HLA-DQA1*0301 allele the 
corresponding levels were identical for homozygotes, since these 3 subjects were 
homozygous for both HLA-DRB1*04 and HLA-DQA1*0301, whilst heterozgotes had a 
mean level of 37.36 (16.01) and those with no HLA-DQA1*0301 alleles a level of 38.60 
(8.70). This is consistent with the pattern of LD in the region. These results are illustrated 
only for the most associated allele (HLA-DQA1*0301), since the results for HLA-
DRB1*04 are similar, in Figure 6.7.  
     This relationship was apparent only in smokers, with levels being higher in associated 
allele homozygotes (HLA-DRB1*04; p=0.018, HLA-DQA1*0301; p=0.021. Figure 6.8 
illustrates this for the most associated allele (HLA-DQA1*0301). The difference in 
antibody levels between non-smokers by genotype was non-significant (both p=0.86). This 
analysis was performed to determine if the generation of anti-elastin antibodies was both 
smoke and genotype dependent. Splitting of the dataset in this way does, however, limit 
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the size of the homozygous groups further and should, therefore, be viewed with caution.  
     Antibody levels did not differ significantly between genotypes for other alleles that 
exhibited a phenotypic association (all p>0.75). 
 232
020
40
60
80
100
120
140
160
Se
ru
m
 a
nt
i-e
la
st
in
 a
nt
ib
od
y 
tit
re
 (I
U
)
HLA-DQA1*0301 absent n=127
Heterozygote including HLA-DQA1*0301 n=46
Homozygote for HLA-DQA1*0301 n=3
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.7: Anti-elastin antibody levels vary between HLA-DQA1*0301 genotypes 
The bar chart shows the mean (SE bar lines) of anti-elastin antibody titre in patients 
stratified by HLA-DQA1*0301 genotype, each column illustrates the number of HLA-
DQA1*0301 alleles present. Levels are significantly higher in patients homozygous for 
HLA-DQA1*0301 (p=0.027). 
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Figure 6.8: Anti-elastin antibody level stratified for both HLA-DQA1*0301 genotype and 
smoke exposure 
The bar chart shows the mean serum antibody level with the dataset split according to 
whether the subject had ever smoked. In subjects who had smoked antibody levels were 
higher in those homozygous for the HLA-DQA1*0301 allele (p=0.021), but in non smokers 
the relationship was not significant (p=0.859). 
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6.5 Discussion 
     The data show an association between the HLA-DQA1 locus and KCO, and individual 
alleleic associations of HLA-DRB1*04 and HLA-DQA1*0301 with lower FEV1/FVC, and 
of the latter with lower FEV1. These 2 alleles, which exhibited LD, were the only alleles to 
show consistent effects across several pulmonary function parameters, although others 
associated with a single measure. Importantly, HLA-DQA1*0301 remained significantly 
associated with FEV1/FVC and FEV1 after a conservative correction for multiple 
statistical testing; the validity of this correction in the HLA region will be discussed 
further later.  
     Anti-elastin antibodies showed no phenotypic associations when considering smoke 
exposed subjects, but did show a genotypic association, in that they were higher in those 
homozygous for either HLA-DRB1*0301 or HLA-DRB1*04. This suggests that an anti-
elastin mediated autoimmune pathology, in which HLA type is a key driver of 
susceptibility exists in AATD, but that it may only be so in those homozygous for one, or 
both of HLA-DRB1*04 and HLA-DRB1*0301. Elastin peptides might be presented to 
the immune system more effectively by proteins encoded by associated alleles, leading to 
generation of an auto-antibody and a subsequent response directed at elastin in the lung, 
as illustrated in Figure 6.9. This hypothesis is consistent with previous work in usual 
COPD[205].  
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Figure 6.9: A possible role for HLA class II type and anti-elastin autoimmunity in lung 
disease in AATD 
1 Cigarette smoke upregulates TNFα which causes neutrophil aggregation in the lung. 
Neutrophil elastase (NE) is released and causes elastolytic damage to normal lung, 
generating elastin peptides 
2 Elastin peptides are presented to the immune system. At this point if HLA-DRB1*04, 
or DQA1*0301, is the HLA class II protein present the peptide could bind preferentially, 
such that it is presented more effectively to T cells, via the T cell receptor. Alternatively it 
might be more able to dock to the T cell receptor after binding. Either of these processes 
would amplify the subsequent immune response. 
3 T-cells activate B cells, such that they express anti-elastin antibodies on their surface, 
and generate similar free antibodies. 
4 Free antibody binds to elastin in the lung, causing an autoimmune response, such that 
other cells of the immune system are activated against the tissue. 
5 Neutrophils release NE, which causes further elastolytic damage. 
6 Macrophages release other proteases, such as matrix metalloproteases (MMPs), which 
also damage components of the extracellular matrix, such as collagen. 
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    Autoimmune diseases have a complex pattern of HLA association, with the strongest 
evidence being for class II alleles[306]. Classical autoimmune diseases have strong 
predisposing effects associated with HLA-DRB1*03 and HLA-DRB1*04. Examples of 
diseases with such associations are type 1 diabetes (T1D)[314, 315] and rheumatoid 
arthritis (RA)[316]. Other HLA-DRB1 alleles, such as HLA-DRB1*1301, have been 
proposed to act as protective variants in RA[317]. These allelic associations may be due to 
an altered amino acid sequence at positions β72-74 in the DRB1 protein (the ‘shared 
epitope’)[317], an area which spans environments involved in autoantigen presentation 
and T-cell antigen receptor docking. This suggests that changes here could determine 
which antigens are presented to the immune system[308]. HLA-DQA1 specific 
associations with autoimmune diseases have been reported in Graves’ disease[309], and 
haplotype associations including this locus and DRB1 are well known[308].  
     The involvement of an allele associated with autoimmunity lends support to the 
hypothesis that development of emphysema could depend, in part, upon an antigen 
presented by HLA class II. If an antigen was more able to be presented to the immune 
system in those with DQA1*0301 (or DRB1*04) the net effect could be a greater immune 
response and more autoimmune lung destruction, or alternatively lesser immune response 
and hence less tissue destruction. Various autoantigens have been suggested in 
emphysema [205, 298] and their binding properties with the protein products of the 
associated alleles are unknown. Many disease mechanisms have been proposed for HLA 
class II in autoimmunity, including variation in autoantigen binding and failure to select 
a good regulatory T cell population[306]. These results could support the former as a 
disease mechanism, but it is of note that lower numbers of regulatory T cells in the lungs 
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have been reported in emphysematous subjects relative to healthy controls[205].                    
Functional effects of variation in the HLA region are an area of current research in 
traditional autoimmune diseases where HLA associations are more well replicated[306], 
though are complex because of the multi-allelic nature of HLA class I and II. Such studies 
may be relevant to pursue in COPD if autoimmunity is accepted as an important disease 
mechanism.  
     Within HLA class II LD is observed between DR and DQ loci, resulting in classical 
haplotypes[313], conventionally described by the DRB1 allele on which they are based. 
Any DRB1 allele typically in LD with DQA1*0301 might, therefore, show the same 
disease association. Indeed, HLA-DRB1*04 is in LD with HLA-DQA1*0301 here, such 
that their associations are in the same direction. However, the pattern of LD also makes it 
impossible to reliably state that the association is due entirely to HLA-DQA1*0301 - it 
might be due to either, or indeed both, alleles. The other allelic associations seen with 
clinical features are less consistent across all measures of pulmonary function, perhaps 
suggesting a risk that a false positive result has occurred. Furthermore none would remain 
significant after applying a Bonferroni correction, unlike HLA-DQA1*0301, so such 
associations would require replication in another patient group before they could be 
considered truly significant. 
     Previous work in COPD unrelated to AATD has reported HLA associations at class I 
and class III loci. The class I associations were reported for different sub-phenotypes of 
COPD - FEV1[204] and chronic bronchitis[311], and were inconsistent. The only class III 
associations reported are with TNFA, which has been considered in detail in chapter 3. 
LD exists between HLA classes I, II and III, such that it may be difficult to ascertain the 
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true associated allele. Whilst a primary HLA class I or class III effect can not be excluded, 
data reported in this chapter is supported by a plausible disease mechanism incorporating 
HLA class II molecules. HLA-DRB1*03 has been reported to be in LD with a TNFA 
promoter region SNP (rs1800629)[312], but in the studies contained within this thesis this 
SNP did not associate with any clinical phenotype, making it less likely to be a 
confounding factor in this case.     
     This study is weakened by small numbers, particularly in the group with no 
emphysema, and by the lack of a replication group. Classically in genetic association work, 
large populations are needed for adequate power. However the current study 
demonstrated a significant association with HLA-DQA1*0301 even after a Bonferroni 
correction, usually deemed overly conservative for genetic association work[68], 
particularly in the HLA region where it is uncertain how best to adjust for alleles in tight 
LD. This suggests that in this population a true effect is more likely than a chance 
association. Other factors that have the potential to influence the result of a genetic 
association study are genotyping error and population stratification. Independent 
verification of genotype by two researchers was used to reduce the chance of genotyping 
error. All subjects were racially matched, which minimises the chance of population 
stratification having affected the results, though this could be further confirmed by the 
addition of racial markers to the loci typed. 
     It is also of interest that antibody levels were higher in subjects who had not smoked, 
albeit not statistically significant. Since non-smokers generally have better lung function, 
as shown by the influence of smoke exposure upon all lung function measures in the 
regression models reported in Chapter 3 (Table 3.6) it may be that non-smokers are 
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influencing the correlation between FEV1/FVC and antibody level. This is supported by 
the observation that the correlation disappears when these subjects are excluded. It is, 
therefore, of interest to consider when non-smokers with AATD may present to medical 
services. In the UK there is no routine screening programme for AATD, and as such there 
is a potential ascertainment bias inherent in the patients studied, such that those with 
worse disease are more likely to present to medical services and undergo the tests needed 
to diagnose deficiency. If anti-elastin autoimmunity dependent on HLA class II type 
alone, rather than a combination of this and smoke exposure, is important, then non-
smokers with the relevant HLA class II type could develop disease and hence present to 
health care services. Conversely those without the associated HLA type may be less likely 
to develop anti-elastin associated disease, and also less likely to develop lung disease by 
the more well-recognised proteolytic and oxidative mechanisms (Figures 1.4 and 1.5), thus 
would not present to health care services. Furthermore, smokers who had the associated 
HLA type could develop disease by both mechanisms and might die before diagnosis, or 
be too unwell to travel to our centre for assessment. All of these issues could lead to a bias 
in our dataset regarding the smoke exposure of individuals pre-disposed to develop anti-
elastin antibodies due to their genotype. The observation that the difference in anti-
elastin antibody with HLA type is not maintained in those who have never been smoke 
exposed suggests that other autoantigens may also be important, or may be an artefact 
due to low numbers in that group. Clearly this hypothesis is speculative in nature, but 
could be tested in a country where AATD is screened for at birth, where such a bias would 
not exist.  
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          Evidence from animal models[206, 235, 300], observation of lymphocyte 
accumulation in the lung[11, 302], clustering of autoimmune disease in individuals with 
COPD[304] and demonstration of autoantibodies in emphysema[205, 298], together with 
our results suggest that autoimmunity may be an important disease mechanism in 
emphysema, which would have implications for treatment. Response to 
immunosuppression, such as steroids, is variable in COPD. Since autoimmune processes 
characteristically respond to such treatments, our results suggest that there may be 
identifiable groups of patients in whom immunosuppression will be valuable. Replication 
of this study in COPD unrelated to AATD is now indicated.  
 
6.6 Conclusions 
HLA class II shows association at the HLA-DQA1 locus with KCO, though no individual 
allele could be confidently identified that might account for this. However, individual 
allelic analyses showed the HLA-DQA1*0301 allele to be associated with both FEV1 and 
FEV1/FVC even after a conservative correction for multiple statistical testing. HLA-
DRB1*04, with which HLA-DQA1*0301 is in tight LD, also showed a phenotypic 
association with FEV1. Both alleles exhibited genotypic association with anti-elastin 
antibody levels, suggesting that anti-elastin mediated autoimmunity may be 
pathophysiologically important in individuals with either of theses alleles and AATD. 
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Chapter 7: The role of pollution and other inhaled agents 
linked to lung disease 
7.1 Introduction 
     Adverse health effects have been linked to levels of air pollution by a variety of 
epidemiological and toxicological studies. Pollutants may be gaseous or particulate, and 
primary (released directly into the atmosphere) or secondary (formed by reactions in the 
atmosphere). The pollutants with most evidence regarding ill effects on health are ozone, 
particulate matter, nitrogen dioxide (NO2) and sulphur dioxide (SO2)[207], though the last 
is somewhat controversial as toxicological studies suggest the concentrations needed to 
cause an effect are far higher than seen in the environment[318]. Two major studies have 
linked long term exposure to particulate matter with deaths from lung cancer and cardio-
respiratory disease[319, 320]. Time series work also suggests similar shorter term effects 
[321]. Other epidemiological work assessing short term exposure effects including hospital 
admission rates for respiratory disease and lung function changes, has found significant 
effects of particulate matter[322, 323], ozone[324, 325] and sulphur dioxide (SO2)[322, 
326]. In the UK reports have been produced that focus on long term effects of all major 
pollutants, with the aim of estimating the overall health burden attributable to pollution, 
and direct public health policy as a consequence. The World Health Organisation (WHO) 
and American Thoracic Society (ATS) have also provided guidance on what constitutes an 
adverse effect of air pollution[207, 327], identifying changes in lung function as an 
important outcome. Both recognise that genetic factors may be important in determining 
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such effects[207, 327]. Subjects with AATD sustain lung damage as a result of the 
relatively unopposed action of neutrophil elastase, which degrades lung elastin[328]. This 
process leads to a greater disease burden in those exposed to inflammatory stimuli, 
predominantly cigarette smoke[17]. Pollutants may contribute to lung disease by 
inflammatory, elastase predominant pathways or by mechanisms relating to oxidative 
stress[44]. By studying subjects with AATD it may be possible to elucidate which 
pollutants contribute to disease by elastase dependent mechanisms, as their effects may be 
more marked in AATD.  
     Another important group of inhaled agents associated with lung disease[329], both 
asthma, interstitial disease and COPD, are those observed in the workplace. Occupational 
exposures may also influence lung function in AATD[330-332], and are appropriate to 
consider alongside pollution. It is certainly conceivable that subjects with AATD would be 
at greater risk of lung damage from occupational agents by the same mechanisms as 
pollution, and such information would be of value to them when choosing work. 
Occupational exposures may be ascertained by direct measurements in prospective studies 
or by the occupational history in retrospective study designs. 
          Several methodological issues must be considered when studying pollution. 
Retrospective study designs may consider effects of day-to-day changes in pollution on 
daily events, such as deaths and hospital admissions, (known as time-series studies), or 
may be cross sectional in order to give an indication of long term effects. Time series 
studies, whilst using detailed pollution data, are only able to use crude measures of health 
effects. Cross sectional designs are limited by the fact that pollutant levels have changed 
over time, and availability of data pertaining to covariates, such as smoking. Prospective 
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longitudinal studies may therefore be the ultimate goal, but will be expensive to conduct. 
The subjects recruited to ADAPT are potentially susceptible to the effects of pollution, 
well characterised regarding respiratory disease, and have information on covariates 
available. They therefore represent a group in whom a cross sectional design might be 
informative. Furthermore, longitudinal data on lung function is available for many, such 
that cumulative pollution effects might be considered, albeit in a retrospective manner. 
 
Much of the data presented here has been published in peer reviewed journals (Appendix 
7).  
 
7.2 Aims of this chapter 
     This chapter describes putative long term effects of outdoor air pollution and inhaled 
occupational agents on lung function and of emphysema severity in AATD, as well as 
associations of air pollution with lung function decline. Other clinical features that predict 
decline will also be described.  
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7.3 Methods 
7.3.1 Long term effects of air pollution and occupation 
     Spatial distribution of pollution remains relatively constant in the UK[333]. 
Consequently, a cross-sectional study including only patients who have lived in one area 
throughout their lives can give some indication of the effect of lifetime exposure. 
Occupation may be assessed in epidemiological work of this nature using a system that 
classifies lifetime exposure risk by the use of a job exposure matrix, which takes into 
account all jobs that a person has undertaken. 
 
Subjects 
     All PiZZ subjects from the ADAPT databases who had always lived within 25km of 
their place of birth were selected for assessment with regard to pollution, giving a total of 
304 individuals. Subjects who had moved (n=118) were studied only with regard to their 
demographic and clinical features, in order to ascertain if differences existed between those 
that had or had not moved. Residential history was ascertained by asking for place of 
birth, current and previous addresses. 
     Patients’ addresses from the year of pollution data collection were mapped to OS co-
ordinates using the National Statistics Postcode Directory[334]. The same database was 
used to obtain a census classification into urban/rural dwelling for the population. All 
subjects were phenotyped as described previously, and information on covariates such as 
smoking and occupational history noted. Lifetime risk of exposure to inhaled agents in the 
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workplace associated with lung disease was ascertained by use of a job exposure 
matrix[335]. This was created using Standard Occupational Classifications (SOC 2000) 
generated using the CASCOT[336] system. Job codes were divided into 3 groups, 
according to the likelihood and probable intensity of exposure to agents known to cause 
occupational lung disease. Patients who had worked at any time in a job where the 
exposure intensity was likely to be less than 30% of the workplace exposure limit[337] 
were classed as low risk, with intensities above this being deemed high risk. Those who 
had never worked in an exposure prone job were classed as zero risk. Clinical and 
demographic features were compared between those of different occupational risk groups, 
and the frequency of at risk professions was compared to that in the UK as a whole, 
obtained using the 2001 census.  
 
Pollutants 
     Annual mean data for SO2, NO2, oxides of nitrogen (NOx), particulate matter <10µm 
in diameter (PM10) and secondary particles was obtained from geographical information 
system (GIS) maps for 2006.  These were used as indicators of long-term exposure to each 
pollutant. Annual mean ozone is not available at the level of resolution of GIS maps, 
hence alternative metrics from similar GIS maps were used for this pollutant: AOT40 
(ozone µg/m3.hr) and days of ozone >120µg/m3. AOT40 is the parameter used to represent 
accumulated ozone dose and is the sum of the differences between the annual hourly mean 
ozone concentration and 40 ppb for each hour when the concentration exceeds this limit 
during daylight hours. Levels of primary particles were calculated by subtracting 
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secondary particles from PM10. The maps detail pollutant levels on a 1km x 1km grid 
across the UK, using data from the National Atmospheric Emissions Inventory and a 
combination of modelling methods, including dispersion kernel approaches and weighted 
regression analyses to calculate effects from major industrial sources. Major roadside 
increments are taken into account where necessary. This methodology is described in 
detail elsewhere[338]. Pollutant levels were mapped to patients using the OS co-ordinates 
from the grid. 
 
Statistical analysis 
     The relationship of pollutants to one another was checked using simple correlations, 
and differences across urban and rural locations ascertained (Kruskal Wallis test) in order 
to validate the data for the cohort against existing evidence regarding pollutant 
distribution. Regression models ascertaining pollution effects took into account pack years 
smoked, age, gender and level of occupational risk prior to addition of pollution data, 
using FEV1, FEV1/FVC, KCO, UZVI and LZVI as the outcome variables.  
     For pollutant associations from the regression models the relationship of current levels 
to that of previous years was checked using data from 1993, 2003 and 2005. These were 
assessed for variability and compared between years using the Kruskal Wallis test and 
Friedman’s test for ozone metrics because the data violated the assumption of sphericity 
for repeated measures ANOVA. 
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7.3.2 Pollution and decline of lung function 
 
Subjects 
     All PiZZ subjects with baseline and follow up data were studied (n=404). Decline of 
lung function for descriptive statistics of the group was calculated using linear regression 
over 4 data points, as described in chapter 2. The number of subjects with 4 data points 
for calculation of decline was 220; those with less follow up than this were assessed as well 
in order to reduce the effect of selection bias on association analyses of lung function 
decline. The years of data collection were noted, such that cumulative pollution exposure 
and mean exposure per year during that period could be calculated. The number of 
exacerbations per year over the time period was also noted.  
 
Pollutants 
     Annual mean levels of SO2, NO2, PM10 and ozone (AOT40, as before) from each of the 
years used for calculation of lung function decline were taken from GIS maps as before, 
matching to patients by the use of the postcode. Secondary particle data was not available 
for sufficient years to calculate primary particles from PM10. Similarly there were fewer 
years with ozone data, reducing the number of subjects this could be matched to. 
 
Statistical analysis of pollutant data 
     Predictors of lung function decline were ascertained using univariate models, and those 
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significant added to multivariate models including a single pollutant on each occasion.   
Generalised estimating equations were used to ascertain predictors of decline, since these 
can account for repeated measures in an individual, as well as including a time function, 
which accounts for differing lengths of follow up. This allowed inclusion of a greater 
number of subjects in the initial analysis for pollution effects, thus maximising power. 
Analyses were then substratifed for those with and without 4 data points for their lung 
function. This was performed in order to see if the increased accuracy of decline 
measurement obtained in those with more measurements available was influencing the 
results in the larger dataset. Subgroup analysis by index status was also carried out, in 
order to exclude any influence of this on the outcome measure. 
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7.4 Results 
7.4.1 Long term effects of air pollution 
Clinical and demographic features 
     The characteristics of the subjects are shown in Table 7.1, with sub-stratification for 
level of occupational risk in Table 7.2, and the most frequent at-risk professions in Table 
7.3. There was no significant difference in any demographic or clinical feature between the 
subjects who had never moved from their place of birth and those who had.  
     No clinical or demographic feature differed between occupational risk groups, though 
at risk professions were over-represented in the patient group compared to the UK 
population (9.45 v 7.48%, p<0.0001). Subjects had worked for a mean of 19 years and 
stopped work at a mean age of 48 years. There was no difference in the duration of 
working life or age stopped work between the occupational risk groups (p>0.1). Since some 
occupational agents are associated with interstitial lung disease this was sought using 
subjects’ HRCT images, but was not present in any subject.  
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  Never moved (n=304) Moved away from place of birth (n=118) 
Subjects of male gender 58.88 (179) 63.60 (75) 
Age  in years 50.29 (42.59-56.22) 51.11 (40.63-58.09) 
Never smoked 23.70 (72) 25.40 (30) 
Pack years smoked 14.00 (1.10-25.38) 13.50 (0-23.50) 
FEV1/FVC 39.60 (30.63-56.63) 36.10 (28.45-59.20) 
FEV1 % predicted 34.79 (24.72-65.23) 38.04 (24.16-58.41) 
KCO % predicted 66.10 (53.84-87.90) 66.67 (50.11-82.62) 
UZVI 29.75 (16.03-42.60) 34.30 (17.90-47.70) 
LZVI 48.30 (27.95-59.20) 49.80 (32.90-63.00) 
 
Table 7.1: Characteristics of subjects stratified by whether they had moved their place of 
birth 
Data are shown as median (IQR) for quantitative data, and as % (n) for frequency data. 
All data were non-normally distributed, except for age – this is shown as median (IQR) for 
consistency within the table. There were no significant differences between those that who 
had or had had not moved (all p>0.05). 
 
 
 
Level of occupational risk   
Zero Low High 
p value 
% of subjects of 
male gender 
60.93 67.65 50.67 NS 
Age 50.40 (0.82) 48.81 (1.32) 49.23 (1.32) NS 
Pack years 14 (0.2-26) 13.5 (5.25-24.5) 15.75 (0-24) NS 
FEV1 36.66 (25.81-58.91) 39.87 (24.13-68.54) 34.7 (25.90-69.91) NS 
FEV1/FVC 38.2 (29-53) 41(30.6-57) 39.1 (32-60.25) NS 
KCO 68.86 (57.37-88.75) 69.87 (2.84) 66.1 (57-85.91) NS 
Bronchodilator 
reversibility (%) 
62.16 64.71 59.46 NS 
 
Table 7.2: Characteristics of subjects stratified for level of occupational risk to the lung 
51.4% of subjects exhibited zero occupational risk, with 23.1% having low risk and 25.5% 
a high risk exposure history. There were no significant (NS) differences between the 
groups. 
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Occupation Number 
Labourers in process and plant operations 8 
Carpenters and joiners 6 
Construction trades 6 
Vehicle body builders and repairers 5 
Welding trades 4 
Motor mechanics and auto engineers 4 
Painters and decorators 4 
Coal mine operatives 4 
Metal working machine operatives 4 
Assemblers (vehicles & metal goods) 4 
 
Table 7.3: Common high risk professions in AATD UK resident subjects who have never 
moved  
 The 10 most common high risk professions in the subject group are shown in the table. 
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Pollutants 
     All pollutants except secondary particles differed across settlement types allocated by 
the census (all p<0.0001, shown in Table 7.4 and Figure 7.1), ozone being greater in rural 
locations, whilst others were greater in urban areas. The two ozone metrics correlated well, 
whilst NO2 and NOx showed a curvilinear relationship (both p<0.0001). Significant 
relationships between all other pollutants were also present (all p<0.0001). These are 
illustrated in Figure 7.2. 
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  Urban  
n=241 
Town   
n=25 
Village  
n=26 
Hamlet   
n=12 
p value 
Primary 
particles 
14.79 (0.16) 11.70 (0.14) 11.26 (0.18) 11.12 (0.29) <0.0001 
Secondary 
particles 
7.46 (0.08) 7.72 (0.26) 7.96 (0.22) 7.12 (0.35) 0.082 
NO2 20.29 (0.38) 11.85 (0.82) 12.93 (0.58) 9.96 (0.94) <0.0001 
SO2 3.99 (0.16) 2.86 (0.48) 2.71 (0.13) 2.14 (0.12) <0.0001 
Ozone days 
>120µg/m3 
14.25 (0.22) 15.98 (0.86) 17.33 (0.61) 16.44 (1.27) <0.0001 
AOT40 11859.13 
(190.24) 
13602.18 
(498.98) 
13673.59 
(735.60) 
13746.80 
(1056.48) 
<0.0001 
 
Table 7.4: Pollutant distribution across census classes  
Pollutants are shown as mean (SE), units being µg/m3 except CO (mg/m3) and AOT40 
(µg/m3.hr). All differences were significant with p<0.0001, with all pollutants bar ozone 
being higher in urban areas. 
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Figure 7.1: Pollution levels between residential areas in the UK 
The graph shows the annual mean level from 2006 for each pollutant with the units shown 
on x axis labels. Primary particles, NO2 and SO2 were higher in urban areas, whilst ozone 
was higher in rural areas. Significant differences are marked with an asterisk (* = 
p<0.0001).  
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Figure 7.2: Intra-pollutant and inter pollutant correlations in the cross sectional study 
(a) and (b) show correlations between measurements pertaining to the same pollutant, 
being for nitrogen oxides and their derivative, nitrogen dioxide, and ozone measures 
respectively. (c), (d) and (e) show the positive correlations observed between nitrogen 
dioxide, primary particles and sulphur dioxide. (f), (g) and (h) show the negative 
correlations between these pollutants and ozone. The correlation coefficients are shown on 
the graphs; all relationships are significant with p<0.0001. 
 
 256
Regression modelling 
     Each regression model was first constructed without pollution data, in order to 
ascertain associations with demographic features. Only those that were statistically 
significant were included in subsequent multiple regression models that included 
pollutants. Increasing age and cigarette smoke exposure were associated with lower KCO, 
FEV1 and FEV1/FVC and worse CT densitometry. The r2 values suggest that smoking 
accounts for 6% of variability in KCO and FEV1/FVC, 16% of FEV1 variability, 2% of 
UZVI variability and 12.7% of LZVI variability. Male subjects had lower FEV1/FVC and 
more severe emphysema as measured by densitometry. Occupational risk was not a 
significant predictor of any clinical outcome. 
     Single pollutant models were used in the regressions, because of multi-collinearity 
between pollutants. AOT40 was used to represent ozone exposure. Although primary 
particles, NO2 and SO2 contributed significantly to regression models the B values 
suggested that lung function and UZVI were better in the presence of high levels. 
Conversely the values for ozone showed that KCO was lower and both FEV1/FVC and 
UZVI higher with increasing ozone levels, the urban-rural difference in ozone (Table 7.4) 
being associated with a 2% decrease in KCO. Addition of ozone to the model accounted for 
only 1% of KCO variability. The regression results are summarised in Table 7.5. 
 
Relationship of current to previous years’ pollution levels 
     Ozone exhibited significant variability over time (p<0.0001, Table 7.6). Despite this 
the cumulative ozone exposure, calculated from the sum of means over 35ppb for all 3 
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years (the only metric available for 1993, 2003 and 2005), correlated well with 2006 ozone 
values. AOT40 showed a closer relationship than ozone days >120µg/m3 (r=0.68 v 0.44, 
both p<0.0001, Figure7.3). The sum of annual mean values for other pollutants also 
showed good linear relationships with the 2006 values (all p<0.0001, Figure 7.3).
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KCO FEV1 FEV1/FVC UZVI LZVI Feature 
B p B p B p B p B p 
Primary particles  1.06 0.02 0.01 0.05 0.01 0.03 -1.10 0.01 -1.45 0.02 
NO2  0.51 0.01 0.004 0.06 0.003 0.052 -0.41 0.02 -0.45 0.06 
AOT40  -0.001 0.05 -5.90 x 10-06 0.19 -6.25 x 10-06 0.03 0.001 0.02 0.001 0.03 
SO2  0.94 0.11 0.002 0.74 0.006 0.16 -1.14 0.01 -1.23 0.01 
Age -0.48 <0.01 -0.003 0.03 -0.003 <0.01 0.41 <0.01 0.68 <0.01 
Pack years -0.41 <0.01 -0.01 <0.01 -0.004 <0.01 0.19 0.05 0.48 <0.01 
Gender -0.73 0.31 -0.03 0.08 -0.06 <0.01 7.30 <0.01 4.57 0.04 
Occupation -0.95 0.54 -0.002 0.90 0.01 0.38 -1.51 0.28 -0.32 0.84 
 
Table 7.5: Results of pollutants in regression models in the cross-sectional study 
The table shows the regression coefficients and significance of each variable. Models for FEV1 and FEV1/FVC used log values whilst those 
for KCO and CT densitometry used untransformed data. All pollutants were measured in µg/m3 except AOT40 (µg/m3.hr). Results for 
covariates are from models prior to addition of pollutants. Gender was coded male=1, female=0.
  Sum of ozone>35ppb 
Year All Urban Town Village Hamlet 
1993 3085.38 
(57.79) 
2920.63 
(62.52) 
4049.00 
(195.02) 
3238.22 
(120.62) 
4055.43 
(239.90) 
2003 3417.98 
(51.80) 
3291.91 
(54.87) 
4186.04 
(182.21) 
3647.42 
(188.15) 
3852.49 
(243.55) 
2005 2185.28 
(42.29) 
2061.80 
(44.45) 
2460.95  
(99.81) 
2596.42 
(146.51) 
2185.28 
(249.24) 
 
Table 7.6: Ozone variability over time 
Levels showed significant variability over time (p<0.0001) but were lower in more recent 
years (p<0.0001 in all locations). 
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Figure 7.3: Correlations of 2006 pollutant metrics to cumulative metrics 
The figure shows correlations between (a) 2006 AOT40 and (b) 2006 ozone days 
>120µg/m3 with cumulative ozone >35ppb over 1993, 2003 and 2005. Both are significant 
at p<0.0001, the r values being 0.68 and 0.44 respectively. (c), (d) and (e) show 
correlations between 2006 levels of SO2, NO2 and PM10 with a similar cumulative measure, 
the r values being 0.51, 0.88 and 0.94 respectively. All are significant (p <0.0001). 
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7.4.2 Pollution and decline of lung function 
Clinical determinants of lung function decline 
     The characteristics of the subjects included in this part of the study are shown in Table 
7.7. All features shown in the table were compared between the whole group and the 
subset with most lung function measures. The only difference between them was in the 
distribution of occupational risk, where those followed up longer were generally working in 
higher risk professions (p<0.01). All other comparisons were non-significant (p>0.05). This 
indicates that if a subset of only those with at least 4 data points to calculate decline were 
studied there may be some selection bias. Some of the observed risk occupations are shown 
in Table 7.8. 
     Age, gender, smoke exposure, current smoking, exacerbation frequency, occupational 
risk and baseline lung function were examined as predictors of decline. More rapid decline 
of FEV1 was associated with male gender (Mean (SE) -38.6 (8.7) v -23.4 (9.7) ml/yr, 
p=0.02) and higher baseline FEV1 (r=0.-22, p=0.003, Figure 7.4). Rapid decline of KCO 
was associated with higher baseline KCO (r=-0.20, p=0.02, Figure 7.5). Occupational risk 
did not predict FEV1 or KCO decline (p=0.50 and 0.64 respectively). Correlation 
coefficients for comparisons of continuous variables are shown in Table 7.9. 
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  Study subjects 
n=399 
Subgroup with at 
least 4 lung function 
data points 
n=218 
Subjects of male gender %  61.2 (244) 62.84 (137) 
Mean age in years 50.12 (0.17) 51.09 (0.70) 
Current smokers % 8.7 (35) 7.80 (17) 
Pack years 16.89 (0.24) 13.50 (1.25-24.88) 
Index cases % 74.1 (296) 79.6 (174) 
Currently working %  67.3 (268) 70.8 (154) 
Level of occupational risk in working 
people % 
High = 10.5 (28) 
Low = 20.4 (55) 
Zero = 69.1 (185) 
High = 18.2 (28) 
Low = 32.5 (50) 
Zero = 49.4 (76) 
FEV1 %predicted 51.28 (0.50) 52.04 (36.00-78.93) 
KCO %predicted 73.31 (0.45) 68.47 (55.82-84.91) 
Decline of FEV1  in ml/yr -32.66 (2.06) -34.84 (3.12) 
Decline of KCO in 
[mmol/min/kPa/l]/yr 
-0.03 (0.004) -0.02 (0.007) 
Exacerbations per year 1.00 (0.33-1.67) 1.00 (0.33-1.67) 
 
Table 7.7: Characteristics of subjects assessed for decline of lung function 
Data for the whole group and for the subset with 4 data points for lung function are 
shown in the 2 columns, and is expressed as mean (SEM) for normally distributed 
quantitative measures and median (IQR) for non-normally distributed quantitative 
measures. Categorical measures are shown as a percentage of the group, with the raw 
numerical data in brackets. The only statistically significant difference between the two 
groups was in the distribution of occupational risk (p<0.01). 
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 Risk level Occupation Number of subjects 
Metal working machine operatives 4 
Builder 4 
Metal welder 3 
Motor vehicle assembly worker 2 
Collier 2 
Wood machinist 2 
Glass making 2 
Printer 2 
Service engineer 2 
Motor mechanic 2 
High 
Farmer 1 
HGV driver 6 
Bus driver 4 
Van driver 3 
Glazier 3 
Heating engineer 3 
Electrician 3 
Maintenance engineer 2 
Low 
Docker 2 
  
Table 7.8: Risk professions observed in the longitudinal model 
The table shows all high risk professions observed in those currently working within the 
group included in the longitudinal study, and all low risk professions occupied by more 
than one subject. All subjects shown here were part of the subgroup who had at least 4 
data points for lung function. 
 
 
 FEV1 KCO Age Pack years Exacerbation 
frequency 
FEV1 decline -0.22 0.15 0.03 -0.03 -0.05 
KCO decline 0.04 -0.20 0.07 -0.02 -0.03 
 
Table 7.9: Correlation coefficients from univariate models 
Significant correlations are highlighted in the table by the use of bold type, and were 
present for FEV1 decline with baseline FEV1 (p=0.003), and between baseline KCO and 
KCO decline (p=0.02). 
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Figure 7.4: FEV1 decline relates to baseline FEV1 
The graph shows the correlation between FEV1 decline and baseline FEV1 - higher 
baseline FEV1 is associated with rapid FEV1 decline (r=-0.22, p=0.003). 
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Figure 7.5: KCO decline relates to baseline KCO 
The graph shows the correlation between KCO decline and baseline KCO – those with 
higher baseline KCO tend to have faster subsequent decline (r=-0.20, p=0.02). 
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Pollution and lung function decline 
     Full data on SO2, NO2 and PM10 was available, such that exposure could be calculated 
for all subjects; cumulative and mean data is shown in Table 7.10. All measured pollutants 
showed significant variability over time (all p<0.0001), the trend being to lower levels of 
SO2 and NO2, but higher levels of particles and ozone in the most recent year. Annual 
AOT40 data has been collected since 2003, so exposure to this metric could only be 
calculated for those subjects whose period of follow up was after this date, such that only 
42 subjects could be studied. Over half of the subjects had decline calculated using 4 data 
points over 3 years, however this was not the case for all, hence the cumulative exposure 
for the decline period could not be compared between subjects without the use of 
generalised estimating equations, which take both this and the repeated measurement of 
lung function into account. 
    In the multivariate analyses performed using generalised estimating equations male 
gender and baseline FEV1 remained predictors of FEV1 decline (p=0.02 and 0.01 
respectively). There was no association with any of the pollutants studied (all p>0.02). 
Baseline KCO associated with more rapid KCO decline (p=0.01), as did PM10, NO2, SO2 
and ozone (p=0.03, <0.001, <0.001 and 0.02 respectively). The results from the generalised 
estimating equations are summarised in Table 7.11. 
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  SO2 NO2 PM10 AOT40 
1997 7.81 (0.34) 34.06 (0.71) 18.25 (0.17)  
1998 6.26 (0.25) 31.01 (0.63) 16.92 (0.13)  
1999 5.01 (0.21) 29.71 (0.62) 16.31 (0.11)  
2000 4.35 (0.19) 27.89 (0.61) 15.91 (0.12)  
2001 3.75 (0.11) 26.07 (0.60) 15.51 (0.13)  
2002 3.82 (0.16) 20.87 (0.51) 14.98 (0.14)  
2003 4.13 (0.16) 23.81 (0.55) 17.56 (0.14) 9887.97 (219.51) 
2004 3.47 (0.15) 18.25 (0.50) 20.43 (0.22) 3236.36 (78.84) 
2005 3.38 (0.13) 18.88 (0.51) 22.04 (0.18) 4335.35 (103.81) 
Cumulative exposure 
over decline period 
10.99  
(8.08-16.32) 
78.36 (2.28) 52.21  
(46.22-59.52) 
19553.09 (815.81) 
Mean exposure per 
annum 
3.48  
(2.60-4.87) 
24.13 (0.64) 16.82  
(15.19-18.66) 
6517.69 (271.94) 
 
Table 7.10: Pollution exposures in decline cohort 
Data are shown as mean (SEM) or median (IQR) dependent on its’ distribution. All 
pollutants are measured in µg/m3 except AOT40 (µg/m3.hr) 
 
 
  B p value 
Baseline FEV1 0.02 0.01 FEV1 decline 
Gender -0.17 0.02 
PM10 -0.001 0.03 
SO2 -0.006 <0.001 
NO2 -0.002 <0.001 
Ozone -0.00002 0.02 
KCO decline 
Baseline KCO 0.02 0.01 
 
Table 7.11: Multivariate models of lung function decline 
The table shows significant predictors of decline from the generalised estimating 
equations. The B value is the regression co-efficient from the equation. A negative value 
indicates an association with faster decline, a positive one with slower decline. Since males 
were coded as 1 and females 0, this means that male gender was associated with faster 
decline, whilst higher baseline lung function values and all pollutants were associated with 
faster KCO decline.  
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7.5 Discussion 
      UK pollution data have been collected for over 60 years, though the range of 
pollutants measured, and the number of measuring stations, has increased with time[339]. 
This  (together with sophisticated statistical modelling methods that can take account of 
meteorological effects, dispersion from large sources and roads in addition to background 
pollution levels) has allowed the generation of GIS maps, which resolve pollution levels on 
a 1km by 1km grid across the UK. The modelling data have been validated by those 
responsible for map generation and published elsewhere[340, 341]. The validation data 
show good correlations between modelled and measured data at either networked or 
verification sites or both for NO2, PM10[341] and ozone[340], with r2 values for the 
correlations lying between 0.63 and 0.95. SO2 showed less robust correlations outside 
network sites[341] probably because the relative contribution of point sources (such as 
coal burning power stations) is reducing, which makes the importance of background 
levels greater than previously. Less is known about these background sources of SO2 than 
for the other pollutants considered in this chapter, which may have influenced the 
accuracy of this GIS map.  
     Extensive longitudinal data exists for some, but not all, pollutants, and for recently 
added datasets (such as PM2.5) relatively few data exist. However, levels of most 
pollutants in the UK have decreased gradually with time[339] and their spatial 
distribution remains relatively constant[333]. The longitudinal data analysis herein 
concurs, showing a good relationship between single and cumulative years. This was the 
main justification for the cross-sectional study, but has the potential for error in exposure 
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assessment. Whilst the longitudinal study of decline uses more accurate exposure than the 
cross-sectional work, and could therefore give a threshold level for an adverse effect, there 
was insufficient data on ozone to study this pollutant well. The two studies must therefore 
be viewed as complementary. 
 
Cross sectional model 
     The clinical data on covariates and clinical attributes concurs with previous studies 
that increasing age[149] and cigarette smoke exposure[17] influence phenotype. The 
pollution data also concurs with known UK data[207] (in terms of correlations and spatial 
distribution), giving a degree of validation to the measurements used in the pollution 
analyses. 
     There was no significant effect of occupation despite a high prevalence of at risk 
professions. This is a relatively small dataset to confidently exclude an effect of 
occupational exposure, and it is possible that ascertainment bias influenced results, since 
higher risk professions for the studied dataset were more common than in the general UK 
population. An arbitrary workplace exposure limit of 30% (used in most studies of 
occupational risk) was set and lifetime risk graded based on any prior or current level of 
exposure using a matrix. Whilst misclassification is possible with matrices[342] it is a 
method which could be used more widely to correct for workplace exposure in 
epidemiological studies. More detailed quantification of risk would require interviews 
and/or contemporaneous data on risk agents in each work environment. For large scale 
studies, as needed to assess pollution effects in the general population, this level of risk 
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measurement would be prohibitively complex and expensive.  
     The cross sectional study results illustrate the difficulties of assessing pollutant effects 
on disease. Firstly, the most significant associations are seen with KCO and CT 
densitometry, neither of which are widely measured in epidemiological studies, nor in 
routine clinical assessment of COPD[8]. Although CT densitometry seems most sensitive 
at detecting disease effects, it is perhaps more realistic to emphasise the need to assess 
KCO in subjects with COPD, especially as it tends to reflect upper zone emphysema 
(common in usual COPD) better than FEV1[18]. Secondly, since all measured pollutants 
correlate closely, study results can be difficult to interpret. However whilst single 
pollutant models, such as ours, may be thought limited, multi-pollutant models do not 
necessarily improve either the direction or degree of associations between ozone exposure 
and health end points (H.Walton, Health Protction Agency, UK; personal 
communication). Different time windows of air pollution exposure, or differences in the 
impact of absolute levels compared to changes in exposure levels, were not possible to 
assess, though such analyses may be more relevant to a fluctuating condition, such as 
asthma, rather than a relatively fixed condition, such as COPD. Finally, as with any long 
term study, it is possible that the data represents a survivor bias. 
         Many measured pollutants have been associated with respiratory disease in 
epidemiological or toxicological studies. Particulate matter contributes to lung disease 
predominantly via pro-inflammatory effects, though oxidative stress also plays a role [44, 
343]. Epidemiological associations of NO2 with admissions and mortality[344] are unlikely 
to be due to the gas itself, rather to a correlated particle metric such as particle 
numbers[345]. SO2 has been associated with bronchoconstriction in asthmatics[346] and 
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mortality[347]. Thus at first glance our regression results for these pollutants do not 
appear to make sense, as higher levels are associated with better lung function.    
     There are, however, a number of interpretations of these results. Firstly, that the 
apparent effects of high levels of NO2, SO2 and particles could be attributed to 
concurrently lower levels of ozone, consistent with its patho-physiological effects. This 
interpretation assumes that current levels are proportional to total exposure, which is 
supported by the data (Figure 7.3). An alternative interpretation could be that this model 
is insufficiently representative of long term exposure to other pollutants to detect their 
effects. Finally indoor exposures may be more important in our cohort, since the UK 
population in general spends most of its’ time indoors. Indoor exposures comprise both 
indoor sources (such as from fuel combustion) and pollutants diffusing in from outdoors. 
The extent to which the latter occurs depends on the penetration coefficient, ventilation 
and decay rates[348]. Indoor exposure could therefore only be included if measured 
prospectively for each individual. However, for ozone there are no relevant indoor sources, 
and indoor concentrations are likely to be reflective of outdoor concentrations, so the 
findings related to this pollutant are unlikely to be affected by daily habits pertaining to 
indoor exposure. 
     Ozone is known to induce airway inflammation, impair host defence to bacterial 
insults, decrease macrophage activity, impair mucociliary clearance and enhance 
bronchial hyperresponsiveness[349]. Any, or all, of these effects could contribute to the 
associations with lung function observed in our cohort, and it is notable that most are 
pathological processes accepted to be important in the pathogenesis of COPD. AAT levels 
in the lung rise within an hour of exposure to ozone [47], and provide over 80% of the 
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lung’s anti-elastase defences in models of ozone induced inflammation [350]. This suggests 
a rationale for enhanced susceptibility to ozone effects in AATD, and lends support to 
elastase driven pathways being of most importance in the effects of this pollutant. It is 
conceivable that in AATD this is so pronounced that any effects from other pollutants are 
overwhelmed. Indeed, the results reported here suggest relative protection from lung 
disease in the presence of low ozone levels, manifesting as a protective effect of high levels 
of other pollutants because of the direction in which they correlate. 
     Ozone is a secondary pollutant: the level varies as it depends less on emissions and more 
on meteorology and atmospheric effects[339]. Since ozone is scavenged by NOx any 
intervention controlling NOx, although beneficial in reducing NO2, will also tend to 
increase ozone. This, together with a rise in background ozone due to air travel across the 
Atlantic, and predicted changes in the UK climate (likely to make it warmer and sunnier) 
underlie projected increases in ozone over the next 15 years[351, 352]. This makes it more 
critical to investigate health effects of ozone, and highlights the importance of the 
observation described here. 
 
Longitudinal model 
     This model assesses factors influencing the decline in FEV1 and KCO with particular 
reference to ambient air pollution. It may be considered more accurate than the cross-
sectional model, because it could account for cumulative exposures reliably, by specifying 
the exposure window as the period over which lung function decline was calculated for 
each individual. 
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     In order to interpret the data consideration of the methods used to calculate decline is 
important. FEV1 has a variability of about 100ml between repeated measures[353] which 
exceeds the average annual decline of FEV1 in AATD. For this reason a simple calculation 
of decline based on two annual measures would not be sufficiently sensitive to determine 
the real change. However the standard error of the measure is inversely proportional to 
the number of years over which it is measured, such that over 3 years the error of the 
slope reduces to 33.3ml/yr, which is less than the decline described in this group of patients 
elsewhere[175].  In the current study decline was roughly equivalent to this, however the 
addition of two more data points to this slope reduces the error further (to approximately 
11.1ml/yr), so that the calculated decline should be reliable for any given individual where 
4 data points are used. This subgroup is by definition smaller in number than the whole 
group, thus there is loss of power, and selection bias could have been an issue. Gas transfer 
shows a greater degree of variability in its measurement than FEV1[175] but is a more 
sensitive measure of decline in AATD than FEV1[354]. The same methodology was 
chosen for gas transfer as for FEV1, in order to minimise error whilst maximising the 
number of subjects studied.  
     Comparison of the subgroup with at least 4 data ponts for lung function and the whole 
group did not show any significant differences in their pattern of lung disease, in that lung 
function measures were similar. However those in the subgroup that had at least 4 data 
points from which to calculate decline tended to work in higher risk professions than the 
whole group. This indicates some selection bias present – it may be that those working in 
high risk professions are more motivated to continue follow up, perhaps because they are 
used to regular assessments as part of occupational health follow up in their workplace, or 
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because of greater concern regarding their respiratory health. Conversely it might be that 
some of the higher risk professions lend themselves to being self-employed, such that 
subjects can choose more easily when to take time off, thus can attend the appointments 
offered. Since subjects travel from across the UK to the registry it will often involve a 
whole day off, which those employed by a company, or in the public sector, might find 
more difficult to do. Such conclusions can only be speculative in nature, but could be 
followed up with questionnaires administered to subjects within the registry, either by 
post or by telephone, to enquire about access issues and occupational health involvement 
at work. To maximise power the analyses were carried out in the larger group before 
moving to this subgroup. Pollution and clinical predictors of decline in the subgroup with 
at least 4 lung function measurements were no different from the whole in terms of 
direction or significance, suggesting that selection bias would not have influenced 
conclusions. In the subgroups defined by index status the results from the multivariate 
analyses were similar once again. An exception to this is ozone, where few measures were 
available from which to calculate exposure, such that the whole group could not be split 
and used in generalised estimating equations because the minimum number for the 
equations to work in SPSS was not reached in non index subjects.     
         FEV1 decline was associated with higher baseline FEV1, consistent with the fact 
that decline tends to be fastest in those with moderately impaired, rather than severely 
impaired or normal FEV1[238]. Male subjects tended to have smoked more, which may 
account for the gender association seen, as smoking is usually associated with faster 
decline in AATD[152]. We did not find any associations between ambient pollution and 
FEV1 decline, which may be because other measures are more reflective of disease in 
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AATD, or because the study was underpowered. A previous population based study of 
FEV1 decline found an influence of PM10, with higher levels being associated with faster 
decline. This was determined from the use of two spirometric measures 10 years apart, 
such that the methodology would be accurate to within 10ml/year during the follow up 
period [355]. However, differences in FEV1 decline attributable to PM10 in the 
multivariate models were less than 10ml, so it is possible the results represent natural 
variation.  
     KCO decline was predicted by baseline KCO which is perhaps intuitive, and in line with 
the association of FEV1 decline with its baseline value. All of the outdoor air pollutants 
studied were associated with KCO decline after adjusting for covariates. In AATD the 
predominant pathology is parenchymal disease[17], such that changes in KCO may reflect 
disease progression better than FEV1. Thus our results could concur with previous work 
[355] that particulates contribute to lung function decline, the difference in the parameter 
associated being reflective of the disease susceptibility and pathophysiology of the 
subjects studied. It is also suggestive of other pollutant effects – in the cross-sectional 
direct linear relationships between all outdoor air pollutants were shown (Figure 7.2) such 
that we would expect both NO2 and SO2 to be high in the presence of high PM10, but 
ozone to be lower[356]. PM10 is associated with airway inflammation[44], acute changes in 
lung function[357] and mortality[319, 320] whilst ozone [6,7] and SO2 [4,8] are associated 
with hospital admissions for respiratory disease and lung function. In the cross sectional study 
of pollution effects, association was seen between ozone and markers consistent with 
parenchymal lung disease[356]. However, the cross sectional study of pollution and 
occupation contained herein was smaller because it considered only subjects who had 
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never moved from their place of birth, in order to provide a model of lifelong pollution 
exposure. Also, although linear relationships were present between current and past 
pollution exposures to validate the model, this could be considered flawed, since it could 
not account for true cumulative pollution exposure, unlike the subsequent longitudinal 
model. The results for KCO decline support the long term exposure model in concluding 
that ozone is important in determining lung function in AATD, but also suggests that any 
pollutant associated with inducing lung inflammation could have an influence. This is 
more consistent with pathophysiology than the cross sectional model.     
     As for the cross sectional work, the study is limited somewhat by patient numbers. It is 
also limited by the lack of available longitudinal data pertaining to ozone, which may be 
of particular importance in AATD, since AAT provides approximately 80% of the lung’s 
protection from ozone induced inflammation [350]. A final point to note is that the 
analyses have not been corrected for multiple statistical testing. This is because both 
FEV1 and KCO decline correlate with one another, as do the pollutants studied. A 
Bonferroni correction would not be appropriate under these circumstances.  
     In summary these data show a significant association between exposure to outdoor air 
pollution of all types and disease progression in AATD, results that concur with 
population based work, and highlight the importance of measurements other than FEV1 
in the follow of patients at risk of COPD. 
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7.6 Conclusions 
      Ozone and other outdoor air pollutants may be of importance in determining disease 
severity and progression in AATD, but further prospective studies are needed to clarify 
the associations described in this chapter. 
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Chapter 8: Discussion 
8.1 Summary of results 
     This thesis concerns genetic and environmental influences on clinical phenotype in 
AATD. As such the results can be split into those describing observed clinical features, 
those describing genetic associations and those describing environmental factors. The 
interpretation of the results in the context of current knowledge of COPD is considered 
using this format. 
 
8.1.1 Clinical phenotypes 
     All of the studies reported in this thesis have relied on detailed clinical phenotyping of 
subjects with AATD. The results concur with previous reports[17] that indicate a range of 
phenotypes occur in people with AATD, with basal emphysema being the most commonly 
observed. In all of the groups of subjects studied here, the majority had impaired FEV1 
and KCO, which usually reflects emphysema (Tables 3.1, 3.2, 6.1, 7.1 and 7.7). This was 
confirmed on CT in most subjects, with a higher lower zone than upper zone voxel index 
being the most common pattern, showing that the disease was more severe in the basal 
areas of the lung (Tables 3.1, 3.2 and 6.1). This is in contrast to usual COPD where 
emphysema is usually worse in the upper zone [358].  
     Chronic bronchitis occurred in around 40% of subjects (Tables 3.1, 3.2 and Figure 3.3); 
a significantly lower proportion than reported in a recent study describing usual COPD 
sub-phenotypes, where it was seen in 72% of subjects with spirometrically defined COPD 
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[359]. This may be because of differences in reporting between the subjects with usual 
COPD in New Zealand [359] and those with AATD in the UK. Alternatively, subjects 
with AATD could exhibit different airways pathology to COPD, a concept worthy of 
further research. In general airway inflammation is thought to be more severe in 
AATD[201], which intuitively would suggest a higher risk of chronic bronchitis. However, 
it is possible that this is not reflected solely by sputum production and that other 
measures of airways disease may be helpful in future. The radiological assessment of 
airways disease has improved markedly over recent years[360] and now includes more 
subtle markers, such as airway wall thickness, a feature whose clinical significance is now 
being studied. However, since airway wall thickness relates to FEV1[361] and smoke 
exposure[362], and airway remodelling is an accepted part of pathophysiology[11], it is 
likely that such measurements also reflect part of the disease process. 
     Bronchiectasis was the predominant lung pathology in 24% of subjects (Figure 3.3), 
and age was a significant predictor of its presence (Table 3.6). A possible explanation for 
this is that bronchiectasis may develop because of repeated infections, and hence the effect 
will accumulate with time. Detailed scoring systems to describe bronchiectasis on CT in 
AATD were published subsequent to the clinical data collection part of the studies 
reported here[22]. When such systems are used to analyse the CT, bronchiectasis is present 
(though not predominant) in a much larger proportion, and tends to co-localise with 
emphysema[22], which might support the hypothesis of bronchiectasis developing in 
diseased, infection prone areas. In usual COPD, bronchiectasis has been reported in 30 to 
50% of subjects, and may be associated with longer periods of critical illness[363]. Widely 
accepted diagnostic algorithms for reporting of bronchiectasis on CT are needed before 
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reliable comparisons of incidence between AATD and COPD can be undertaken. Few 
longitudinal studies of airways disease on CT scan have been performed, but these will be 
central in determining if subtle airway wall changes predict an infection prone phenotype 
or precede bronchiectasis. In asthma a recent longitudinal study has reported gradual 
accumulation of airway wall thickening, and bronchiectasis[364], and in COPD changes in 
airway wall thickness have been shown to relate to FEV decline[365]. Neither study 
reported data specifically relating airway wall thickness to bronchiectasis. Indeed, in 
cystic fibrosis the two pathologies are distinct, and progress separately [366]. Further 
research is needed to clarify these issues in COPD. 
     Lung function decline was studied in a subset (n=110) of the unrelated case-control 
group who participated in the genetic studies reported here, and a larger group (many of 
whom had no stored blood for DNA extraction) who participated in the pollution study. 
In the latter work there were 220 subjects who had at least 4 data points over which to 
calculate decline, and a further 181 with 2 or 3 data points. In general, those participating 
in the genetic studies were recruited earlier in the evolution of ADAPT, though not 
exclusively so. Decline of FEV1 was 42.00ml/yr on average in the genetic study group, 
34.84ml/yr in the 4 data point pollution group, and 32.66ml/yr in the whole pollution 
group. The difference between the latter two was non-significant. It may be that decline 
was faster in the genetic group because they had smoked more heavily than the majority 
of registered subjects (Tables 3.1 and 5.2), or their earlier recruitment date and the more 
limited range of treatments available previously. This level of change over time is, 
however, better than that reported in previous studies of AATD[367] and of usual 
COPD[368], being much closer to that of a healthy individual. This may reflect good 
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management of subjects’ lung disease which has effectively stabilised decline or inclusion 
of more healthy, non-index subjects in the analyses. Alternatively it may be that the 
measures reported here are more accurate than others reported previously, because of the 
number of data points available, and the strict quality control measures employed in the 
lung function laboratory in Birmingham. Gender was a significant predictor of FEV1 
decline in both the genetic and pollution groups (Tables 3.6 and 7.5), even after 
adjustment for smoking. This suggests gender specific differences in the pathophysiology 
of COPD, possibly a consequence of gender differences in immune response [369]. 
Oestrogen is also recognised as a protective factor in acute lung injury, sepsis and 
myocardial infarction, where effects are thought to be mediated by differences in 
vasomotor tone, resulting in relative protection from hypoxic damage in females[370]. 
Oestrogen metabolites may also interact with components of the oxidant-antioxidant 
system in some tissues [371]. All of these mechanisms are potentially relevant to COPD, 
but further research is needed to clarify why gender differences occur. 
     Decline of KCO was very similar in the genetic group and the 2 pollution groups (0.03, 
0.03 and 0.02 [mmol/min/kPa/l]/yr respectively, Tables 5.1 and 7.7). This has recently 
been reported to be a more sensitive measure than FEV1 to measure decline in 
AATD[159]. Since some of the subjects in this study were from the UK, and indeed 
participated in the studies herein prior to the augmentation therapy described by the 
authors, it would be inappropriate to make comparisons between the groups as they are 
not truly independent. No studies of this feature in usual COPD have been published. 
Hence the data here are novel and may help to inform future work in the area. 
     Bacterial colonisation of the airway was the final clinical phenotype assessed in the 
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studies reported here. It occurred in the stable state in 70% of subjects who produced 
sputum, with mixed normal flora alone in 20% and potential pathogens in 50% (Table 
4.10). Colonised subjects did not differ from those who were not (Table 4.11), though all 
exhibited significant lung function impairment and emphysema on CT. The incidence of 
potential pathogens in the stable state has been studied widely in usual COPD, with 
varying results. Incidence ranges from 33%[372] to 70.9%[373] in recent studies. The 
bacterial species’ observed also show significant variation, though Haemophilus influenza 
is often the most commonly seen [276, 373, 374], as in the AATD group reported here. 
Pseudomonas spp were uncommon in this AATD group, but have been highly prevalent in 
some COPD cohorts [373, 375], where selection may have influenced the results. The 
AATD group studied here are, however, similar to usual COPD in their incidence and type 
of bacterial colonisation. 
 
8.1.2 Genetic associations 
     When the studies contained in this thesis were designed, published genetic association 
studies in COPD were generally relatively small, variable in their level of phenotyping and 
poorly replicated. Some exceptions to this rule were seen, notably studies of the Boston 
Early Onset COPD cohort and the NETT cohort [72, 87, 88, 108, 376, 377]. Although the 
groups studied for genetic association in this thesis were also relatively small, particularly 
the familial group, the detailed level of phenotyping was, at the time, unique. The aim of 
the studies in general was to dissect specific sub-phenotype associations, in order to lend 
support to the hypothesis that COPD is a heterogenous group of conditions, and 
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determine which aspects of pathophysiology were most important in each sub-phenotype. 
Case-control with familial replication was chosen as the study design, since no other 
AATD cohort with this level of phenotyping, and stored DNA, was available for study. It 
was, therefore, necessary to accept, at the outset, that there were weaknesses including 
probable under powering of both the test (Tables 3.5, 4.3, 4.5 and 4.8) and replication 
groups to detect associations confirming the level of OR seen in complex disease, and lack 
of a replication group for some phenotypes. In an attempt to minimise the effect of these 
issues on the studies, relatively well replicated loci (TNFA, SFTPB, GC, TGFB, MMP1), 
and those with prior evidence in AATD (MMP1, 3 and 12) were chosen for the candidate 
gene work. This was combined with a focus on those phenotypes most likely to relate to 
each protein product, from current knowledge of pathophysiology. Issues of power and 
replication have also been discussed in sections 3.5 and 4.5. 
     Since the start of my work progress in COPD genetics has been rapid, and genome-wide 
association studies (GWAS) are now being performed. These have the potential to discover 
associations in areas not previously considered important in COPD, implying 
pathophysiological roles for their protein products, and thus extending our understanding 
of the condition more than candidate gene work. Disadvantages of GWAS include the 
large numbers needed for adequate power (probably at least 3000 cases and controls[217]), 
the difficulty of interpreting associations in intergenic areas and high costs. Problems with 
reproducibility of results may also occur if different genotyping platforms are used, such 
that different SNPs in a given area are typed, whose LD is either unknown, or incomplete. 
The expansion in GWAS in all diseases has occurred in part because of technological 
advances in genotyping, with consequent improvements in both feasibility and cost. Older 
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genotyping methods, such as traditional gel based techniques (like the HLA typing 
performed for the studies in chapter 6), are time consuming and require a lot of DNA. 
Fluorescence based techniques, such as TaqMan®, are more reliable at low DNA 
concentrations and lend themselves better to high throughput. Advances in statistical 
programming for analysis of large datasets have also aided progress towards GWAS. 
Nevertheless, determining statistical significance remains a hotly debated subject and it is 
still unclear if correction for multiple statistical testing, particularly in areas of high LD, is 
appropriate (an issue discussed in section 6.5) even when methods exist to do so[378]. In 
parallel with these changes in genetics it has become widely accepted in respiratory 
medicine that COPD constitutes many sub-phenotypes [359], that quantitative CT is 
important in defining them [361] and that genetic associations may not be meaningful 
without full clinical data pertaining to delineate parenchymal and airways disease. Large 
well characterised groups of subjects with usual COPD are now being collected, which will 
have adequate power for GWAS, such as ECLIPSE (Evaluation of COPD longitudinally 
to identify surrogate end points) [379] and COPDGene®[380].  
     One GWAS based on the Bergen cohort, with replication in the Boston Early Onset 
COPD, International COPD Genetics Network (ICGN) family cohort[90] and NETT 
cohorts has now been published, in which 3 loci have achieved genome-wide significance 
[73]. From this it is possible to be reasonably confident of association with COPD for 2 
SNPs (rs8034191 and rs1051730, both p<1x10-9) within the α-nicotinic acetylcholine 
receptor (CHRNA3/5) and 2 SNPs within hedgehog interacting protein (HHIP, rs1851851 
and rs13118928, both p<2x10-7). The risk alleles within CHRNA3/5 conferred a mean OR 
of 1.32 for disease, whilst the 2 SNPs within HHIP exhibited a protective effect with a 
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mean OR of 0.72[73]. The findings for the HHIP loci are supported by a GWAS 
examining lung function in the general population [381]. The functional significance of 
these associations is not yet clear – the associations with CHRNA3/5 may represent 
nicotine addiction effects (though the authors attempted to control for this in their 
analyses) or a role for non-neuronal nicotonic signaling in the lung[382]. This relates to 
immune function via lymphocytes[383], which are known to be present in the lungs of 
subjects with COPD[11]. HHIP encodes a signalling molecule (HIP1), which is present in 
most mammalian tissues[384] and interacts with other hedgehog proteins to control 
morphogenesis[385]. Its precise role in the lung is not yet known. This GWAS has, 
therefore, revealed at least one putative new pathophysiological process in COPD, and 
will require follow up with functional work. A second GWAS has been reported solely in 
abstract form, and found association in the ECLIPSE cohort and in the Bergen COPD 
cohort for several SNPs with a quantitive measurement of emphysema on CT scan [79]. 
The most associated SNP was rs615098 in MMP3, the combined p value from meta-
analysis of the 2 groups (a controversial method) being 1.92x10-7. The 2 genes flanking 
MMP3 (MMP1 and MMP12) have been the subject of candidate gene studies in COPD, 
so this is a less novel result. 
     A candidate gene study, using the same test cohort as the above GWAS, with 
replication in the Bergen COPD cohort, achieved statistical significance with the overly 
conservative Bonferroni correction[90]. Meta-analyses have also been published on many 
candidate genes [228, 386, 387]; both these strategies are accepted as proof of association. 
Loci from these non-GWAS with good evidence of association lie within SERPINE2[90], 
TNFA[228], TGFB[386], GSTPs[386], IL1B[386], and EPHX1[387]. The potential role 
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within COPD pathophysiology for most of these candidates and the function of associated 
SNPs has been considered in Chapter 1 (section 1.1.4). 
     It is in the context of this expanding evidence, and changing levels of confidence in 
their results, that the genetic associations reported here must be seen. One SNP in TNFA 
(rs361525) conferred an OR of 1.99 for chronic bronchitis (section 3.2.3), and an elevated 
level of its protein product (TNFα) was seen in airway secretions of those with the 
associated allele (Figure 3.11). Although it was not possible to assess for replication, this 
functional effect, consistent with known pathophysiology, together with supportive 
evidence in a recent meta-analysis (albeit in Asians)[386], suggests it is a true effect. It is 
not yet clear why a compartment specific genotypic effect is seen - the level of TNFα was 
not elevated in the plasma of subjects with the associated allele (Figure 3.10). Local 
differences in gene expression are a possible explanation, but further research will be 
needed. Minor allele homozygotes for rs2118177, in SFTPB, had an OR of 0.28 of COPD 
in the case-control dataset and the same genotype associated with higher FEV1 in the 
familial replication dataset (section 4.4.1). Since the direction of effect was replicated it is 
likely to be a true association, but the gene is not close to any of the GWAS peaks seen so 
far[73] and has not been studied in a meta-analysis, hence has little other evidence 
supporting this at present. It is possible the existing GWAS was underpowered to detect 
the effect, or that it is specific to AATD.  Three SNPs in TGFB showed a suggestion of 
association with lung function, but this did not replicate in the familial group. However, 
this locus now has meta-analysis data to support a role for it in COPD, so perhaps 
warrants further analysis in a better powered replication cohort in AATD, to ascertain if 
the effects are truly absent in this population.  The association seen between 
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bronchiectasis, airway bacterial colonisation and SNPs within GC in the case-control 
dataset could not be tested in the family cohort, and has to be viewed with caution, 
despite a biologically plausible role for its protein product in airway host defence. It 
should however prompt research into the role of the protein in the lung, which will be 
discussed in section 8.2.2. The association of the MMP cluster detailed in chapter 5 
represented follow up of a prior linkage study in AATD, and although this is not true 
replication it is suggestive of an effect. It is also of interest that an area on chromosome 
11, not vastly distant from this (approximately 3Mbp) appeared protective in one of the 
study populations in the recent GWAS [73], and that a SNP within MMP3 was associated 
in a smaller GWAS looking at emphysema on CT[79] Further work on this region is 
indicated, given the relatively strong candidate gene work in the area (section 1.1.4), and 
the surprising lack of study in recent meta-analyses. 
     The association of an HLA type commonly seen in autoimmunity with lung function 
(Table 6.4), which remained significant after a Bonferroni correction for the locus is a 
novel finding. Genotype specific differences in anti-elastin antibody level (Figures 6.7 and 
6.8) suggest a possible local gene-environment interaction, such that genetically 
predisposed individuals perpetuate the lung damage initiated by smoke because of 
autoimmune activity directed against lung elastin. In this case the environmental factor is 
the circulating elastin peptide, which interacts only with the associated HLA protein. In 
individuals with the risk genotype (HLA-DQA*0301 or HLA-DRB1*04) a high level of 
antibody results, and there is then subsequent perpetuation of elastin breakdown (Figure 
6.9). Although some confidence in the association is gained from the Bonferroni 
correction, and putative functional effect, it is by no means certain. Methods for 
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confirming the association are considered in section 8.2.3. Further support for genetic 
susceptibility to autoimmune processes in COPD is taken from the report of CTLA4 
associations [388] in the ICGN and Bergen cohorts. These polymorphisms are associated 
with a number of traditional autoimmune diseases, including diabetes and Grave’s disease 
[389]. 
 
 
 8.1.3 Environmental factors 
      The most important environmental factor to influence type or severity of lung disease 
in AATD is cigarette smoking. This is well known[17] and is confirmed by the regressions 
analyses pertaining to both lung function and CT diagnosed emphysema presented in 
chapter 3 (Table 3.6). A role for other inhaled agents with the potential to cause lung 
inflammation was assessed in chapter 7. The results showed a consistent deleterious effect 
of ozone on lung function, whether a long term, cross-sectional model, or a medium term, 
longitudinal model was used (Tables 7.5 and 7.9). The cross-sectional model had several 
weaknesses, discussed in section 7.5. It is possible that the lack of effect of other outdoor 
air pollutants is due in part to this, since further possible harmful effects of PM10, NO2 and 
SO2 were seen in the longitudinal model. This is the first cohort of AATD subjects to 
undergo study with regard to their risks from outdoor air pollution, and it is not yet clear 
whether the associations will be specific to AATD, or seen in usual COPD as well. 
Intuitively, since the pathophysiology of the respiratory problem is much the same in the 
2 conditions, it is likely an effect will be seen. However, given that AAT provides the 
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majority of the lung’s protection from inflammation [350], it may be that effects in usual 
COPD will be even more subtle and very large cohorts will be needed to have adequate 
power to detect them. Relatively speaking, cigarette smoke accounted for 6 times the 
amount of variability in KCO of ozone in the study reported here (section 7.4.1), so it 
remains more important to advise against smoking that advising on an ideal residence site 
for subjects with AATD.  
     Occupational agents may cause a range of lung diseases and were assessed in the studies 
reported here only by questionnaire based information about their job, or past work. This 
graded the possible risk of their work to the lung, but is not without its problems, as 
discussed in section 7.5. No significant associations between respiratory phenotype and 
occupation were seen in either long term (Table 7.2) or medium term models of this risk 
(section 7.4.2). It is, however, likely that the study was underpowered, as even common 
risk professions were observed in less than 10 individuals (Tables 7.3 and 7.8). Prospective 
studies of occupational risk in subjects with AATD are unlikely to be funded or carried 
out, since accurate exposure measurement would be prohibitively expensive, adequate 
numbers difficult to recruit and the potential benefits of such results to the population 
small. It will probably be of greater value to pursue such investigations in subjects with 
COPD, or in the general population. 
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8.2 Future directions 
8.2.1 Replication dataset 
     As with all genetic studies a statistically significant result requires further independent 
validation. Therefore, the studies within this thesis will require replication not only in 
AATD, but also in COPD unrelated to AATD, particularly for those which were neither 
significant at genome wide level, nor replicated in the family dataset. A protocol has been 
designed to recruit such a dataset in usual COPD and ethical approval obtained (South 
Birmingham LREC, reference 07/H1207/231). The patient information leaflet and consent 
form are included in Appendix 1. Direct, reliable comparisons between usual COPD and 
the UK AATD cohorts will be facilitated by use of the same data collection techniques, 
and an identical database to that used throughout this project. Data collection for this 
cohort is now underway.  
     Replication in AATD is also necessary. The ADAPT programme continues to recruit 
subjects so this will be possible in the next 5 years. In addition, collaboration with the 
American group headed by Professor EK Silverman, who is also studying genetic 
modifiers in AATD, at Harvard University (Boston, USA) has also been arranged. This 
has an added benefit with regard to the HLA region, which has already been typed in 
their patient group, albeit by a different method. It will now be critical to cross validate 
the two methods in order to compare the results between the two patient groups. It should 
also be noted that differences between the 2 groups due to geographical variation could be 
present, and this will need to be taken into account in any replication work in the USA. 
     Ultimately a genome-wide association study could be performed in the above cohorts, 
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as the genotyping technology and statistical methods to interpret the results are now 
available. Commercially available chips capable of genotyping hundreds of thousands of 
SNPs for each individual have been available for some time, but are now falling in price, 
making such a study more viable. Many companies now provide software for integrated 
results formatting and analysis. It would be critical to have at least 2000 well 
characterised subjects for adequate power[217], for comparison to control subjects. An 
application could be made to the 1958 birth cohort[390] for DNA geographically and 
ethnically matched to the subject group, or it may be possible to request access to 
genotypes of controls already typed in other studies. The concept of using shared control 
subjects has been demonstrated in a large Wellcome Trust sponsored study in the 
UK[217]. A replication dataset in usual COPD would be the most sensible choice for 
replication. Genome wide studies have been performed in COPD [73, 79, 391], so it may be 
possible to approach those managing these collections for their genotype data, or to 
perform new genotyping where necessary. Since Professor Silverman has been closely 
involved with these collections, and is currently collecting even larger COPD cohorts in 
several populations worldwide a comprehensive replication study should be possible via 
this existing collaboration. 
 
8.2.2 The role of protein products of associated genes in COPD 
     Since the majority of the studies contained in this thesis concerned candidate genes and 
their protein products, their role in disease pathogenesis has been studied in some detail, 
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most notably for TNFα. However, neither SFTPB nor GC has been studied widely in any 
COPD phenotype.  
 
SFTPB 
     Levels of SFTPB are low in animal models of emphysema[252], so it would be useful to 
establish if this is the case in human subjects. Since the protein is likely to be of 
importance in the alveoli, rather than larger airways, the most appropriate samples in 
which to measure it would be broncho-alveolar lavage (BAL) fluid. Alternatively it might 
be possible to study the protein in tissue cultures and histological specimens obtained 
during lobectomies performed on emphysematous subjects for suspected malignant 
processes, or resections performed for lung volume reduction surgery. Tissue samples could 
also be used to extract RNA to analyse gene expression and measure product formation 
and compare to samples from subjects without emphysema. Ethical approval for 
collection of such tissue samples from subjects with and without emphysema, which could 
contribute to the above work, has recently been obtained (Midlands Lung Tissue 
Consortium, North West REC reference 07/MRE08/42; consent form located in Appendix 
1) and local systems to facilitate sample collection are currently being put in place. It is 
also of note that another surfactant protein (SFTPD) has shown promise as a biomarker 
in COPD when measured in the circulation[392, 393]. Similar studies could be performed 
for SFTPB in stored samples from the AATD subject group, which could also be 
compared to associated SNP genotype to give an indication of the functional role of the 
variant. 
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GC 
     GC has a role in macrophage activation and neutrophil chemotaxis[267, 268], and 
whilst genetic variation has been shown to influence the former, effects on neutrophil 
chemotaxis have not been proven. New techniques in the measurement of neutrophil 
migration in COPD[394] mean that studies of chemotactic patterns can now be more 
sensitive. Fresh blood samples from patients of known GC genotype could be compared for 
the direction and speed of neutrophil migration towards a known chemoattractant, such 
as IL8. It will also be important to study this protein further in the airway, given the 
genetic association with bronchiectasis. The sol phase of sputum would be appropriate for 
this, and such samples are available for some of the AATD subjects already genotyped. 
Alternatively bronchial biopsies, lung tissue samples taken at resection or tissue cultures 
could be used for studies of gene and protein expression. Such a study should select groups 
with and without AATD, with and without bronchiectasis and other COPD sub-
phenotypes in order to ascertain precisely the sub-phenotype in which the protein plays a 
role.  
 
Vitamin D 
     Circulating levels of vitamin D relate to disease severity in asthma[395] and the 
vitamin D endocrine system is known to be important in animal models of the 
disease[396]. Genetic association with vitamin D binding protein suggests that a similar 
axis may be important in COPD. It would be necessary to compare vitamin D levels 
between sub-phenotypes in the AATD group, using plasma or serum samples (of which 
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many are available) and to relate the data to associated genotypes. This analysis, in 
combination with study of its binding protein’s role might indicate which aspect of the 
vitamin D axis would be important to target in drug design in the future for therapies of 
COPD. Comparisons of exacerbation frequency or disease progression between subjects 
receiving either vitamin D or placebo would also be considered if studies of vitamin and 
GC levels suggest a biological role for vitamin deficiency in protection from infection. 
 
8.2.3 Mechanism of disease in anti-elastin autoimmunity 
     The association of HLA and anti-elastin antibody levels with features of COPD 
suggests that anti-elastin autoimmunity may be of importance. However, this remains 
theoretical until the study has been replicated, and further functional work has been 
performed. At the most basic level the functional relevance of HLA type would need to be 
studied by assessing the binding properties of anti-elastin antibodies with the associated 
HLA proteins. Since the level of resolution of the technique used in the studies reported 
here is relatively low, it would be insufficient for studies of protein structure. A higher 
resolution typing method, such as the Dynal kit, would need to be used in a larger dataset 
to ascertain the associated genotypes and therefore associated protein products. Once this 
step is completed the relation of anti-elastin antibodies to these proteins could be studied 
further.  
     An alternative approach to obtain evidence of this putative mechanism would be to 
correlate anti-elastin antibody levels to elastin breakdown products. A desmosine cross-
link is unique to elastin and may be used as a marker of its degradation[397]. Desmosine 
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and elastin peptides are elevated in the plasma, urine and sputum of COPD patients[398], 
whilst urinary levels positively correlate with the annual rate of decline in FEV1 in 
smokers[399]. These studies show the importance of tissue destruction in COPD, but not 
the reason by which it occurs. If antibody driven elastin breakdown is the key disease 
mechanism then antibody and desmosine levels would be directly related. The HLA 
association of antibody levels would suggest that this mechanism will only be of 
importance in those with associated HLA types, so an HLA typed group should be 
studied. Desmosine may be measured in a number of ways[397-401], the most sensitive is 
likely to be mass spectrometry[398]. 
     Finally, antibody-elastin complexes could be sought in lung tissue, such as that 
obtained by the Midlands Lung Tissue Consortium. This may be possible by 
immunohistochemistry using formalin fixed tissue slices, or by immunofluorescence using 
frozen sections. Both techniques will be explored when the tissue becomes available. 
 
8.2.4 Gene-environment interactions 
     If the AAT level is important in susceptibility to the effects of ozone in the lung, as 
suggested in toxicological models [47], then this could indicate a gene-environment 
interaction. This could be confirmed by studying pollution associations in subjects with 
different AAT levels, for instance studying PiSZ and PiMZ subjects together with PiMM 
controls. This should be performed using the same methodology as the studies contained 
in Chapter 7 in order to facilitate comparison of the results with those reported here.  
     It would also be possible to study other COPD associated genes with regard to gene-
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environment interaction. The results here suggest that ozone and particulate matter are 
the most relevant air pollutants to consider in this respect. However, very large datasets 
will be needed to have adequate power, particularly if large numbers of SNPs are to be 
studied in the same subject group. Thus far genome-wide studies of gene-environment 
interaction have been limited by the exploratory nature of the statistical analyses needed.  
     The definition of interaction also needs clarification. Currently the main type of 
interaction considered is at the statistical level, such that interaction is deemed present if 
the effect of a genetic and environmental influence together deviated from the additive 
model. However, this does not consider interaction at the biological level (as suggested by 
the ozone results in AATD) a combination of statistical and biological interaction, or gene-
gene interaction. Newer statistical methods employing neural network technology[402] 
may be able to overcome these uncertainties, assuming a sufficiently large cohort could be 
recruited to have adequate power. Such techniques might also be employed in 
pharmacogenetic studies[403], which are perhaps the ultimate gene-environment 
interaction in modern medicine, potentially allowing targeted treatment for every 
individual. 
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8.3 Conclusion 
COPD is a complex group of diseases with many components contributing to the 
pathophysiology and consequent clinical manifestations. There are multiple genetic and 
environmental influences acting upon clinical phenotype, which are likely to be additive, 
or synergistic. In AATD genes shown to influence usual COPD show such additive effects, 
but they segregate to clearly defined clinical phenotypes. This gives some indication of 
disease mechanisms, and in the future may help to guide individual therapy. 
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Appendix 1: Consent forms and ethics 
 
CONSENT FORM FOR PARTICIPATION IN RESEARCH 3359 
Assessment for Alpha1 Antitrypsin Deficiency 
 
What is the study about? 
You or a member of your family has been identified as having alpha1 antitrypsin 
deficiency.  This is an inherited condition that is believed to increase the risk of 
development of lung health problems.  However very little detailed information has been 
collected on the way this deficiency affects patients and some studies have suggested that 
lung disease may run in families even without the deficiency.  It is likely however that the 
deficiency highlights the tendency to develop these diseases and when present will make 
them worse. 
 
We wish to learn as much as possible about the deficiency and its relationship to lung 
disease and for this reason invite you to participate in our alpha1 antitrypsin deficiency 
assessment programme. 
 
What will I have to do? 
In broad terms you will undergo all the routine questioning, examination and tests that 
we normally undertake when assessing somebody who presents with lung disease.  
However we hope to do this more carefully and in more detail than is routinely carried out 
by your own doctor or specialist. 
 
We will ask many questions about your past and present symptoms, health and wellbeing.  
In addition you will be examined thoroughly to determine the presence of signs related to 
lung disease.  After this screening programme you will be asked to perform some lung 
function testing which assesses how your lungs work and their ability to take oxygen in 
and out of your body.  We may also perform a specialised CT scan of your lungs (if you 
have not had one) which is a very sensitive technique of detecting damage that has 
occurred.  Finally we will ask you to provide one blood sample and if you have a cough 
productive of sputum we will arrange for you to collect this over several hours on one day 
before coming to see us. 
 
Once all these tests have been performed we will be able to determine whether you have 
lung disease related to alpha1 antitrypsin deficiency.  This will be explained to you and 
any modifications in your treatment that are indicated will be communicated to both 
yourself and your own doctor. 
 
It is our general clinical routine to follow patients with established lung disease on a long-
term basis.  Patients are usually seen once every 4-6 months to assess their wellbeing and 
follow any progress in the condition.  If you have alpha1 antitrypsin deficiency we would 
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wish to see you once a year to assess your symptoms, clinical signs and repeat the 
extensive lung function tests and the CT scan to confirm the extent or any progression of 
your disease will be carried out every 2 years.  After the first year the lung function may 
be repeated less frequently (2 or 3 yearly) depending on whether these are changing or are 
stable. 
 
NOTE The CT scan exposes you to a small degree of radiation – about the equivalent of 6 
months background radiation in the UK.  Although this dose is safe (it is the same as a 
single x-ray of the abdomen), it is important that you inform us if you are likely to be 
pregnant as we will not carry out the test in these circumstances.   
 
What are the benefits? 
The major purpose of the study is to find out as much as possible about the lung disease 
associated with alpha1 antitrypsin deficiency.  This will provide the background 
information that enables us to design studies to assess the role of alpha1 antitrypsin 
replacement therapy in both the short and long term.  The investigations that we 
undertake will allow us to advise upon the degree of lung disease that you have and simple 
measures that you can undertake with your current treatment in order to try and stabilize 
the lung disease.  In addition the breathing tests that we will perform will help us to 
optimize your current treatment in order to improve your breathlessness where possible. 
 
What are the risks? 
All the investigations that are taking place are entirely routine, used in the assessment of 
patients with lung disease.  As such they are repeated on many occasions in the same 
patient without any adverse effects.  The only minor problem that is likely to occur is a 
slight degree of bruising in some patients when they have their blood taken. 
 
What are the alternatives? 
There are currently no alternatives to finding the information that is required other than 
the assessment programme outlined above. 
 
What happens if I do not wish to take part? 
If you do not wish to participate in the assessment programme or the short term follow up 
programme this will be fully understood.  Your own general practitioner, or the consultant 
chest physician who normally looks after you, will be informed of the diagnosis and 
provided with advice on how to assess and manage your follow up along the lines outlined 
above.  If for any reason they or you require further advice from us in the future we will 
be only too pleased to see you.  It is important to emphasize that your overall 
management by your doctor will not be affected by your decision. 
 
What happens to the information? 
The important information that we collect over the next year or two will be written up as 
a report and submitted to medical journals so that other doctors may read about the 
problem.  The research information obtained from the samples that we have collected will 
be the basis for future studies on the role of alpha1 antitrypsin replacement therapy which 
we hope to start within the next 12-18 months.  Neither your name or any details relating 
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to you personally will be released to any other person outside the research programme. 
 
Who is taking part? 
All subjects that we identify with alpha1 antitrypsin deficiency and in some cases members 
of their family will be asked to take part.  At present we know of over 800 such patients as 
yourself and it is likely that there are several thousand similar people in the West 
Midlands alone.  It is hoped over the next year or two to identify and assess all people 
with the deficiency in the Midlands. 
 
What if something goes wrong? 
The question largely relates to clinical trials and at present that is not part of the 
assessment programme.  If you develop new symptoms for any reason during the 
assessment day this will be in the presence of a doctor who will take any steps that are 
necessary to help you.  In between visits to the assessment centre your own doctor will be 
largely responsible for your care but (depending on where you live) we may collaborate 
with your doctor and help by seeing you if you become unwell. 
 
What happens at the end of a study? 
At the end of the study we will have learnt a lot about alpha1 antitrypsin deficiency.  If 
you remain part of the programme for assessment we will be having regular meetings for 
all patients to attend to discuss how the assessment programme is going and how our 
understanding is developing.  If for any reason you are unable to attend we will be keeping 
in touch with you by letter and newsletter to inform you of the progress of the 
programme. 
 
What if I have more questions or do not understand something? 
The doctors, co-ordinator and nurse involved in the alpha1 antitrypsin assessment 
programme will happily answer your questions on any occasion when you visit.  If 
questions arise between visits you will be able to contact the centre and either speak to 
somebody at that time or arrange to do so if for any reason if it is inconvenient. 
 
What happens now if I decide to take part? 
If you decide to take part in the programme now we will arrange an appointment in the 
not too distant future for you to come to the assessment centre for the investigations 
outlined above.  This will be arranged to suit everybody’s convenience and all the 
assessment will be completed where possible on a single visit. 
 
What happens if I change my mind during the study? 
If you change your mind during the study, it is important that you notify the assessment 
centre.  This will enable any investigations that have been organized or visits to be 
cancelled.  Your decision will be passed on to both your own doctor and where appropriate 
your own specialist in order that they can arrange for appropriate appointments to 
monitor your progress.  Providing you are agreeable we would like to contact your own 
doctor or specialist from time to time in order to find out how you are progressing.  
However if in the future you once again decide to join the programme, we would be only 
too pleased to see you. 
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Bayer Lung Resource Centre, (Antitrypsin Deficiency Assessment and Programme for 
Treatment), 1st Floor, Nuffield House, Queen Elizabeth Hospital, Birmingham. B15 2TH 
 
Mrs. Rebecca Bray, Co-ordinator, Registry Office  Tel: 0121 697 8257 
 
 
  Please 
Initial 
    
  Yes No 
I …………………………………………………………………………………… 
voluntarily agree to participate in the alpha1 antitrypsin deficiency assessment 
programme. 
   
  Yes No 
I have been given a full explanation of the programme and read the patient 
information sheet and have had all my questions answered and agreed to 
cooperate where possible with this programme. 
   
  Yes No 
I understand that that if I suffer from any unexpected problems that it may be 
important to contact both my own doctor and the staff at the alpha-1-
antitrypsin resource centre. 
   
  Yes No 
I understand fully that I am free to withdraw from the programme at any time 
without giving a reason and that this will not adversely affect my future 
management. 
   
    
 
Signed (Patient)……………..…………………………………………..…  
Date ……………………………………………………………………….. 
 
 
 
 
Signed (Witness)…………………………………………………………. 
Date………………………………………………………………………... 
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CONSENT FORM FOR PARTICIPATION IN RESEARCH 3359a 
Alpha-1-Antitrypsin Deficiency Genetic Variation Study 
 
What is the study about? 
You or a member of your family has been identified as having alpha1 antitrypsin 
deficiency.  This is an inherited condition that is believed to increase the risk of 
development of lung and liver health problems.  However very little detailed information 
has been collected on the way this deficiency affects patients and some studies have 
suggested that lung and liver disease may run in families even without the deficiency.  It 
is likely however that the deficiency highlights the tendency to develop these diseases and 
when present will make them worse. 
 
However, our studies have shown that even in families with alpha-1-antitrypsin deficiency 
the tendency to develop these diseases also varies.  This suggests that there may be some 
other genetic influences of importance even in alpha-1-antitrypsin deficiency. 
 
We wish to learn as much as possible about the deficiency and its relationship to lung and 
liver disease and for this reason invite you to participate in our alpha1 antitrypsin 
deficiency assessment programme.  In particular, we wish to study your blood for any 
other genetic influence that may determine whether lung or liver disease develops.  This 
may be of importance both to alpha-1-antitrypsin deficiency and to emphysema or liver 
disease in patients who don’t have deficiency. Our recent study funded by the European 
Union has identified two areas of genes that relate to the likelihood that lung or liver 
disease will develop. In order to determine the reasons we now need to repeat the study, 
focusing on these genes to understand their role, and hence how to prevent or treat the 
lung and liver disease. 
 
What will I have to do? 
As part of the genetic study we store part of a sample of your blood, or of a mouthwash, 
from which we can extract your DNA. It does not matter which sample we use – if you are 
attending the centre as a patient or with your relative we can take a blood sample, or if it 
is more convenient we can send you a mouthwash kit through the post.  No information 
about the genetic research study will be released to you (unless you specifically request 
this) or your family or family doctor.  The sample collected will be coded once it is 
processed and separated from any information that identifies it as yours.  It will have a 
code but no one will be able to tell directly that it has come from you.  There will be no 
reference in your medical file that you have taken part in this gene variation part of the 
study.  However as medical science progresses new ideas and new genes related to lung or 
liver disease are likely to become known.  For this reason we will store the sample for such 
future studies.  It is important to emphasise that the whole study will be confidential and 
specific procedures have been put in place to separate all confidential information that 
could help identify you from the results of genetic DNA analysis.   
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What are the benefits? 
The major purpose of the study is to find out as much as possible about the lung or liver 
disease associated with alpha1 antitrypsin deficiency including the association with any 
other unrecognised genetic factors.   
 
What are the risks? 
The only minor problem that is likely to occur is a slight degree of local bruising in some 
patients if they have their blood taken. 
 
What are the alternatives? 
There are currently no alternatives to finding the information that is required other than 
the genetic programme outlined above. 
 
What happens if I do not wish to take part? 
If you do not wish to participate in the genetic study this will be fully understood.  It will 
not affect your care, or that of any relative of yours who may be participating in the 
alpha1 antitrypsin deficiency programme. 
 
What happens to the information? 
The important information that we collect over the next few years will be written up as a 
report and submitted to medical journals so that other doctors may read about the 
problem.  The research information obtained from the samples that we have collected will 
help us understand the development of emphysema and liver disease.  The data may 
provide clues to help develop new forms of treatment.  Neither your name nor any details 
relating to you personally will be released to any other person outside the research 
programme (including insurance companies). 
 
Who is taking part? 
All subjects that we identify with alpha1 antitrypsin deficiency will be asked to take part.  
At present we know of over 1700 patients with the deficiency and it is likely that there are 
several thousand similar people in the West Midlands alone. It is hoped over the next year 
or two to identify and assess as many people with the deficiency as possible and obtain 
DNA samples from most of them for these studies. Wherever possible we hope to assess 
patients’ family members too, so that we can be more certain of other genetic influences 
on the development of emphysema and liver disease. 
 
What if something goes wrong? 
The question largely relates to clinical trials and at present that is not part of the DNA 
study. 
 
What happens at the end of a study? 
At the end of the study we will have learnt a lot about alpha1 antitrypsin deficiency.  
There are regular meetings for all patients and their relatives to attend to discuss how the 
assessment programme is going and how our understanding is developing. You may wish 
to attend these, or we can keep in touch with you by letter and newsletter.  
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What if I have more questions or do not understand something? 
The doctors, co-ordinator and nurse involved in the alpha1 antitrypsin genetic programme 
will happily answer your questions on any occasion when you visit, or over the phone.  If 
questions arise you will be able to contact the centre and either speak to somebody at that 
time or arrange to do so. 
 
What happens now if I decide to take part? 
If you decide to take part in the programme now we ask that you contact us using the 
details below. We can then send you a mouthwash kit, containing instructions for use. 
You should follow the instructions and return to us. Alternatively if you are attending the 
centre soon with your relative and you would prefer to give a sample of blood or 
mouthwash whilst you are here, we can arrange this. 
 
What happens if I change my mind during the study? 
If you change your mind during the study, it is important that you notify the assessment 
centre.  The sample of DNA that we have stored will then be destroyed. 
 
Bayer Lung Resource Centre, (Antitrypsin Deficiency Assessment and Programme for 
Treatment), 1st Floor, Nuffield House, Queen Elizabeth Hospital, Birmingham. B15 2TH 
 
Mrs. Rebecca Bray, Co-ordinator,  
Registry Office      Tel: 0121 697 8257 
 
 
I ……………………………………………………….. voluntarily agree to 
participate in the alpha1 antitrypsin genetic study. Yes 
 
I have been given full information including reading the information sheet 
and had all my questions answered. Yes 
 
I understand that I can change my mind at any time and the sample will be 
destroyed. Yes 
 
I am happy for my name to be held on the genetic database but know that 
this will not be disclosed to anyone outside the research study group. Yes 
 
I understand the information will not be filed in my general notes. 
 Yes 
 
 
Signed (Patient) ………………..……………………………………………………… 
Name (Print) …………………………………………………………………………… 
Date …………………………………………………………………………………… 
 
 
Signed (Witness) ………………………………………………………………………. 
Name (Print) …………………………………………………………………………… 
Date …………………………………………………………………………………… 
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PATIENT INFORMATION LEAFLET AND CONSENT FORM 
Study code: RRK3404 
Title: A study of clinical phenotypes, disease progression and 
genetic susceptibility in patients with chronic obstructive 
pulmonary disease and bronchiectasis 
 
You have been asked to participate in a clinical study for research purposes. Before you decide 
to take part it is important that you understand why the study is being performed, what it 
involves, and the possible risks and benefits for you. Take your time reading the following 
information and discuss it with others if you wish. 
 
Introduction to the research & invitation to take part 
This study is being carried out by the research department in the Lung Investigation Unit 
at the Queen Elizabeth Hospital, which is part of University Hospitals Birmingham NHS 
Foundation Trust, and is led by Professor RA Stockley. Several hospitals in the West 
Midlands are working closely with Professor Stockley in order to help with the study. The 
department has a special interest in understanding and treating chronic lung disease, in 
particular chronic obstructive pulmonary disease, or COPD for short, and bronchiectasis. 
You have been chosen because your hospital doctor has identified you as suffering from 
COPD or bronchiectasis and believes that you are suitable to take part in the study. 
 
What is the research about? 
The main purpose of the study is to find patterns of symptoms, breathing tests, blood and 
sputum tests that identify particular groups of patients. We also hope to establish the 
importance of environmental influences, such as chest infections, in the development of 
COPD and bronchiectasisand how they progress over time. Other research suggests there 
may be genetic influences in COPD, which may affect particular groups of patients, or 
affect how their breathing tests change over time. We plan to study this in more detail to 
find out which genes are important.  
 
What will I have to do? 
 
Please read this section carefully as it details the procedures that are specific to 
research and not part of usual clinical care 
 
If you agree to take part you will be seen by a research doctor at the time of your usual 
out-patient clinic appointment. They will explain more about the study and what it would 
mean for you. The study will take place over 5 years, and will involve seeing a research 
doctor after one of your out-patient appointments each year for at least 3 years. There will 
be no extra visits to the hospital other than those for your usual out-patient 
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appointments. If you would rather participate for only one visit, rather than several, 
please inform the research doctor. 
 
If you have brought a sample of sputum with you, you will be asked if some could be used 
for the research. If you have not brought any sputum with you, and usually cough it up 
every day, you will be given a container in which you may bring a sample on your next 
visit.  
 
A blood sample will be collected from you. This can be done at the same time as any other 
blood tests your hospital doctor has asked for. We will collect 4 small tubes of blood for 
the study, which is the equivalent of about 2 tablespoons.  
 
We will process the blood and sputum samples so that they can be stored safely in secure 
freezers at the University of Birmingham. For this study they will be used to examine 
markers relevant to COPD and bronchectasis. They may also be valuable for future 
research in other areas, but will not be used for other studies without prior ethical 
approval.  
 
We will also extract your DNA from your blood, which will be stored in the same way. 
Your DNA will be used to look for genes that may influence the development of COPD. 
Your DNA will not be used for other studies. 
 
As well as collecting these samples we will also collect information about you by talking to 
you and by looking at your medical notes. This will include your date of birth, gender, 
height, weight, date you were diagnosed and whether you smoke now, or have done so in 
the past. We will also ask some questions about symptoms that people with COPD  and/or 
bronchiectasis often experience, and ask you to fill in a questionnaire about the way your 
lung disease affects you. We will also look in your medical notes to see what medicines you 
take, the results of any breathing tests you have had done recently, and scans (if you have 
had one). All of this information will be recorded in written form only. 
 
All of the above procedures should take no more than half an hour on the first occasion, 
and be a little shorter on later visits. This will be in addition to seeing your usual hospital 
doctor. 
 
What are the benefits? 
You will have no personal benefit from the study. Your participation and donation of 
samples may benefit patients with COPD and bronchiecatsis in the future by helping us to 
understand the disease better, and helping us to develop new treatments. 
 
What are the risks? 
We do not expect any harm to come to you as a result of providing samples or talking to 
the researchers. Sometimes blood tests can be uncomfortable, or leave bruising, but this 
will be temporary. 
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What are the alternatives? 
There are many ways of looking at blood and sputum samples, but relating them to 
breathing tests, symptoms and genes has not been done together before. It is therefore a 
new area of research, and there are no similar studies being done in the UK at present. 
 
What if I do not want to take part? 
The study is entirely voluntary and if you do not wish to participate it will not affect your 
future care. 
 
What happens to the information? 
If you decide to take part you will need to allow access to your medical records. They may 
be looked at by the research team, by the hospital research and development department 
and by regulatory authorities who check that the study is being carried out properly. By 
signing this form you are giving permission for this to be done. 
 
The information collected will be stored on a secure computer, but your name will not. 
This is known as linked anonymised data, meaning that only Professor Stockley will be 
able to link any of your information to your name. He will have sole access to a written 
record of your information, stored in a secure facility at University Hospitals 
Birmingham. All the data collected, samples you provide, and their results, including any 
information about your genes, will be coded with a number. The results of tests on your 
samples and about your genes will not be available to anyone outside of the research team 
and our collaborators. The link to your name will be destroyed after 15 years. Once the 
data is collected it will be the property of the research department. 
 
The results of the study may be published in a medical journal, but your identity will not 
be revealed. The results may be used in statistical tests, research and development of new 
treatments, diagnostic tests and medical aids. 
 
Who else is taking part? 
At least 500 other patients with COPD and with bronchiectsis will be asked to take part. 
 
What if something goes wrong? 
Since the study involves only simple tests that could form part of your routine care, we do 
not expect any harm to come to you. Whatever part of the study you choose or decide not 
to take part in will not affect your future care. If you are harmed by taking part in this 
research project there are no special compensation arrangements.  
 
What happens at the end of the study? 
Throughout the study, and when it ends, your hospital doctor and general practitioner 
will continue to treat your chest problems. 
 
What happens if I have more questions? 
If you do not understand something in this leaflet, or have further questions you may ask 
the researcher now, or your hospital doctor. 
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What happens now if I decide to take part? 
If you decide to take part you will be asked to read, sign and date the Written Consent 
Form attached to this sheet. By signing it you acknowledge that you have understood the 
aims of the research, and what you are being asked to do.  
 
 
In summary 
• The research aims to find out patterns of symptoms, breathing tests, blood and 
sputum tests and scans in patients with COPD and bronchiectasis 
• If you take part you will be asked to provide blood and sputum samples, and answer 
questions about yourself and your chest problems at one out-patient appointment per 
year for 3 years, or as many as you can manage 
• All information will be stored in such a way that you cannot be identified by anyone 
without Professor Stockley’s permission 
 
Will my General Practitioner (GP) be informed? 
If you give your permission, your GP will be told about your participation in the study.  
 
What happens if I change my mind during the study? 
You are free to withdraw your participation at any time, and it will not affect your future 
care. If you withdraw your consent after your samples have been analysed it will be the 
responsibility of your hospital doctor to ensure that the samples are destroyed if you so 
wish. 
 
Who can I contact about the study? 
In the first instance any concerns or questions should be addressed to either your GP or 
hospital doctor. If you have further concerns you can contact  
 
Professor Robert Stockley     Telephone: 0121 472 1311 
Thank-you for reading this information leaflet 
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I………………………………………………………………… (Name in BLOCK 
CAPITALS) 
Initials  
Have read the attached information concerning my participation in this study and  
have had the opportunity to discuss it and ask questions. All my questions have  
been answered in a satisfactory way. 
 
I voluntarily consent to take part in this study. 
 
I know that at any time, and without giving a reason, withdraw my participation in  
the study and that my future care and management will not be affected. 
 
I understand that I will have a copy of this Patient Information Leaflet and  
Written Consent to keep. 
 
I hereby give my permission to authorise personnel from the research team to examine  
my medical records. 
 
I hereby give permission for samples taken as part of this study to be stored for future  
use by the research team. 
 
I understand that samples taken as part of this study will not be used in other  
studies without prior ethical approval. 
 
I hereby give permission for my GP and hospital consultant to be informed about  
my participation in this research study. 
 
………………………………………………………………………………………..      
…………………… 
Patient’s signature                                                                                     Date 
 
……………………………………………………………………………………….. 
Name in BLOCK CAPITALS 
 
 
 
Responsible investigator 
I have explained the nature and purpose of this study for the person named above 
 
…………………………………………………………………………………………      
……………………. 
Responsible investigator/representative signature                             Date 
 
………………………………………………………………………………………… 
Name in BLOCK CAPITALS 
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STUDY INFORMATION SHEET AND CONSENT FORM 
Study Title: Molecular and Functional Mechanisms of Human Lung 
Disease 
Midlands Lung Tissue Consortium 
 
You are being invited to take part in a research study.  Before you decide it is important 
for you to understand why the research is being done and what it will involve.  Please take 
time to read the following information carefully and discuss it with others if you wish.  
Ask us if there is anything that is not clear or if you would like more information.  Take 
time to decide whether or not you wish to take part. 
 
Introduction 
Lung disease causes pain, discomfort and can prevent sufferers from carrying out 
everyday activities. Whilst available treatments including steroids and other drugs may 
relieve symptoms, none provide a cure. Operations may help some people. More research is 
needed to find new treatments that can cure lung disease. 
 
What is the purpose of the study? 
In order to find the causes of lung disease such as COPD and lung cancer and to find new 
ways of treating these diseases we have to do more research. It is ideal to do the research 
on tissue from human lungs because we are investigating a human disease.  The lung 
research teams at Glenfield Hospital, Leicester Birmingham Heartlands Hospital, 
Walsgrave Hospital, Coventry and  pharmaceutical companies  (including Astrazeneca) 
have joined together in order to collaborate on studies into lung disease using human lung 
tissue.  A numbers of diseases will be studied and the lung tissue will be used in a number 
of different laboratory studies. Pharmaceutical companies (including AstraZeneca) will 
use the lung tissue in research to further the understanding of lung disease and 
development of new treatments for lung disease.  These experiments will be done on lung 
tissue that has been removed from patients as part of their medical treatment, which 
would otherwise be destroyed.  In some cases we may also wish to take a blood sample to 
compare the findings in the lung tissue and blood. 
 
Why have I been chosen? 
You have been chosen because your doctor has said that you may need to have some of 
your lung removed to treat your disease.   
 
Do I have to take part? 
It is up to you to decide whether or not to take part.  If you do decide to take part you will 
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be given this information sheet to keep and be asked to sign a consent form. If you decide 
to take part you are still free to withdraw at any time and without giving a reason.  A 
decision to withdraw at any time, or a decision not to take part, will not affect the 
standard of care you receive. 
 
What will happen to me if I take part? 
Your surgeon has recommended having an operation that should help you with your 
current condition. Some samples of lung tissue removed as l part of your operation would 
normally be destroyed. If you are willing to take part in our research, your surgeon will 
provide the collaborating hospitals and pharmaceutical partners including AstraZeneca 
with some of the lung tissue that has been removed as a normal part of your operation. 
The surgeon will not remove extra lung tissue for this research. We will also record some 
information about your recent medical history, medicines taken and reason for the 
operation from your medical records. In terms of your operation, stay in hospital and 
subsequent follow up there will be no difference to what will happen to you whether you 
take part in the study or not except that in a few cases we may wish to take an extra 
blood sample of approximately 30mL (about three tablespoons full) before your operation.  
 
What happens if I don't want to take part?  
Nothing, you simply don't sign this form.  This will not affect your medical care or your 
legal rights in any way. 
 
What rights do I have to the results of the research? 
Any information derived directly or indirectly from this research by the collaborating 
hospitals or by pharmaceutical companies such AstraZeneca, as well as any patents, 
diagnostic tests, drugs, or biological products developed directly or indirectly as a result, 
are the sole property of the company (or their successors, licensees, and assigns) and may 
be used for commercial purposes. You have no right to this property or to any share of the 
profits that may be earned directly or indirectly as a result of this research. However, in 
signing this form and donating a blood sample, you do not give up any rights that you 
would otherwise have as a participant in research. 
 
What do I have to do? 
There is nothing extra to do as a result of being part of this study 
 
What are the possible disadvantages and risks of taking part? 
There are no disadvantages or risks to taking part in the study over and above the normal 
risks associated with this surgery, which you require as part of your care.  If you are asked 
to donate an additional blood sample there may be some discomfort of the needle being 
inserted into a vein in your arm and the possibility of bruising developing afterwards 
around the area that the needle was inserted. This should disappear in a few days 
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What are the possible benefits of taking part in the study? 
There are no direct benefits.  Taking part in this study means that you may possibly help 
suffers of lung disease in the future, as information about the changes that occur in the 
lung may be used to develop new treatments. 
 
What if something goes wrong? 
We do not think there is any significant risk of any harm occurring as a result of 
participating in this study. However if you are harmed by taking part in this research 
project, there are no special compensation arrangements.  If you are harmed due to 
someone’s negligence, then you may have grounds for a legal action but you may have to 
pay for it.  Regardless of this, if you wish to complain, or have any concerns about any 
aspect of the way you have been approached or treated during the course of this study, 
the normal National Health Service complaints mechanisms would be available to you.’ 
 
Will my taking part in this study be kept confidential? 
All information resulting from you taking part in the study will be stored and analysed in 
a computer and will be treated confidentially. You will be identified in the computer by a 
number and only your doctor will be able to identify the number as belonging to you. The 
study records will not be made available in any form to anyone other than authorised 
representatives of the health authorities and our pharmaceutical partners such as 
AstraZeneca. In all instances, your confidentiality will be maintained, in accordance with 
the Data Protection Act or as local laws permit. 
 
The pharmaceutical partners such as AstraZeneca and Regulatory authorities may wish to 
check that this research has been done properly, they may have access to your files and 
know your identity, but they are under a duty of confidentiality not to disclose details to 
others. 
 
What will happen to the samples that I have donated?  
The samples will be processed by the research team and used in a range of experiments 
into the causes of lung disease. Samples may be transported to our pharmaceutical 
partners e.g. AstraZeneca or other hospitals in the collaborating group to do further 
experiments including tests to develop new drugs.  Those samples that are not fully used 
up in experiments may be stored by the research team or by pharmaceutical partners 
including  AstraZeneca, for use in future experiments, for up to 20 years.  
 
Who is organising and funding the research? 
The research is a collaboration between the lung research teams at the hospitals in 
Leicester, Coventry, Birmingham and pharmaceutical partners including AstraZeneca. 
The pharmaceutical partners including AstraZeneca will be contributing to costs of the 
research at the collaborating hospitals. The income obtained from the pharmaceutical 
partners will only be used to support the work carried out as part of this project.  
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Can I withdraw my consent? 
You may withdraw your consent to the use of your data and samples at any time. If you 
withdraw your permission consent before your donated tissue and data are used, we will 
not use the data and the samples will be destroyed. If you withdraw your consent after 
your tissue sample has been sent for analysis we will ensure that your sample(s) are 
destroyed. However, if analysis has already been performed neither AstraZeneca nor 
ourselves are obliged to destroy results of this research. 
 
Who has reviewed the study? 
The study has been reviewed by the research teams within the consortium and by the 
members of the Department of Respiratory Medicine, Allergy and Thoracic Surgery.  
Individual research projects where we use the lung tissue have been reviewed by a variety 
of charities and funding organisations 
 
If you have any further questions about this study please do discuss them with: 
 
Dr David Thickett, Honorary Consultant in Intensive Care, Critical Care Research 
Department, 2nd Floor Lincoln House, Birmingham Heartlands Hospital, Bordesley Green 
East, Birmingham – B9 5SS. Tel. 0121 424 0662. Fax: 0121 424 2971 
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CONSENT FORM 
Initials 
 
1. I confirm that I have read and understood the patient information form on 
the above project and have been given a copy to keep. I have had the 
opportunity to ask questions about the project and understand why the 
research is being done and any foreseeable risks involved. 
 
 
2. I agree to give a sample of tissue for research in the above project. I 
understand how the sample will be collected and that giving the sample is 
voluntary. I am free to withdraw my approval for use of the sample at any 
time without giving any reason and without my medical treatment or legal 
rights being affected. 
 
 
3. I give permission for my medical records to be looked at and information 
taken from them to be treated in strict confidence by responsible people 
from (Insert name of relevant hospital) and AstraZeneca.  
 
 
4. I understand that my doctor will be informed if any of the results of 
the tests done as part of the research are important for my health. 
 
 
 
5. I understand that I will not benefit financially if this research leads to a new 
treatment or medical test. 
 
 
 
6. I do know where to contact (David Thickett), if I need further information. 
 
 
 
7. Do you agree to take part in this study? 
 
YES/NO 
 
Signed: ……………………………………….  Date: ………………………………….. 
 
Name (Block capitals) ………………………………………………………………….. 
 
I, (Name of investigator, block letters) ……………………………………………… 
have explained the nature and purpose of the study to ………………………. 
and believe that he/she understands what the study involves. 
 
Signed: ……………………………………..    Date: ………………………………….. 
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Appendix 2: Reference equations 
Pulmonary function tests 
Reference equations that generate predicted lung function values are available from the 
Association for Respiratory Technology and Physiology in the UK (www.artp.org.uk). 
These were generated using regression models from a cohort of subjects aged 18-60, and 
include height, age and gender components. The equations are as follows. 
 
Regression equation  Unit 
Male Female 
FEV1 l 4.30H - 0.029A - 
2.49 
3.95H - 0.025A - 
2.60 
FVC l 5.76H - 0.026A - 
4.34 
4.43H  - 0.026A - 
2.89 
TLC l 7.99H - 7.08 6.60H - 5.79 
RV l 1.31H + 0.22A -1.23 1.81H + 0.016A - 
2.00 
TLCO mmol.min-1.kPa-
1 
11.11H - 0.066A - 
6.03 
8.18H - 0.049A - 
2.74 
KCO mmol.min-1.kPa-
1.l-1 
predTLCO/predTLC 
 
CT densitometry 
This is not an area that has been pubished upon widely. Values at -912HU from healthy 
subjects who have never smoked have been published[214], and are taken as the threshold 
for normality for the purposes of this thesis. These are as follows: 
 
Upper zone voxel index Lower zone voxel index 
5 13 
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Appendix 3: Solutions 
REAGENT A  10ml Triton X 
   110g sucrose 
   1ml Tris HCl pH 7.4 
   1.02ml 4.9M MgCl2 
   Make up to 1l with distilled water 
 
REAGENT B  400ml 1M Tris HCl 
   120ml 0.5M EDTA 
   30ml 5M NaCl 
   40ml 25% SDS 
   Make up to 1l with distilled water 
 
PBS   8.0g NaCl 
   0.2g KCl 
   1.44g Na2HPO4 
   0.24g K2HPO4 
   Add 1l of distilled water, followed by acid or alkali as needed  
   to achieve a pH of 7.2-7.4 
 
TE   10ml Tris HCl 
   0.1ml 0.5M EDTA 
   Make up to 1l with distilled water 
 
10 x TBE  108g Tris buffer 
   55g Boric acid 
   40ml 0.5M EDTA pH8.0 
   Make up to 1l with distilled water 
 
Loading dye  0.25g Bromophenol blue 
   40g sucrose 
   Make up to 100ml with distilled water 
 
TDMH   16.7ml MillQ water 
   6.75ml 25mM MgCl2 
   8.45ml 10 x buffer 
   600µl dNTPs 
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Appendix 4: Statistical methods 
Power 
Both false positive and false negative associations are more likely to occur in small, 
underpowered datasets. In an ideal world for complex disease genetics the dataset should 
have at least 80% power to detect an allele OR of 1.5, but this may not be achievable if 
the allele frequency is low. The power of the studies in this thesis to detect a disease effect, 
as an OR, was predominantly calculated after genotyping to aid interpretation of the 
results, since the dataset used was the largest possible in the UK.  
 
Power was calculated using a programme designed and provided to my supervisor by 
Heather Cordell (University of Cambridge, UK). 
  
Hardy Weinberg equilibrium 
Hardy-Weinberg law states that allele and genotype frequency in a large population does 
not change formone generation to the next provided there is random mating with regard 
to a trait (i.e. mating does not depend upon the trait). Factors that can change this 
include mutation, population migration, genetic drift and selection. In general in genetic 
association work the Hardy-Weinberg equibrium is checked to aid detection of genotyping 
error, and as such it may be of more importance to check the control cohort rather than 
cases, since by definition cases have been selected. However this is controversial, thus any 
cohorts out of Hardy-Weinberg equilibrium in this thesis were excluded from further 
analysis, regardless of their case/control status. 
 
Hardy Weinberg equibrium was checked using the χ2 test, where the expected genotype 
frequencies are as follows: 
 
 Observed Expected 
Minor allele homozygote x           x + (y/2)     
 (x + y + z)(x + y/2) 
Heterozygote y          2(x + y/2)    
 (x + y + z)(x + y/2) 
Major allele homozygote z           z + (y/2)     
(x + y + z)(z + y/2) 
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Appendix 5: Abbreviations 
 
For all abbreviations if the text is in italics it refers to a gene, and if in plain text a protein 
of the same name. 
 
°C Temperature in degrees celcius 
6MWT 6 minute walk test 
AAT Alpha 1 antitrypsin 
AATD Alpha 1 antitrypsin deficiency 
AB Antibody 
ABI Applied Biosystems 
ADAPT Antitrypsin deficiency Assessment and Programme for Treatment 
Ala Alanine 
Arg Arginine 
AOT40 Sum of the differences between the hourly mean ozone concentration and 
40 ppb for each hour when the concentration exceeds this limit during 
daylight hours 
ATS American Thoracic Society  
BAL Bronchoalveolar lavage 
BMI Body mass index 
bp Base pair 
CHRNA Alpha nictonic acid receptor 
COMEAP Committee on Medical Effects of Air Pollutants  
COPD Chronic obstructive pulmonary disease 
DLCO Diffusing capacity for carbon monoxide 
DNA Deoxyribonucleic acid 
dTNP Deoxynucleotide triphosphates 
ECLIPSE Evaluation of COPD longitudinally to predict surrogate end points 
EDTA Ethylene diamine tetracetic cid 
ELISA Enzyme linked immmunoadsorbent assay 
EPHX Micorsomal epoxide hydrolase 
FEF Forced expiratory flow 
FEV1 Forced expiratory volume in 1 second 
FVC Forced vital capacity 
GC Vitamin D binding protein 
GIS Geographical information system  
Glu Glutaminc acid 
Gly Glysine 
GROα Growth related oncogene alpha 
GST Glutathione S transferase 
GWAS Genome wide association study 
His Histidine 
HHIP Hedgehog interacting protein 
HLA Human Leukocyte Antigen 
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HMOX Heme oxygenase 
HRCT High resolution computed tomography 
HU Hounsfield Units 
IBD Identity by descent 
IC Intracellular 
ICGN International COPD genetics network 
IL Interleukin 
Ile Isoleucine 
IQR Interquartile range 
KCO Diffusing capacity for carbon monoxide corrected for alveolar volume 
LD Linkage disequilibrium 
Leu Leucine 
LHS Lung Health Study 
LOD Logarithm of the odds 
Lsy Lysine 
LTB4 Leukotriene B4 
LZDE Lower zone dominant emphysema 
LZVI Lower zone voxel index 
MAF Minor allele frequency 
MMP Matrix metalloprotease 
NCBI National Centre for Biotechnology 
NE Neutrophil elastase 
NETT National Emphysema Treatment Trial 
NFκβ Nuclear factor kappa beta 
NHLBI National Heart Lung and Blood Institute 
NO2 nitrogen dioxide  
NOS3 Nitrogen oxide synthase 3 
NOx oxides of nitrogen  
OR Odds ratio 
p Level of significance (p value) 
PAR Proteinase activated receptor 
PBS Phosphate buffered saline 
PCR Polymerase chain reaction 
PDE4 Phosphodiesterase 4 
Phe Phenylalanine 
PLAU Plasminogen activator urokinase 
PM10 Particulate matter <10µm in diameter 
ppb Parts per billion 
Pro Proline 
RANKL Receptor activator for nuclear factor kappa beta  
RNA Ribonucleic acid 
ROS Reactive oxygen species 
rs Reference SNP - refers to the number allocated to the SNP in NCBI 
databases 
RV Residual volume 
SE Standard error 
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Ser Serine 
SERPINA3 Alpha 1 antichymotrypsin 
SFTPB Surfactant protein B 
SNP Single nucleotide polymorphism 
SO2 Sulphur dioxide 
SOD3 Superoxide dismutase 3 
spp Species 
T1D Type 1 diabetes 
TBE Tris borate EDTA buffer 
TDMH Taq polymerase reaction buffer 
TE Tris-EDTA buffer 
TGF Transforming growth factor 
Thr Threonine 
TLC Total lung capacity 
Tm Annealing temperature 
TNF Tumour necrosis factor 
Tyr Tyrosine 
UV Ultraviolet 
UZDE Upper zone dominant emphysma 
UZVI Upper zone voxel index 
Val Valine 
WHO World health organisation 
χ2 Chi squared 
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Appendix 6: HLA typing sheets 
 
Phototyping method 
When using this typing sheet if a band is seen in a given lane other than the control bands 
this corresponds to the allele listed, though an additional check of the PCR product size to 
ensure that it corresponds to the expected size should also be carried out. 
  
Locus Alleles amplified Position in 96 well 
plate 
Apply photo from 
gel 
0101/2/4 1A  
0103 1B  
1501-5 1C  
1601-6 1D  
03011/12/2/3/4/5, 1107 1E  
0301/4 1F  
0302/5, 1302/3, 1109/20, 
1402/3/9/13/19 
1G  
0401-22, 1410, 1122 1H  
0701 2A  
0801-11, 1415 2B  
0901 2C  
1001 2D  
1101-21 2E  
1201/2/3 2F  
1301/2/4/8/15-17/19/20/22, 1416,  
1102/3/11/14/16/20/21 
2G  
1301/2/4/8/9/16/20, 1116/20, 1416 2H  
1301/2/10/15/16, 1116/20, 1419/20 3A  
1305/6/10, 1109, 1419/21 3B  
1303/10, 1419/21 3C  
1303/4/12/21, 1413 3D  
1305/7/11/14/18/21, 
1101/4/6/9/10/(11)/12/15 
3E  
1301/2/5-9/10/11/14-16/18/19/20/22,  
1402/3/6/9/12/14/17/19-21, 0301-5 
3F  
1401/3-5/7/8/10-12/14/15/18, 1318, 
0809, 1117 
3G  
1401/7/16 3H  
DRB1 
1402-3/6/9/12/13/17, 1318, 
(1418/19/21),  
(0301/2/3/5) 
4A  
DQB1 0305 4H  
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 02 5A  
04 5B  
05 5C  
0601-3 5D  
0603-9 5E  
0301/4 5F  
0302 5G  
03032 5H  
0101/4 6A  
0102/3 6B  
0201 6C  
03011/12 6D  
0302 6E  
0401 6F  
0501/2 6G  
DQA1 
0601 6H  
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Dynal DRB1 typing sheets 
The first page is used to indicate positive lanes, and the subsequent pages for 
interpretation.  
 
These pages are better viewed or printed at A3 size, and can be accessed at: 
http://products.invitrogen.com/ivgn/en/US/adirect/invitrogen?cmd=catProductDetail&en
tryPoint=adirect&messageType=catProductDetail&showAddButton=true&productID=4
515010&CID=Search-45150-10 
 
The pages can be found in the Manuals and Documents section, under lot specific data.  
 
The lot specific worksheet for lot number 010 is that used for the studies herein. 
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Dynal DQB1 typing sheet 
 
The table shows the specificity of each well in the batch number EK0128, being that used 
for the studies herein. 
 
Lane PCR product size 
(bp) 
Amplified DQB1 alleles 
A 220 050101-0504 
B 215 060101-0622, 0624-0627 
C 205 020101-0204 
D 130, 150 020101-0202, 0204, 030201, 030202, 030501, 030503, 0307, 
0308, 0311, 0318 
E 170, 165 030101, 030102, 0304, 0309, 0310, 0312-0314 
F 125 030201-030203, 030501-0308, 0311, 0312, 0315, 0317, 0318 
G 125 0203, 030101, 030102, 030302, 030303, 0306, 0309, 0310, 
0312, 0313, 0315-0317 
H 210 0401, 0402 
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Appendix 7: Publications resulting from this thesis 
 
In order to avoid repetition within the following list for data that has been presented in 
both abstract and paper form only the paper is listed. 
 
Original papers 
Chapter 3 
1. AM Wood et al, The TNFα gene relates to clinical phenotype in AATD, Resp Res 
(2008) 9: 52-67 
 
Chapter 4 
1. AM Wood et al, Phenotypic differences in alpha 1 antitrypsin deficient sibling pairs 
may relate to genetic variation, Journal of COPD (2008) 5: 353-9 
 
Chapter 5 
1. CJ McAloon, AM Wood et al, Matrix metalloprotease polymorphisms are 
associated with gas transfer in AATD, Therapeutic advances in respiratory disease 
(2009) 3: 23-30 
 
Chapter 7 
1. AM Wood et al, Outdoor air pollution associates with pulmonary function in 
AATD, ERJ (2009) 34: 346-53 
 
Abstracts 
Chapter 3 
1. AM Wood et al, Sputum TNFα levels are associated with TNFA genotype, 
AJRCCM (2009) 179: A2942 
 
Chapter 4  
1. AM Wood et al, Variation in the transforming growth factor β gene is associated 
with small airways disease in AATD, AJRCCM (2008) 178: A200 
2. AM Wood et al, Variation in the Vitamin D binding protein gene is associated with 
the development of bronchiectasis in AATD, AJRCCM (2008) 178: A776 
3. AM Wood et al, Bacterial colonisation in AATD, ERJ (2008) 32: E4496 
 
Chapter 6  
1. AM Wood et al, Anti-elastin autoimmunity in AATD, AJRCCM (2009) 179: A1009 
 
Chapter 7 
1. AM Wood et al, Occupational exposure in AATD, ERJ (2008) 32: P3825 
2. AM Wood et al, Air pollution & decline of lung function in AATD, Thorax (2008) 
63 (Suppl VII): A41 
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Reviews, editorials and book chapters 
1. AM Wood & RA Stockley, The genetics of COPD , Resp Res (2006) 7: 130-167 
2. AM Wood & RA Stockley, AATD: from gene to treatment, Respiration (2007) 74: 
481-92 
3. AM Wood & RA Stockley, Unifying the genetics, comorbidities and management 
of COPD, Therapeutic advances in respiratory disease (2008) 2: 113-117 
4. SL Tan & AM Wood, Chronic obstructive pulmonary disease and co-morbidities: a 
review and consideration of pathophysiology, Panminerva Medica (2009) In press 
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